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Part A: Introduction to the Portfolio 
 
I. Preface 
 
This preface will introduce the various components of this Structured Doctor in 
Philosophy. The portfolio focuses on three different areas related to counselling 
psychology. The novel piece of research assesses the utility of voucher based 
incentives in reducing crack cocaine misuse in clients in opiate maintenance 
treatment. To the author’s knowledge, this is the first study that systematically 
employed and documented this type of programme in the UK. This, is followed by a 
client study using relapse prevention therapy in a flexible way, adapting the 
theoretical framework and relational values in line with the clients’ presentation and 
own style of being in the world. This piece of work is intended to demonstrate my 
professional practice and competence in the field of drug misuse. Finally, a critical 
review of the literature pertaining to the self of the therapist in counselling 
psychology is provided, drawing on one of the unique features in counselling 
psychology, which is its dialogue with other fields, such as philosophy and 
psychotherapy. The literature review attempts to bridge the gap between theory and 
practice, and conceptualises human activity and meaning relationally. A crucial 
aspect of this is the place of consciousness, subjectivity and lived experience in our 
therapeutic practice. As a counselling psychologist1, I recognise that the therapeutic 
relationship is a significant component of therapy (Woolfe, 1996), and that people 
have a need to relate. People suffer not just from their thoughts and feelings but also 
from the limits of their relationships. People are understood and restored in 
relationships.  
 
The preface will now detail each of these three areas in turn, and conclude with an 
exploration of the thematic strands binding the sections together. 
 
 
 
 
                                                
1 The terms ‘counselling psychologist’, ‘therapist’, ‘counselor‘ and ‘clinician’ will be used 
interchangeably throughout this portfolio. 
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I.1. The Empirical Paper 
 
The use of financial incentives for changing health related behaviour dates back to 
the 1960s and the advent of behaviour modification and behaviour therapy. The 
approach is commonly referred to as contingency management (CM), especially in 
the addictions field, where the largest body of health related incentives research has 
been conducted (Lussier, Heil, Mongeon, Badger & Higgins, 2006). This portfolio 
contains an original piece of research that evaluates whether voucher based 
contingency management reduces crack cocaine misuse among opiate maintenance 
clients in a community based drug service. A group of 21 clients agreed to participate 
in the 12 week CM intervention. The central tenets of the CM intervention were to 
(a) urine test clients on fixed intervals according to a standardised incentive protocol 
in a 12 week intervention period, (b) provide monetary based incentives when 
cocaine abstinence was demonstrated, (c) withhold the incentive when cocaine use 
was detected. The results were compared to a sample of 21 clients that received 
standard treatment of opiate maintenance. Between-group analysis was used to 
compare the frequency of self-reported crack cocaine use between the two groups at 
baseline, 1 week after the CM programme concluded and at 6 months follow up. At 6 
months follow up, compared to their counterparts receiving standard treatment, the 
group participating in CM intervention had significantly decreased their crack 
cocaine use over time. A within-group analysis using the clinical significant change 
method to assess meaningful change on an individual basis revealed that 24% of 
participants demonstrated statistical and clinical improvement. Additionally, a 
survival analysis revealed that the estimated median time to study dropout was 14 
days. Overall, these results seem to indicate that the onset of crack cocaine 
abstinence is likely to occur early in treatment or not at all.  
 
The results of the study provide a tentative overview of the acceptability and 
generalisibility of a voucher based contingency management programme reducing 
crack cocaine use among clients in opiate maintenance treatment in the UK. Finally, 
a critical appraisal, which is provided after the discussion section, highlights the 
rationale and the ethical issues of the use of incentives in healthcare and how these 
issues impact on clinicians’ views, and therefore on clinical practice. This 
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information will be useful in expanding this evidence-based approach into 
community settings. 
 
I.2. Professional Practice: Case Study  
 
This case study is a reflexive account of my work with a client using relapse 
prevention therapy (RPT), a cognitive-behavioural intervention with empirical 
support as a treatment for substance misuse behaviours. Given that the client’s 
physical dependence on opiates was not severe, it was possible to offer supervised 
gradual detoxification. With regards to structured psychosocial support, I 
implemented relapse prevention therapy including motivationally focused techniques 
in a creative way, adapting theoretical and relational values in line with my clients’ 
presentation. My ‘cognitively-oriented’ client seemed to embrace the RPT model. 
She seemed to relish ‘doing’ therapy in a supportive working alliance, not wishing to 
get ‘bogged down’ in emotional aspects of her being, but taking great pride in 
increasing her self-efficacy in relation to her substance use and engaging in recovery 
related activities. She also took great comfort in her deepening cognitive self-
understanding and experimenting with different pleasurable drug-free activities. In 
short, she slowly developed a new way of life. Also, given that my understanding of 
RPT is far less technical, I value and incorporate the relational aspects of therapy, as 
typified in the Rogerian core principles (Rogers, 1951, 1957). 
 
After 12 weeks of therapy and detoxification from methadone, my client was drug 
free for the first time since she was 14 years old. She also experienced improvements 
in her life, such as strengthening meaningful relationships, finding paid work and 
taking up hobbies. As indicated by empirical research, the relapse prevention 
approach proved to be an efficacious therapy to assist my client in initiating her 
journey of recovery. I learnt that my ability to respond openly and flexible to her 
needs and requirements was essential in supporting her behaviour change. Further, 
my training and experiences allowed me to integrate my professional and personal 
‘selves’ in a way that allowed me to fully engage in the therapeutic process and 
relationship.  
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I.3. Critical Literature Review 
 
This critical review aims to provide a historical and philosophical overview of the 
Western concept of self in the context of counselling psychology. The use of self is a 
concept employed to describe the therapist’s self in the therapeutic relationship. This 
is particularly relevant to counselling psychology because the actual contact between 
the therapist and the person who is seeking help lies at the heart of what counselling 
is about. Although a therapist may be able to use theory to make sense of the client’s 
difficulties, and may have a range of techniques at her or his disposal for revealing 
and overcoming these difficulties, the fact remains that theory and technique are 
delivered through the presence and being of the therapist as a person: the basic tool 
of counselling is the person of the therapist. An interest in the nature of the 
therapeutic relationship represents a common concern of all therapy practitioners and 
theorists. Even if different approaches to counselling make sense of the client 
therapist relationship in different ways, they all agree that effective counselling 
depends on how this kind of relationship operates (McLeod, 2010).  
 
This review outlines philosophical roots of the self with an emphasis on existential 
thinkers such as Søren Kierkegaard and Martin Buber, and epistemologies that focus 
on the multifaceted nature of the self. Exemplified by Buber's relational notion of 
being, some implications on counselling psychology are then discussed in light of 
this perspective. Buber conceives of I-Thou, the ultimate state of relation through 
which being and self can be actualised. Most pertinent to the therapeutic encounter, 
Buber states that the highest expression of I-Thou manifests in the mutual 
confirmation with another. In this sense, rather than a pre-occupation with 
methodology or techniques, Buber places an importance on the therapist being open 
and accepting. As such, the flexible nature of work is emphasised. Therapy is not 
dogmatic or rigid in technique but about establishing a bond of mutual confirmation 
through being open and genuinely authentic. In this review, I aim to emphasise that 
the self of the therapist is a crucial element of the deeply personal therapeutic 
relationship. I conclude that, ultimately, what therapists offer is not theory or 
technique, but who we are. 
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II. Thematic Connections for the Structured Phd. Portfolio and 
Personal Reflections 
 
This portfolio reflects the culmination of my professional and personal experience 
over the course of my training and beyond. Each section is relevant, in content, to the 
practice of counselling psychologists working in the filed of substance misuse and 
counselling psychology in general. Given that the world in which we live consists of 
a multiplicity of people, of experiences, attitudes, beliefs and claims to the truth, 
counselling psychology, as a part of this world, adopts a pluralistic standpoint which 
recognises the variety within it (McAteer, 2010). Counselling psychology in the UK 
promotes openness to virtually any theoretical approach to psychotherapy, for those 
tied to experimental psychology, such as behavioural therapies and to those 
influenced by Eastern philosophies. Such openness fosters variety, vitality, creativity, 
adaptability to context and demonstrates the overall strength of the discipline. It also 
presents us with the challenge to accommodate unlimited theoretical diversity and 
yet to avoid confusion and contradiction.  
 
While owing an epistemological and philosophical debt to humanism, we (as 
counselling psychologists) have to navigate different models. Addiction is a 
profoundly complex phenomenon and counselling psychology recognises that 
psychological distress has many causes and maintaining factors, and that it is 
impossible for any single model to capture all of these. In order to understand and 
practice in this challenging field, I have adopted a pluralistic stance. A stance of 
pluralism acknowledges that no theoretical, methodological or epistemological 
approach is any ‘truer’ or more appropriate than another and that different people are 
likely to find different meanings or practices useful at different times (Cooper & 
McLeod, 2007). Whilst models overlap to some degree, each is unique and makes a 
specific contribution which can place it in marked disagreement with others. These 
differences are not always insignificant and, at times, we must engage with a range 
of competing theoretical frameworks.  
 
The inclusion of the empirical paper and the case study will inherently make sense to 
the reader. Relapse prevention therapy has its origin in behaviour therapy and theory, 
and CM is a behavioural therapy. Both treatments are derived from the principles of 
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social learning theory with its key concepts of classical and operant conditioning. As 
a result, CM and RPT are compatible and the integration of these interventions could 
prove to be beneficial for some clients. Cognitive-behavioural approaches like RPT, 
for example, bring to counselling psychology an extremely useful set of 
conceptualisations, theoretical understandings and practical tools and techniques that 
are readily accessible in the service of therapeutic work and ultimately to clients. 
 
The presentation of the literature review, however, may have surprised the reader. 
Commonsense dictates that the therapist and the client must inevitably affect each 
other as human beings. This involvement of the therapist’s self or person occurs 
regardless of, and in addition to, the treatment philosophy or the approach. 
Techniques and approaches are tools. They come out differently in different hands. 
Yet counselling psychologists are committed to personal development and place the 
therapeutic relationship, and indeed the ability to form relationships with other 
people, at the forefront of their practice (British Psychological Society, 2005). From 
this follows that the theoretical basis and values of using one’s self in this person-to-
person setting are vital to our understanding as therapists.  
 
Accordingly, the present portfolio embodies a collection of theoretical knowledge 
and therapeutic work conceived of from a pluralistic perspective and practice. 
 
II.1. The Empirical Paper 
 
The rationale to investigate CM as a treatment approach to crack cocaine misuse was 
informed by two reasons; a) the limitations of the currently offered interventions to 
crack cocaine use, as well as the difficulties reaching this client group, suggested the 
need for an innovative and more intensive approach, b) my openness to other 
therapeutic approaches and my continuous attitude of curiosity prompted me to 
investigate an evidence-based approach that has demonstrated positive results in the 
US.  
 
Counselling psychologists are scientist-practitioners who navigate different models 
in a constant process of reflection. Incorporating CM is an illustration of how 
counselling psychology can facilitate creative and sophisticated interventions within 
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its practice. Although as a counselling psychologist, I was at first hesitant about an 
approach that is derived from behaviour modification, implementing the CM 
programme at our service has shown me and some other colleagues that CM has its 
place as an intervention for crack cocaine misuse. Besides the presentation of the 
empirical paper (and its conclusions), I would like to highlight some anecdotal 
evidence in support of this statement. Conducting informal short interviews with 
most of the CM participants allowed for some interesting insights. For example, 
some of the clients that chose to attend the CM programme stated that they were glad 
that the service offered an intervention that had a clearly defined goal and did not 
relate to a ‘talking therapy’. A few participants cherished the idea of ‘earning money’ 
through the monetary based vouchers because it was ‘extra money’ that was not 
anticipated and could be spend on leisure activities with family or friends (such as 
the purchase of a ball to play football in the park). This is in line with the CM 
literature that stipulates that the presented incentive should assist the client to engage 
in behaviours that support a drug free lifestyle. Two other participants stated that 
they used the vouchers to purchase birthday presents for their children, which they 
had not been able to effort before. 
 
Some clients voiced that they were thinking about reducing or abstaining from crack 
cocaine prior to the programme, but were ambivalent about changing their behaviour. 
The participation in the CM programme seemed to resolve their ambivalence and 
moved these clients towards the ‘action’ stage (to use the language from the ‘Stages 
of change theory’; Prochaska & DiClemente, 1986). On the other hand, several 
participants disliked the frequent attendance that was required, particularly at the 
beginning of the intervention. Others struggled to deliver a cocaine negative urine 
specimen because they consumed high doses of crack cocaine and the reinforcing 
effects of the drug was overwhelming. It seemed that the reinforcement from the 
incentives could not compete with the reinforcement of crack cocaine. As will be 
discussed in the empirical paper, modifications to the present structure of the CM 
programme may increase the acceptability and the success rate.  
 
Clearly, CM is a mechanistic intervention and in order to implement it successfully, 
it must be employed systematically. However, its application helps to achieve 
defined and realistic goals that were discussed and set in collaboration with the 
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client. Furthermore, CM is a treatment that can flexibly be combined with other 
treatment approaches and it therefore is a natural candidate for incorporation into 
community services. Contingency management is an effective method in establishing 
initial abstinence, which can be a necessary prerequisite to engage a client in the 
therapeutic relationship and further therapy, not least because it can be extremely 
difficult to engage clients effectively in treatment and, if they do attend, their mental 
state may be adversely affected by substance misuse. Thus, implementing CM 
alongside opiate maintenance treatment can be very beneficial for some clients. 
Although contingency management says nothing about internal change processes that 
may be occurring during a period of change, it is likely that clients are reflecting on 
the consequences, both positive and negative, of their behaviour. One can therefore 
surmise that cognitions at least mediate behaviour change. Developing cognitive 
interventions that maximise the changes an individual can make through a CM 
programme may be worthwhile. It can be argued that paying attention to the 
cognitive change processes is a valuable exercise and an important source of 
information to help individuals sustain changes made in their substance use and 
achieve lasting recovery. Additionally, natural recovery processes that take place 
during periods of sustained abstinence, including gradual diminution of response to 
drug-related cues and lifestyle changes that provide alternative competing 
reinforcers, may then form the mechanisms for longer-term recovery of substance 
dependent individuals (Stitzer & Petry, 2006).  
 
Counselling psychology through its plurality of expression and relation in the way 
that it engages with different contexts extends into arenas beyond therapy without 
undermining what it is or devaluing the principles at its core (McAteer, 2010). Its 
dialectical nature means that it is not a static discipline with fixed and unchangeable 
features – it is evolving, organic and adaptable and it has much to say. 
 
I have not raised any ethical issues in the preface. I have however, addressed this 
topic in section V in the empirical paper.  
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II.2. Professional Practice: Case Study 
 
In the first, relapse prevention therapy is a theoretically heavy and technique oriented 
approach to treating substance misuse problems (and other addictive behaviours). It 
is a relatively modern therapeutic approach to the human condition, evolving from 
the work of Marlatt and Gordon in the 1980s. The approach emphasises the role of 
our thoughts and beliefs (cognitions) in initiating and then maintaining our state of 
mind and mood (with the added complicity of our behaviours). Over the course of 
my training, as well as my work in a Women’s prison and in substance misuse 
services, I read much CBT2 oriented and specifically RPT literature. This 
background experience since qualification and a number of conversations with 
colleagues ‘in the profession’ have drawn me to the conclusion that when we talk of 
CBT, we may be coming from an array of quite different understandings. While there 
may be forces at work which seem to be promoting a narrow, unitary and dogmatic 
understanding of CBT and its application to practice, I also see other forces 
promoting CBT in a more open, pluralistic and flexible manner. In this 
understanding and application, CBT is a far less technically oriented approach where 
theory floats gently on the sea of core relational principles: warmth, respect, 
empathy, positive regard, congruence and autonomy (Boucher, 2010). 
 
In my field – substance misuse and addiction – I regularly meet professionals who 
incorporate the concepts of motivational interviewing (Miller & Rollnick, 2002) and 
mindfulness reflection and meditation (Segal, Williams & Teasdale, 2002) into their 
practice, and seek out new ways of working in their particular areas of interest (as 
hopefully illustrated with the present portfolio). In my own practice, I find the 
theoretical concepts and framework of CBT, with its emphasis on assessment and 
case formulation, very valuable. It sensitises my attention to the interplay between a 
client’s early experiences, beliefs about themselves and the world, patterns and rules 
for living, critical life-events, coping strategies and current thoughts and presenting 
issues. In so doing, it often but not always offers a structure on which I can build the 
therapeutic approach taken, as the ‘assessment’ phase evolves into the ‘treatment’ 
                                                
2 CBT (cognitive behavioural therapy) is used as an umbrella term in the preface, unless I am 
referring to a specific type of therapy within the cognitive behavioural framework. 
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phase (arbitrary and medicalised terms necessitated by my therapeutic context) of 
therapy, with a client’s guidance. In this building process, I am particularly attuned 
to a client’s own understandings of their issues, the context and systems in which 
they exist, as well as their own values, and the meanings they draw from their life 
thus far (Boucher, 2010). Here, theoretical models other than CBT, drawing from 
humanistic, existential, psychodynamic and systemic traditions, are variously 
engaged within my own internal narrative of formulation as they emerge through a 
client’s discourse, which I am actively exploring. I might be drawn to a transactional-
analytic understanding (Harris, 1995) and think that relational difficulties are circular 
(Vetere & Dallos, 2003), due to a system need around a client’s ‘basic fault’ (Balint, 
1968), or be struck by Winnicottian ideas about true/false self-formation (Winnicott, 
1969). Also, by giving the client the time and space to engage with past emotional 
experiences, s/he may feel validated and come to accept these emotions, which may 
enable her/him to move on. In this, I have made use of concepts such as limited re-
parenting as understood by schema therapy (Young, Klosko & Weishaar, 2003) and 
mindfulness-based cognitive therapy (Segal et al., 2002).  
 
I simply do not know where my thinking will go; what will turn up in my ‘free-
floating theoretical attention’ (Boucher, 2010). I am with the client, with myself, and 
in this with-ness, I manage my anxieties about what a particular model might tell me 
to do and draw from an acceptance that at different points in time, different 
explanations will be true for different people (Cooper & McLeod, 2007). While this 
stance allows me an expansive array of ideas and concepts from which to draw, I 
find myself in my practice integrating what I take from different explanations, 
according to three considerations. First and foremost, a client’s presentation, in the 
context of our relationship (i.e. what appears to resonate most with them during our 
explorative encounter) and second, in the context of how our encounter has impacted 
on me – I use my-self. Thirdly, the cognitive-behavioural ‘mainframe’ of my 
therapeutic context. While I find, with my less prescriptive take on CBT and my 
relative autonomy in my current service, that such considerations more often than not 
coalesce with a general ease in helping clients, at times when they do not, I generally 
find support and understanding from my supervisor and colleagues when I explain, 
often in the language of CBT – the dominant language of my service – why an 
alternative approach to a ‘straight’ cognitive-behavioural one might be better taken. 
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While in many ways the discussion and practice outlined above could be taken as 
simply focusing on how I integrate CBT into my practice, in fact my aim is broader. 
What I am suggesting is that CBT, with its strengths and its limitations, can be used 
in the service of our therapeutic practice as a model in itself due to its strengths, and 
as a conduit to the introduction of other models due to its limitations. I feel that if we 
are open to and discursive about such issues, we could use CBT to broaden our 
professional practice, as well as that of other professionals, modelling pluralism and 
benefiting clients. To summarise my approach, and making use of an accurate and 
poignant metaphor from Boucher (2010, p. 167): “CBT is one arrow in my quiver, 
not my full crop (other theoretical models), and certainly not the bow (the therapeutic 
relationship). To extend the metaphor: I am the hand that holds and draws the bow, 
the client is the eye that guides the arrow and says when to release it. The 
relationship between us (both conscious and unconscious) determines the outcome. 
Sometimes we hit the target (unique to every client), sometimes we miss. We 
practice together, learning how we might work together and refine our skills.” It is 
through being in this process that I believe the relationship becomes therapeutic. The 
more sensitive we are to this process the better the relationship; the better the 
relationship the better the outcome (Keijsers, Schaap & Hoogduin, 2000; Krupnick et 
al., 1996).  
 
II.3. Critical Literature Review 
 
The literature review was the first piece of work I wrote towards this Phd. portfolio. 
My decision to focus on this particular aspect of counselling psychology was the 
desire to learn and understand more about the self of the therapist. Reading about the 
different philosophical concepts of the self and relating it to therapeutic practice has 
kept me intrigued and contributed (inter alia) to the formation of my-self as a 
practitioner. Also, I perceive it as a privilege that my work as a counselling 
psychologist entails thinking and learning about the paradox of human existence; 
well-being is necessarily intertwined with despair. As Kierkegaard argued, life is not 
a problem to be solved, but a reality to be experienced.  
 
It is in this spirit that counselling psychology has created a legacy promoting the 
importance of personal and professional development through engagement with 
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personal therapy and supervision across one’s professional career (British 
Psychological Society, 2005). Both activities are seen as invaluable to the 
practitioner’s growth and competence since (self-) knowledge and meaning-making 
are viewed as the products of an engagement with others, rather than an internal 
monologue detached from our social context and other people (Wosket, 1999). The 
dissolution of dichotomies which the relational stance demands situates practitioners 
and clients, as well as supervisors and supervisees, in the interworld where everyday 
activity and the construction of ways of being take place (Carroll & Tholstrup, 2001; 
Shillito-Clarke, 2008).  
 
Counselling psychology embraces the relational stance which springs from a 
philosophy that bridges the gap between body and mind, behaviour and experience 
and subjective/objective. It focuses on the space in between where life unfolds and 
offers an experiential account of human existence. Consequently, terms such as lived 
experience, life-world, temporality, embodiment and embeddedness replace the 
initial focus on the individual and emphasise the unitary phenomena of ‘being-in-the-
world’ and ‘being-in-the-world-with-other-people’ – Heidegger’s (1962) concepts of 
Dasein and Mitsein. Thus, being-in-the-world-with-other-people reflects the unity of 
the world and other people. This relational framework highlights the intersubjective 
nature of human existence. Emotions, no matter how extreme, reflect our clients’ 
particular modes of being-in-the-world and ways of engaging with others. In therapy, 
it is important to clarify meaning so that their often pre-reflective – and hence 
uncontained – nature can become reflective and open for contemplation (Strasser, 
2005). It is through this process that clients can begin to realise themselves and their 
place in the world and, consequently, shift to a position that will enable them to 
embrace different possibilities. As Camus (2000) argued, passionate engagement 
with life is tragic in nature because the heroes – ourselves – are conscious!  
 
Counselling psychology pays great attention to the process in the therapeutic 
encounter as other meets otherness – a dynamic and ever-changing situation. It 
considers the mechanisms and values of using ‘one’s self’ in this person-to-person 
setting. This is where counselling psychology stands out, through its underlying 
reflexive and reflective client-centered tradition, as a profession well positioned to 
generate creative, new and open-minded ideas about how process issues might be 
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recognised, valued more holistically and integrated into the practice of different 
therapeutic models. 
 
Counselling psychology, with its inquisitive and open-minded attitude to how we 
come to ‘know’ and its relational framework, enshrines many of the principles that 
are part of a pluralistic stance. It resists theoretical dogma, repeatedly questioning its 
own assumptions in an attempt to gain a richer perspective on what it is to be human. 
It encourages a diversity of research perspectives and evidence sources as it attempts 
to build a collage of understandings rather than a single definitive image of truth. It 
challenges ‘pathologising’ trends and traditional ways of seeing the ‘individual’ as 
self-contained entities, pointing to the relational ways of humans being with each 
other, in both their internal and external states. But most importantly, counselling 
psychology holds a relational therapeutic model, where being with another’s 
‘otherness’, in all its richness and diversity, is the apex of the therapeutic encounter 
from which a broad theoretical literature can be drawn on. Thus, a pluralistic 
approach allows for creativity in the therapeutic work that not only reflects an 
individual’s uniqueness, but also responds to and is nurturing of it.  
 
The basic tenet of pluralism is very simple – there are many people and they are all 
unique – but on elaboration, what this implies is quite staggering. There are many 
ways of thinking; there are numerous ways of behaving; there are multiple ways of 
feeling; there are different ways of relating to ourselves and to others in the world; 
there is a large variety of ways of understanding the world, each as rich and as valid 
as the others (I have stressed ‘valid’ as beliefs as to the ‘truth’ of this underlie 
epistemological difference between competing theoretical models). The therapeutic 
encounter is by necessity a place where this multiplicity of ways of being human is 
likely to play out with regard to how one individual might approach and help another 
individual with their difficulties. Drawing from this perspective, Cooper and McLeod 
state of pluralistic therapeutic practice:  
 
“A pluralistic standpoint holds that a multiplicity of different models of 
psychological distress and change may be ‘true’ and that there is no need to 
try and reduce these into one unified model… Different explanations will be 
true for different people at different points in time and, therefore, different 
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therapeutic methods will be most helpful for different clients at different 
instances.” (2007, p. 6)  
 
In this, theoretical pluralism is embraced as a vital and necessary therapeutic stance, 
tailoring the therapeutic encounter to an individual’s uniqueness, in the here and 
now, and thus, making that encounter therapeutic. The pluralistic and dialectical 
counselling psychology’s professional identification has placed me, at times, as a 
trainee (and still does) in emotional turmoil with the struggle to get to grips with 
multiple theories, and the realisation that it is not possible to follow one single clear 
set of rules and thus, to navigate my way through the complex therapeutic landscape. 
I would like to think that these emotional challenges associated with my personality, 
allegiances, world views, value systems and ethics, contributed to my personal and 
professional growth. In pondering this, could it be that, as developing professionals, 
we are engaged in a process of ‘professional actualisation’ as we move, with greater 
experience, towards a more pluralistic outlook. Committing myself to such personal 
explorations will hopefully benefit the clients that receive my support. 
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Incentivising Crack Cocaine Abstinence among 
Clients in Opiate Maintenance Treatment using 
Voucher based Contingency Management in a 
Community Drug Service 
 
ABSTRACT 
The present study was part of a nationwide multisite trial of contingency management (CM) 
implemented by the National Treatment Agency for Substance Misuse (NTA). The research 
programme aimed to target drug using, health and attendance related behaviours to gain an 
understanding of the acceptability and feasibility of contingency management to the UK 
substance misuse population. The use of CM to incentivise abstinence from an illicit 
substance was recommended in the guidelines of the National Institute for Health and 
Clinical Excellence (NICE, 2007). This study examined whether CM reduced concurrent 
crack cocaine misuse among opiate maintenance clients at a community drug and alcohol 
service (NHS). The study employed a quasi-experimental design in which twenty-one (n = 
21) opiate maintenance clients voluntarily chose to participate in the CM group. The 
incentive consisted of monetary based vouchers in the CM group, contingent upon the 
submission of cocaine free urine samples. A natural unplanned comparison group (n = 21) 
developed from participants that initially agreed to participate in the CM intervention but did 
not attend any of the scheduled reinforcement sessions. These clients continued to receive 
standard treatment (ST), including opiate maintenance treatment and key working. The data 
analysis consisted of two parts of data analysis; the first part employed a between-group 
analysis to compare the frequency of self-reported crack cocaine misuse for the CM and ST 
groups at baseline, 1 week after the 12-week CM intervention concluded and at 6 months 
follow-up. The analysis showed that there was a significant difference in crack use at follow-
up and that there was a decrease in crack use over time in the CM group but not in the ST 
group. The second part utilised a within-group analysis, investigating study results for 
evidence of clinically meaningful changes on an individual participant level in the CM 
group. Accordingly, 5 participants (24%) demonstrated statistical and clinical improvement. 
Additionally, a survival analysis revealed that the estimated median time to study dropout 
was 14 days. These results seemed to indicate onset of crack abstinence is likely to occur 
early in treatment or not at all. The results of the study provide a tentative overview of the 
feasibility and generalisability of a voucher based contingency management programme 
reducing crack use among clients in opiate maintenance treatment in the UK. The 
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implications of the study will be discussed in relation to clinical practice and future research. 
Finally, a brief discussion of the moral and ethical concerns about using incentives in health 
care will be provided. This information will be useful in expanding this evidence-based 
approach into community settings. 
 
 
Part B: Empirical Paper 
 
I. INTRODUCTION 
 
I.1. Background of the Area of the Study 
 
The ‘drug problem’ has become perhaps the archetypal social problem of our time – 
cross-cutting, globalised and apparently intractable. Its complexity is daunting, 
requiring engagement with some of the thorniest domestic and international issues, 
from poverty and crime through to international development and terrorism.  Nor is 
this just a ‘phantom’ played up by the political classes – there is public concern and 
anxiety about drugs too (Seddon, 2010). History is replete with examples and reports 
of drug use, despite the current popular perspective that drug use is a relatively recent 
behavioural anomaly (Plant et al., 2011). The use of drugs has occurred for a very 
long time – probably ever since the time that early humans, eating plants that grew 
around them, found that some plants had medicinal properties and that some made 
them feel different. Since that time drug use has been part of the human lifestyle, 
with different societies using different ‘natural’ intoxicants depending on the 
indigenous flora (Ghodse, 2010). A few of these drugs have become familiar to 
many, beyond the confines of their original use and have been used for centuries, for 
example; opium, cocaine, cannabis, alcohol and coffee.  
 
Many of these drugs were first used for medicinal purposes, even though they are 
now considered to have minimal or no therapeutic value, for example; alcohol, 
tobacco and LSD (lysergic acid diethylamide) (Plant et al., 2011). In the seventeenth 
century, shortly after its introduction to England, tobacco was believed to be good for 
the ‘the megrim, the toothache, obstructions proceeding of cold and for helping the 
fits of the mother (hysteria)' (Arber, 1895). Although medical opinion remained 
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divided for centuries about the usefulness or harmfulness of tobacco, its dependence-
producing properties gradually came to be acknowledged (Ghodse, 2010). Besides 
their medicinal value, many drugs (e.g. opium, cannabis, cocaine, mescaline and 
coffee) have been used in religious rituals, and the use of alcohol continues today in 
two of the world’s three monotheistic religions. It is of interest that the third and 
youngest religion, Islam, bans its use altogether (Ghodse, 2010). A third way in 
which drugs are used is for social and recreational purposes. All of the ‘old’ drugs 
(those with a long history, e.g. opium, cocaine, cannabis and alcohol) were used in 
this way, and drug use was often the reason for a group coming together; the drug 
became the very substance of communication, the dynamic of the group activity 
(Berridge & Edwards, 1987). This continues with alcohol today in public houses, 
nightclubs, cocktail parties and so on, and for some drugs, notably cannabis and 
other psychedelic drugs, taken specifically by those interested in mysticism and 
exploration of the inner world, the setting in which the drug is taken and the shared 
group experience remain important. As far as illicit drug use is concerned, the very 
fact the drug is forbidden encourages the formation of a group (and often of a whole 
subculture), concerned, among other things, with obtaining the drug and concealing 
its use from the authorities (Ghodse, 2010).    
 
The availability of the drug is obviously a prerequisite for misuse and dependence, 
and the rapid transport methods of the modern world ensure that most drugs are 
obtainable everywhere. Transportation of drugs is not, of course, a recent occurrence 
– opium was moved halfway round the world centuries ago – but modern 
communications have greatly increased the speed and volume of this traffic. For 
centuries there has been travel not only across countries but continents and humans 
have taken drugs with them on their travels (ibid). There is no doubt, however, that 
modern methods of travel and communication have had a profound effect on drug 
use and misuse because the physical transportation of drugs is so much easier and 
speedier. In addition, the rapid movement of large numbers of people allows 
exposure to the drug-taking practices of another culture. This is increased further by 
the effect of the media, so that no drug or drug-taking practice can remain localized. 
They are bound to spread and because of that, there is usually a loss of the traditional 
constraints upon drug use imposed by the family and society as a whole (ibid). This 
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means that new drugs and novel ways of taking them gain acceptance much more 
easily than when drug use was under strict, local, sociocultural control (ibid, p. 2). 
 
In addition to the availability of a drug, the form in which it is available is very 
important. Modern chemical techniques permit the extraction of highly purified and 
very potent forms of drugs at source, making them easier to transport and smuggle, 
and because of their greater potency, much more efficient at causing dependence 
(Palfai & Jankiewicz, 1997). One example is cocaine, which is extracted from coca 
leaves, it is one of the oldest psychoactive substances. Coca leaves have been chewed 
and ingested for thousands of years, yet one can only conjecture how long it would 
take a Native South American to chew sufficient coca leaves to obtain the same dose 
of cocaine as that in a single vial of ‘crack cocaine’, the purified version of cocaine 
currently misused in the USA and Europe; and it is unlikely that the Native 
American ever achieved blood levels (or nervous-system levels) of cocaine sufficient 
to cause serious dependence (ibid).  
 
Crack cocaine3 misuse is a substantial and growing public health problem in the UK 
(Strang et al., 2008). Within the opiate-dependent treatment population in Britain, 
two thirds of clients also now use crack cocaine (Lewis & Horgan, 2013). The 
National Treatment Outcome Research Study neatly captured the emergence of this 
trend, with one quarter of non-crack-using participants at the start of the National 
Treatment Outcome Research Study having initiated crack cocaine use by the end of 
the 5-year follow-up period, two thirds of whom reported this as their first 
experience of crack cocaine (Gossop, 2006; Marsden et al., 2002a; Gossop, Stuart, 
Treacy & Marsden, 2002b). 
 
Crack use within the methadone maintenance population is associated with poorer 
psychological health and increased incidence of acquisitive crime compared to non-
crack users (Gossop, 2006; Marsden et al., 2002a; Gossop et al., 2002b). One feature 
of the opiate dependent crack using population is the high incidence of the practice 
of injecting crack, often as a ‘speedball’ – a cocktail of heroin and cocaine (Rhodes, 
                                                
3 
Cocaine is used in this thesis to refer to cocaine powder (usually injected or ‘snorted’). Crack 
cocaine (colloquial termed ‘crack’) is used to refer to the smokable base form of cocaine, sold as 
small lumps or ‘rocks’.  
 
 32 
Briggs, Kimber, Jones & Holloway, 2007). Studies of crack injectors have also 
reported high rates of sharing injecting equipment and increased sexual risk 
behaviours (NIDA, 2010). This suggests increased risk of contracting blood-borne 
viruses in this population, with the potential for diminishing some of the HIV risk 
behaviours gained from receiving oral methadone maintenance. 
 
Crack use is also associated with poorer compliance with methadone maintenance, 
which in itself can lead to poorer treatment outcomes (Magura, Nsakeze & Demsky, 
1998; DeMaria, Stering & Weinsten, 2000; Rowan-Szal, Chatham, Joe & Simpson, 
2000; Mitcheson, McCambridge & Byrne, 2007). Despite the growing importance of 
crack use, methadone maintenance itself is also now known to have a minimal 
impact on reducing crack cocaine use (Ball & Ross, 1991; Hser, Grella, Chou & 
Anglin, 1998; Williamson, Darke, Ross & Teesson, 2006). Against this backdrop, 
targeted interventions to reduce crack use in opiate treatment populations have been 
proposed by the UK National Treatment Agency (NTA, 2002a). In reality, however, 
there has been a wide variation in the uptake and implementation of psychosocial 
approaches to treatment across services (NICE, 2008). Furthermore, psychosocial 
interventions for crack cocaine dependence generally show modest results, and there 
is a lack of effective pharmacological interventions to treat crack cocaine dependence 
(Mitcheson et al., 2007; Nuijten, Blanken, van den Brink & Hendricks, 2011). Given 
the extent of multiple and complex problems found within opiate treatment 
populations which may preclude clients accessing high threshold psychological 
interventions, there are grounds to consider the potential of a systematic and 
comprehensive approach, that can provide a firm and consistent structure for the life 
of a person that is dependent on crack cocaine. 
 
There is robust empirical evidence from the US that cocaine dependence is treatable 
with contingency management (Lussier, Heil, Mongeon, Badger & Higgins, 2006; 
Prendergast, Podus, Finney, Greenwell & Roll, 2006; Dutra et al., 2008). Based on 
the principles of operant conditioning, contingency management (CM) interventions 
offer incentives or rewards to encourage specific behavioural goals. In the case of 
treatment for cocaine dependence, monetary and non-monetary rewards typically 
have been made contingent on negative toxicology screens, indicating abstinence 
from cocaine use. The approaches have shown consistent success, with substance use 
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behaviours ranging from opiate and cocaine dependence to nicotine dependence 
(Dutra et al., 2008; Kidorf & Stitzer, 1996; Budney, Radonovich, Higgins & Wong, 
1998; Higgins, Wong, Badger, Ogden & Dantona, 2000; Higgins et al., 2003; 
Shoptaw et al., 2002; Miller & Willbourne, 2002). Contingency management may be 
targeted at assisting clients to make decisions to change some aspects of their drug 
using behaviour, rather than itself providing skills to maintain change. It aims to 
promote reflection on drug use and consequences in the context of the individual’s 
goals and values, for example, through the prolonged abstinence from drug use.  
 
As the use of drugs both licit and illicit has become a major issue particularly for 
industrialised countries, and our understanding of the issues has become more 
dimensional in nature, then more and more professional groups are required to have 
an understanding of drug use and its related issues. Substance misuse is a complex 
multidisciplinary field, ‘there’s no one lead discipline that is committed to the drug 
abuse problem comprehensively’ (Edwards, 2008, p. 37). Thus it is essential, 
whether one engages in theory building, researching or practically helping people, to 
leave one’s professional specialism (Chick, 2002) and to collaborate across the broad 
areas of biology, psychology and sociology. Over recent years the developing 
consensus around biopsychosociality, which hypothesises that addiction is about 
more than the sum of its individual parts (Lindstrom, 1992; Lende and Smith, 2002) 
has challenged academics and practitioners to break out of their traditional areas of 
study, and to start to become acquainted with these other disciplines.  
 
Yet, having acknowledged this complexity, the question remains how the present 
thesis can do justice to such a complex field. It may be that subject specific 
practitioners are left disappointed by a perceived lack of depth. Yet other readers 
may feel that some of the covered topics in the thesis are irrelevant. However, whilst 
acknowledging that danger, the purpose is to cover the ideas, knowledge and theories 
from other disciplines that seem relevant to gain a reasonable understanding of the 
material under discussion. 
 
The present study is situated in the field of drug treatment outcome research. The 
behavioural treatment that is introduced here; contingency management, is 
investigated as an ‘add-on’ to standard key working, hence complementary to 
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standard treatment. For the sake of clarity, the introduction consists of 7 sections and 
is structured in the following order: (1) The first part is dedicated to a brief history of 
coca leaves and cocaine powder in Europe and specifically in Britain. (2) This 
section describes the psychological and physical effects of cocaine, and its purified 
and more potent version – crack cocaine. (3) The function of this part is to discuss 
and define some of the relevant terms regarding drug-related behaviours. (4) There 
exists a plethora of weighty tomes and a wealth of research literature that try to 
explain the causes of drug use and dependence. However, in a project of this size, it 
is only possible to introduce the most relevant factors that seem to interact to lead to 
a variety of drug-related behaviours. (5) Covers the National Institute of Clinical 
Excellence (NICE, 2008) recommended psychosocial interventions for the treatment 
of crack cocaine dependence. (6) Contingency management originated and was first 
systematically investigated in the US, thus the current research evidence base was 
derived from the US healthcare system prior to the changes that took place in 2014. 
The implementation of opiate maintenance programmes varies internationally with 
respect to structure, procedures and practice. Thus to gain an understanding, this 
section highlights some of the salient and relevant differences in the implementation 
of opiate substitution programmes in the US and UK. (7) Describes the two measures 
that were employed to monitor treatment outcome; Treatment Outcome Profile 
(Marsden et al., 2008) and Christo Inventory for Substance Misuse (Christo, Spurrell 
& Alcorn, 2000). (8) Serves as an introduction to contingency management. It 
discusses the theoretical foundations of the operant behaviour conceptualisation and 
the brain mechanisms underpinning instrumental learning. Next, an outline of the 
implementation of CM is provided. The remainder will be dedicated to the empirical 
research evidence of voucher based CM in cocaine misuse, and a discussion of the 
CM parameters that seem to impact on treatment outcome. The last section briefly 
discusses predictors of CM treatment outcome. (9) The concluding paragraph 
outlines the aims and the background of the study, and states the research questions. 
 
I.2. A Brief History of Cocaine 
 
In 1858 the Austrian frigate SMS Novara (Austro-Hungarian Navy, 1857 – 1859) 
was sent to South America on a most unusual mission. On board the Novara was a 
trade expert, Doctor Karl von Scherzer, who was intrigued by an Italian ‘renaissance’ 
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started by Milan neurologist Paola Mantegazza (Siegel, 1984). Doctor Mantegazza, 
who had practiced medicine for some time in Peru, on his return to Italy, published in 
1858 “Sulle virtù igieniche e medicinali della coca e sugli alimenti nervosi in 
generale” in which, while describing the hallucinatory effects which the coca leaves 
had on him, he recommended it for a range of illnesses including toothache, digestive 
disorders and neurasthenia (Berridge & Edwards, 1987). This paper was the newest 
curiosity of the European medical community which awarded Mantegazza a prize for 
this work in 1859 (Mortimer, 1901) The Novara stopped in Peru and Doctor Scherzer 
took a quantity of coca leaves back to the great chemist Professor Friedrich Woehler 
at the University of Gottingen in Germany. In 1859-1860 Woehler’s assistant, Albert 
Niemann, named the isolated alkaloid from the coca leaves ‘cocaine’ - a white 
crystalline powder that can be sniffed, dissolved and injected (Phillips & Wynne, 
1980). After his death, his work was carried on by his disciple Wilhelm Lossen, who 
finally, in 1865, described its chemical formula and a description of other coca 
alkaloids followed later in the century (Grinspoon & Bakalar, 1976). This signalled 
the start of 125 years of changing patterns of cocaine use. Prior to that time, only 
coca products were available, and the patterns of their use had not changed 
substantially in over 4700 years (Siegel, 1984). 
 
It was at about this time - in the mid nineteenth century - that a more scientific 
evaluation of the alkaloid began to prepare the way for its introduction into European 
medicine. The interest in the alkaloids of the drug can be seen as another illustration 
of the growth of scientific inquiry and specialization in the early decades of the 
century (Ashley, 1975). Yet, it was not until the powers of the alkaloid as a local 
anaesthetic were fully understood that the drug won complete medical acceptability 
(Markel, 2011).  
 
Sigmund Freud, the founder of psychoanalysis and, for better or worse, probably the 
most influential psychological thinker of the 20th century, had considerable personal 
involvement with drugs, particularly cocaine (Gossop, 2007). Freud's use of cocaine 
was, because of his own enormous fame, well-known. What can almost be termed 
Freud's love affair with cocaine was an interesting episode in his career, albeit one 
which he preferred to disguise in later life (Platt, 1997). His enthusiastic advocacy 
owed something to his own personal circumstances, in particular the desire as a 
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young medical researcher to establish a serious reputation (Markel, 2011). He first 
became interested in the drug and its properties after reading a report in 1883 of how 
Dr. Theodore Aschenbrandt, a German army physician, issued cocaine 
experimentally to some Bavarian soldiers during autumn manoeuvres to overcome 
fatigue. The results were promising. Freud obtained some cocaine hydrochloride for 
himself from Merck in Germany, a pharmaceutical and chemical company and began 
to experiment (Linn, 2002). His central experimental subject was himself. But as 
impressive as his work was, Freud neglected to describe cocaine’s most practical 
application: it was a superb local anaesthetic that completely numbed a living being’s 
sensation to the sharp blade of a scalpel. Dr. Carl Koller successfully demonstrated 
the drug’s power to eliminate pain. The discovery excited the entire medical world, 
much to Freud’s chagrin (Markel, 2011). 
 
In May 1884, influenced by American reports of the drug's use as a cure for 
morphine addiction, he began to administer cocaine to his friend Ernst von Fleischl-
Marxow, who had become addicted to morphine to dull the pain of an amputated 
thumb (Platt, 1997). In his paper “Über Coca” (On coca) published in July 1884, he 
reviewed the scientific literature available on cocaine at the time (approximately 
twenty studies) and described the drug's therapeutic uses. Contending that it should 
be regarded as a stimulant rather than a narcotic, he blamed past failures on bad 
quality preparations (Linn, 2002). From his own experience, he recommended the 
drug for a variety of illnesses and especially for symptoms such as fatigue, 
nervousness, neurasthenia and, most significantly, as a cure for morphine addiction 
(ibid). Freud also treated his depression with cocaine and reported feeling 
“exhilaration and lasting euphoria, which is in no way differs from the normal 
euphoria of the healthy person. . . You perceive an increase in self-control and 
possess more vitality and capacity for work. . . . In other words, you are simply more 
normal, and it is soon hard to believe that you are under the influence of any drug” 
(Jones, 1981, p.82). Freud himself continued to experiment with the drug for several 
years; he published five papers in all on it, the last, “Bemerkungen über Cocainsucht 
und Cocainfurcht.” (Craving for and Fear of Cocaine), published in 1887. It is 
possible that his use of cocaine (which seems to have continued to some degree after 
the last paper was published in 1887) had mediated his change from physiological to 
mainly psychiatric interests (Linn, 2002). 
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The medical community became enthusiastic about this new wonder drug, the patent 
medicine manufacturers exploited it, and the non-medical use of cocaine for pleasure 
began to grow (Markel, 2011). There was general agreement among the medical 
profession that cocaine was a most valuable drug. Freud had called it an instrument 
of almost unbelievable curative power and an editorial in The Lancet (1885, p. 123) 
commented:  
 
“The therapeutical uses of cocaine are so numerous that the value of this wonderful 
remedy seems only beginning to be appreciated. Almost daily we hear of some 
disease or combination of symptoms in which it has been tried for the first time and 
has answered beyond expectation.” 
 
In addition to the numerous coca products, cocaine itself started to appear in flake 
crystals, tablets, solutions for injection, ointments, and nasal sprays (Berridge & 
Edwards, 1987). Both coca and cocaine were also used in a variety of soft drinks and 
tonics, the most famous being Coca-Cola. Indeed, from 1891 until 1903 Coca-Cola 
contained two main stimulants coca leaves and kola nuts, hence its name. The drink 
and drug became so closely identified that ‘dope,’ as in “let’s have a dope became 
the established, common term for Coca-Cola” (Ashley 1975, p. 49). It originally 
contained about 3% coca leaves, a significant dose (ibid).  
 
Angelo Mariani, a Parisian chemist and entrepreneur, took a fancy to the drug and 
mixed coca extract into many of his products, which were intended for the temporary 
relief of hunger, thirst, fatigue, exhaustion, distaste for food, or nervous depression 
and weak digestion (Gossop, 2007). He successfully marketed Vin Mariani, Elixir 
Mariani, Pate Mariani, Pastilles Mariani, The Mariani (a non-alcoholic variety) and 
tea, in Europe. His crowning achievement, though, was the phenomenally successful 
Vin Mariani, a concoction of coca and wine. It had many faithful and famous 
devotees and advocates: President McKinley, Thomas Edison, the Czar of Russia 
and, eminent among them, Pope Leo XII, who issued Mariani a gold medal and cited 
him as a Benefactor of Humanity (Palfai & Jankiewicz, 1997). Mariani's were not the 
only commercial coca products on the market. In 1888, Messrs Ambrecht, Nelson & 
Co. of Duke Street, London, had several varieties of coca wine, including sweet 
Malaga (used by ladies and children) and a Burgundy coca wine for gouty and 
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dyspeptic cases; there was also coca sherry and coca port. In 1894 there were at least 
seven firms producing coca wines for the domestic market (Berridge & Edwards, 
1987). 
 
Medical approval began to wane in the late 1880s (Markel, 2011). In the scientific 
investigation of cocaine, negative effects were found. Consequences such as toxic 
reactions during ophthalmic surgery, cocaine related stroke, cardiac arrhythmias, and 
others were reported (Karch, 1993). Commercial coca products were separated from 
their previous semi-medical status and were incorporated in the general medical and 
pharmaceutical campaign against the availability of all patent medicines. This was 
part of a remarkable medical volte face on the use of cocaine in general (Markel, 
2011). The euphoria of 1884-5 was soon replaced by an appreciation of the dangers 
which such unrestrained use could give rise to. By 1887 cocaine addiction had been 
reported in the literature and Dr. Mattison could comment in The British Medical 
Journal that, “the inevitable reaction against the extravagant pretensions advanced on 
behalf of this drug has already set in” (Mattison, 1887, p. 1229). The use of cocaine 
to treat morphine addiction was strongly called in question. Freud had praised the 
drug for its utility in this way. Ernst von Fleischl-Marxow, to whom he had 
administered the drug, became dependent on cocaine in place of morphine (Byck, 
1974). When Albrecht Erlenmeyer, a fellow psychiatrist, charged Freud with 
unleashing the “third scourge of humanity” on the world – the first two being alcohol 
and opiates – Freud had begun to distance himself from his earlier opinion about the 
drug (Gold, 1992, p. 427). By 1888, 90 cases of toxicity, including 6 deaths, had 
been reported (Karch, 1993), in 1892, 21 fatalities were documented in France from 
accidents involving hypodermic injections of cocaine (Platt, 1997). The whole 
pattern of events was very similar to the earlier medical enthusiasm for, and 
subsequent partial rejection of, hypodermic morphine. With cocaine, the process was 
completed in a much shorter time. The wonder potion of the early 1880s cocaine had 
become, for at least some in the European scientific community, the “devil’s own 
device” by the late 1880s (Mattison, 1887, p. 1025). This disenchantment with 
cocaine was also found in the United States during the 1890s. 
 
Withdrawal of scientific and popular praise of, and support for, the drug did little to 
curb its use (Platt, 1997). Reports from Europe in the period immediately after World 
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War I indicated widespread use of the drug, perhaps encouraged by the casualness in 
which physicians had prescribed it prior to the war (Spotts & Shontz, 1980). Thus in 
the 1900s recreational cocaine use spread in Europe and the United States. It became 
popular to snort cocaine, although to limited circles. It was carried around in small 
ornate boxes and snorted in a similar fashion as snuff. Early cocaine snorting was 
known as 'cocaine snuffing’ and Harrods in London started selling cocaine, over the 
counter in 1910 (Berridge & Griffith, 1999). Observations on these patterns of use 
were made in both the medical and lay press during the early 20th century. Many of 
these articles suggested that cocaine was associated with uncontrollable addiction, 
physical and psychological deterioration, demoralization, and criminal violence 
(ibid). As a result, the UK government decided to prohibit cocaine as an illegal 
substance under the Dangerous Drugs Act in 1920 (Gossop, 2007). This started an 
illegal importation trade. Some enterprising traffickers used homing pigeons sent 
from France to bring in a gram at a time (Spotts & Shontz, 1980). Thus cocaine 
prices increased, due to tighter controls on dispensing and illicit dealing. Illicit 
cocaine became available  (and still is) as a fine, white, crystalline powder and is also 
known as ‘coke,’ ‘C,’ ‘snow,’ ‘flake,’ or ‘blow.’ It is generally diluted with inert 
substances such as cornstarch, talcum powder, or sugar or with active drugs such as 
procaine (a chemically related local anaesthetic) or amphetamine (another stimulant). 
There are two chemical forms of cocaine that are abused: the water-soluble 
hydrochloride salt (cocaine) and the water insoluble cocaine base or freebase (crack 
cocaine), for a detailed description please see below (NIDA, 2010).  
 
Between 1930 and the mid-1960s, both the medical and non-medical use of cocaine 
gradually declined, and general interest in the drug all but disappeared (Berridge & 
Edwards, 1987). From the late 1960s into the mid-seventies, the view of cocaine was 
once more that of an expensive and glamorous upscale treat – the ‘Champagne of 
drugs’ and was mainly associated with the so called ‘rich and famous’ (Palfai & 
Jankiewicz, 1997, p. 306). The popular image of the cocaine abuser centred on the 
glitter people: Hollywood actors, athletes, artists, jazz musicians, designers, etc. 
although the drug was in all social classes to some extent (ibid). 
 
The 1990s were a turning point, bringing another surge in use, a leap in the practice 
of smoking was reported, and slang terms ‘crack’ and ‘rock’ began to appear in the 
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media (Parker et al., 1998). Crack is a freebased form of cocaine. In making it, the 
original, purer alkaloid (base) is freed from the cocaine hydrochloride by treating the 
crystals with a basic solution – usually water and baking soda. The result is small, 
white chunks of crack that resemble pieces of crumbled soap and that make a 
crackling sound when smoked. This turned out to be a great marketing innovation, 
and a vast improvement over the previous form of freebasing, which involved 
vaporizing the cocaine with hot, potentially explosive gases, such as ether, in a 
device known as base pipe (Ford, 2004). With crack, the freebase was sold 
readymade in small plastic vials containing one or two rocks, and costing ten to 
twenty pounds per rock, depending on the weight (ibid, 2004). This decreased the 
street prices, users could go to the ‘crack house’ more frequently with less money – a 
development that brought crack to the inner city. The small rocks could also be easily 
hidden or disposed of in the event of a police raid (Palfai & Jankiewicz, 1997).  
 
Crack cocaine was used as far as Jersey and as far north as Aberdeen. Crack spread 
to heroin injecting users and was then distributed through heroin dealing networks, 
which made it easily accessible for even more heroin users (Shapiro, 2011). It also 
gained popularity with the dance drug culture/bars and clubs. Over that time, crack 
established itself as one of the main problem drugs in the UK alongside heroin. Until 
2008 the estimated prevalence of crack cocaine users had increased steadily in to 
337,000 (Drug Misuse Declared: Findings from the 2008/09, British Crime Survey, 
Home Office, 2009) Additionally, cocaine powder was estimated to have been used 
by nearly 800,000 people aged 25–59, and 360,000 16–24 year olds (Shapiro, 2011). 
However, between 2009/10 and 2010/11 the national prevalence estimates of opiate 
and/or crack users decreased to 298,752 in 2010/11 (Drug Misuse: Findings from the 
2012/2013 Crime Survey for England and Wales; Home Office, 2013).  
 
The latest Forensic Science service results showed an average purity of 26.4% 
although samples can fall into single figures (Shapiro, 2011). Cocaine purity has 
dropped off considerably over the last decade. DrugScope figures for 2009 revealed 
that cocaine and crack were implicated in 154 deaths, more than any other drug apart 
from heroin, methadone and similar opiate drugs. Overall, cocaine deaths have been 
steadily increasing over the years (Shapiro, 2011). As such, crack use remains visible 
as a serious drug and social problem.  
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I.3. Short- and Long-term Effects of Cocaine and Crack Cocaine 
 
I.3.1. Routes of Administration  
 
Cocaine may be administered by almost any route; a common way of taking cocaine 
is by sniffing (snorting) it (Gay, Sheppard, Inaba & Newmeyer, 1973). A line of 
cocaine hydrochloride (20–30 mg) is laid out and inhaled through a straw and the 
drug is absorbed through the vascular mucous membranes lining the nose (Cox, 
Jacobs, LeBlanc & Marshman, 1983). Because cocaine causes vasoconstriction 
(narrowing of the blood vessels), drug absorption is slowed and there is no rush. 
However, a period of pleasurable stimulation occurs, lasting 20 – 40 minutes 
(Higgins et al., 1990). Intravenous use is popular with some drug users because the 
drug reaches the brain rapidly, and subjective effects, including an intense rush of 
high, are reported within 1 or 2 minutes. They also abate rapidly over the next 30 
minutes or so (Weiss, Mirin & Bartel, 1994). 
 
Purified cocaine base (crack) is usually smoked in a glass water pipe, or it may be 
sprinkled on a tobacco or marijuana cigarette. It produces a sudden, intense high (the 
‘rush’ or ‘flash’) comparable to that produced by intravenous injection, because 
cocaine is absorbed very rapidly by the large surface area of the lungs and reaches 
the brain within seconds (Weiss, Mirin & Bartel, 1994). The euphoria abates equally 
quickly, leaving the person feeling restless and irritable and craving for another dose 
(Palfai & Jankiewicz, 1997).  
 
I.3.2. Effects of Cocaine 
 
Cocaine is a powerful central nervous system stimulant producing increased energy, 
activity, confidence, and facilitating social interchange, and mental alertness, 
especially to the sensations of sight, sound and touch (Gossop, 2007). Some users 
reported that the drug helped them perform simple physical and intellectual tasks 
more quickly, although others have experienced the opposite effect (NIDA, 2010). 
Most important of all, it is a powerful euphoriant, giving the person a great feeling of 
wellbeing (Plant et al., 2011).  
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The physical effects of cocaine include a raised pulse rate, blood pressure and 
temperature, and dilated pupils. In addition to its local anaesthetic properties, it can 
also temporarily decrease the need for food and sleep (NIDA, 2010). 
 
I.3.3. Tolerance  
 
It used to be believed that tolerance to cocaine did not occur and that large doses 
were taken only in a search for greater euphoria, rather than because small doses 
were no longer effective (Fischman, 1984). These observations were based on 
cocaine users who snorted cocaine hydrochloride intermittently, in what was 
described as ‘usual’ recreational doses, which were probably insufficient to induce 
tolerance (Ghodse, 2010). Now that pure cocaine freebase is available, a very 
different picture has emerged. Some users may take large doses – 30g in 24 hours 
has been reported – that would undoubtedly be toxic to a cocaine-naive individual, 
but which the regular user can take without serious complication because of the 
development of tolerance to the hyperthermic, convulsant and cardiovascular effects 
of cocaine (Platt, 1997).  
 
I.3.4. Physical Dependence  
 
A variety of symptoms have been described following cocaine withdrawal by users 
who habitually consume very large doses. The symptoms include lethargy, 
depression, apathy, social withdrawal, tremor, muscle pain and disturbances of eating 
and sleeping. When severe, they form a syndrome known as the ‘crash’ (Gawin & 
Kleber, 1986a), which begins 15 – 30 minutes after a ‘binge’ and which may last for 
a few hours or up to a few days, accompanied by dysphoria and high levels of 
craving (Gawin & Ellingwood, 1990; Schifano, 1996). There may also be excessive 
sleepiness, paranoid ideas, agitation and suicidal thoughts. When this acute phase 
subsides, there is a longer period, lasting for several weeks, when anxiety, craving 
and dysphoria may recur and when the risk of relapse is high. Only later, in the 
‘extinction’ phase, which lasts for 3 – 12 months, do symptoms subside completely 
but, even then, exposure to particular cues may stimulate craving again (Grabowski, 
1984; Margolin, Evants & Kosten, 1996). Despite long-standing opinion to the 
contrary, it is difficult to believe that the crash could be anything but the cocaine 
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abstinence syndrome, although it does not cause the major physiological disruption 
associated with the more familiar abstinence syndromes of opioids, alcohol or 
sedative hypnotics (Platt, 1997). 
 
I.3.5. Psychological Dependence 
 
Cocaine can cause severe psychological dependence, with craving and drug-seeking 
behaviour so intense that the normal pattern of life is disrupted and everything 
becomes subservient to the need to obtain cocaine (Platt, 1997). Until recently, there 
was little evidence that cocaine has such compelling effects in humans and it was 
thought to be a ‘safe’ recreational drug. The advent of pure cocaine freebase has 
dramatically changed this view. Not only has it become apparent that cocaine can 
cause tolerance and physical dependence, but new patterns of consumption of 
cocaine have developed, with freebasers smoking cocaine almost continuously until 
either they or the supply of drug are exhausted (Ghodse, 2010). It has been suggested 
that this pattern of drug use is caused by the high concentrations of cocaine in the 
brain that are achieved by smoking crack, and that last for only a few minutes before 
a rapid decline in concentration occurs. It is possible, for example, that it is the sharp 
contrast between the ‘rush’ and withdrawal that generates the drive to use more drugs 
within a short period (ibid). 
 
I.3.6. Cocaine Toxicity/Psychosis 
 
As the dose and frequency of use of cocaine increase, adverse reactions may occur. 
These start with feelings of anxiety, restlessness and apprehension and progress to 
suspiciousness, hypervigilance and paranoid behaviour. Stimulation of the nervous 
system occurs, causing muscle twitching, nausea and vomiting, increases pulse and 
blood pressure, irregular respiration and sometimes convulsions (Sherer, Kumor & 
Jaffe, 1989). In cases of severe toxicity, this is followed by depression of the nervous 
system with circulatory and respiratory failure, loss of reflexes, unconsciousness and 
death (Shapiro, 2011). 
 
Cocaine psychosis has also been described with persecutory delusions and repetitive 
(stereotyped) behaviour, such as compulsively taking a watch or radio apart and 
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reassembling it or repeatedly tidying or rearranging a set of objects. There may be 
auditory hallucinations and sometimes tactile hallucinations, classically described as 
a sensation of insects crawling under the skin (‘cocaine bugs’) and causing incessant 
picking at the skin, or scratching (Mitchell & Vierkant, 1991; Serper, Chou, Allen, 
Czobor & Canero, 1999). 
 
I.4. Drugs and Drug-Related Behaviours: Terminology 
 
A number of terms to describe drug and alcohol use and one of the consequences of 
this behaviour: addiction or dependence, which have already been used in the text. 
There is a great deal of debate about the meaning of the term ‘addiction’ and 
‘dependence’. It is used in academic circles as well as in everyday discourse 
(Mitcheson et al., 2010). However, as psychologists, wherever possible, we seek to 
describe behaviour and therefore also use the term ‘addictive behaviour’. To be more 
specific, the term ‘substance use problems’ or ‘substance misuse’ will be used to 
indicate that the focus of this thesis is on the problematic use of substances (for 
example, cocaine misuse) not substance use per se. The term ‘substance use 
problems’ includes a range of substance-related difficulties, including addiction, and 
all the generally used diagnostic criteria for dependency and misuse (ibid). The term 
‘substance misuse’ is also used in the context of describing services and with 
reference to the treatment field as this term is commonly used in these contexts 
(ibid). Other terms, such as substance abuse, are used with reference to their use in 
original texts. Whatever one prefers, but one must keep in mind that it is the 
language the client uses that is key. Language, even when technically accurate, can 
alienate and confuse, and medical descriptions in particular can stand in the way of 
sharing intimate experiences (ibid). The next paragraphs will elaborate on the terms, 
drug, drug dependence, psychological dependence and craving, and finally, physical 
dependence and withdrawal syndrome.  
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I.4.1. Definition of the Term - Drug 
 
A drug is ‘any substance, other than those required for the maintenance of normal 
health, which, when taken into the living organism, may modify one or more of its 
functions.’ This very broad definition was developed by the World Health 
Organisation (WHO, 1969), and had the advantage of being used and understood 
internationally. Definitions change with time however and, more recently, the WHO 
has developed a Lexicon of Alcohol and Drug Terms, which acknowledges that 
‘drug’ is a term of varied usage (WHO, 1994). In medicine it refers to any substance 
with the potential to prevent or cure disease or enhance physical or mental welfare, 
and in pharmacology to any agent that alters the biochemical or physiological 
processes of tissues or organisms. Hence a drug is a ‘substance that is, or could be, 
listed in a pharmacopoeia’ (Ghodse, 2010). In common usage, however, the Lexicon 
recognises that ‘drug’ often refers specifically to psychoactive drugs, which are 
separately defined as ‘substances that, when ingested, affect mental processes, i.e. 
cognition or affect’. ‘Psychotropic drug’ is used as an alternative and equivalent term 
for the whole class of substances, licit and illicit, with which drug policy is 
concerned (Palfai & Jankiewicz, 1997). The terms ‘psychoactive drug’ and 
‘psychotropic drug’ share the advantage of being descriptive and neutral (i.e. non-
judgemental). It is also worth noting that, nowadays, ‘substance’ (meaning 
psychoactive substance) is often used as synonymous with ‘drug’. The present work 
is concerned with psychoactive substances, and the term ‘drug’ and ‘substance’ will 
be used interchangeably.  
 
I.4.2. Drug Dependence 
 
Within this definition are two components of very different importance: 
psychological dependence, without which the state of dependence cannot be said to 
exist, and physical dependence, which may or may not be present (Ghodse, 2010). 
Thus an individual may be dependent on a drug without manifesting any physical 
dependence and, conversely, an individual taking drugs that cause physical but not 
psychological dependence, is correctly described as physically dependent, but not as 
drug dependent (ibid). However, in practice, physical and psychological dependence 
are often so closely linked that it can be difficult to make the distinction.  
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Therefore, in line with the approach adopted in The ICD-10 Classification of Mental 
and Behavioural Disorders (WHO, 1992), the WHO’s Expert Committee developed 
the following more modern definition for drug dependence: 
 
A cluster of physiological, behavioural and cognitive phenomena of variable intensity in which the use 
of a psychoactive drug (or drugs) takes on a high priority. The necessary descriptive characteristics 
are preoccupation with a desire to obtain and take the drug and persistent drug-taking behaviour. 
Determinants and the problematic consequences of drug dependence may be biological, 
psychological or social, and usually interact (WHO, 2012, p. 23). 
 
I.4.3. Psychological Dependence, Craving and Drug–Seeking Behaviour 
 
It will be perceived that at the core of the definition of drug dependence lies 
psychological dependence upon the drug. This is a “feeling of satisfaction and a 
psychic drive that requires periodic or continuous administration of the drug to 
produce pleasure or to avoid discomfort” (Eddy, Halbach, Isbell & Seevers, 1965, p. 
723). Psychological dependence is an overriding compulsion to take the drug even in 
the certain knowledge that it is harmful, and whatever the consequences of the 
method of obtaining it. 
 
Craving seems to be a fundamental component of psychological dependence and 
implies a constant preoccupation with the drug, with intrusive thoughts and obsessive 
thinking about the drug related lifestyle and context – particularly its desired effects 
and the need to obtain it (West & Brown, 2013). This in turn may be translated into 
action in the form of drug-seeking behaviour, which may involve literally searching 
for drugs, through different activities, both legal and illegal, to obtain money to buy 
them, identifying the source of supply, purchasing, etc (Preston et al., 2009). When 
craving is severe, drug-seeking behaviour dominates daily activity. 
 
I.4.4. Physical Dependence and the Withdrawal Syndrome 
 
Physical dependence is “an adaptive state manifested by intense physical 
disturbances when the drug is withdrawn” (Eddy et al., 1965, p. 723). Many, but not 
all, drugs cause physical dependence and of those that do, not all are drugs of abuse. 
The development of physical dependence depends on the drug being administered 
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regularly, in sufficient dosage over a period of time; the necessary dose and duration 
of administration depend on the particular drug and may also vary from person to 
person. Also, tolerance may develop over time which is a reduction in the sensitivity 
to a drug following its repeated administration in which increased doses are required 
to produce the same magnitude of effect previously produced by a smaller dose 
(WHO, 1993). 
 
In the condition of physical dependence, the body becomes so ‘used’ or accustomed 
or adapted to the drug that there is little, if any, evidence that the person concerned is 
taking it (Eddy et al., 1965). However, sudden drug withdrawal is followed by a 
specific array of symptoms and signs collectively known as the withdrawal or 
abstinence syndrome (Palfai & Jankiewicz, 1997). The nature of the withdrawal 
syndrome is characteristic of each drug type, and the symptoms and signs tend to be 
opposite in nature to the effects of the drug when it is acutely administered (Eddy et 
al., 1965). Thus, physical dependence on a stimulant drug such as cocaine is 
manifested by drowsiness, apathy and depression when drug administration ceases. 
The withdrawal syndrome associated with cocaine was briefly described in the 
section on psychological and physiological dependence on cocaine. 
 
Physical dependence is sometimes confused with the more general term of drug 
dependence, the WHO Expert Committee decided to focus on the phenomenon of 
abstinence and to use the term ‘withdrawal syndrome’, which is described in terms of 
its consequences: 
 
After the repeated administration of certain dependence producing drugs, e.g. opioids, barbiturates 
and alcohol, abstinence can increase the intensity of drug-seeking behaviour because of the need to 
avoid or relieve withdrawal discomfort and/or produce physiological changes of sufficient severity to 
require medical treatment (WHO, 1993, p. 5). 
 
 
I.5. Causes of Drug Use and Dependence  
 
The cause or causes of drug dependence are not known. More specifically, it is not 
known why some people but not others in the same situation start experimenting with 
drugs, or why some but not others then continue to take them and, finally, why some 
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but not all become dependent on drugs (Ghodse, 2010). A vast range of dependence 
behaviour exists today; for example, the young drug abuser taking a wide range of 
drugs; the housewife dependent on benzodiazepines; the Middle Eastern opium 
smoker; the American freebasing cocaine; the mystic seeking truth with LSD; the 
doctor self-injecting with pethidine, to describe just a few (ibid). These many 
different scenarios of psychoactive drug consumption can be summarised in four 
categories which are not mutually exclusive: traditional/cultural, medical/therapeutic, 
social/recreational and occupational/functional. For example, drug consumption may 
start with a prescription for a diagnosed condition but may continue illegally; or 
stimulant drugs, taken initially to promote alertness when studying, may be 
continued purely for recreational purposes (ibid).  
 
The social, cultural and even historical contexts in which a substance is taken can 
significantly affect both the drug experience and consequences of use for any one 
person or group of people (Keenan, 2004). “Substance use is fundamentally a social 
act—we obtain, consume, and construct the experience of using alcohol or other 
drugs in relation to others. The rituals associated with the consumption of alcohol 
and other drugs are an important part of creating meaning in relation to this 
behaviour” (Keenan, 2004, p.65). The media, cultural and religious practices, 
workplaces, families and friends, as well as the legal and health care systems, are all 
part of the spectrum of influences creating our beliefs and actions associated with 
substance use. 
 
It is perhaps not surprising, therefore, that there are almost as many theories about 
dependence and its causes as there are types of dependence behaviour. The first 
comprehensive review of more than 40 theories of drug use and dependence was 
published in 1980 by the American National Institute on Drug Abuse (NIDA) (see 
Lettieri, Sayers & Pearson, 1980). The number of theories proposed today is even 
greater than this number (see Blane & Leonard, 1987; Baker 1988; Goode, 2011; 
West & Brown, 2013). Within a diversity of approaches and different models, three 
factors – the individual, the society and the drug – interact to lead to a variety of 
drug-related behaviours (Mitcheson et al., 2010). These factors can be translated into 
four main theories: (1) biological theories, (2) psychological theories, and (3) 
sociological theories; none of them alone is sufficient to cause drug misuse or 
 49 
dependence and their relative importance varies in different circumstances (ibid). 
Most cover different aspects of the same phenomenon and may be regarded as 
complementary rather than contradictory (Seivewright, 2009). Of course, even within 
each broad type, there is a range of specific theories. All biological theories, and 
nearly all psychological theories, are individualistic in that they focus on differences 
between and among people. In contrast, most sociological theories tend to focus not 
on individual differences but group or category differences (persons belonging to 
group X are different from persons belonging to group Y), or structural differences 
(the larger structures or circumstances in which persons are located differ, such as 
cities, neighbourhoods, time periods, social conditions, or countries) (Goode, 2011). 
Further, macro processes may or may not be relevant to micro phenomena, and vice 
versa; accounting for drug experimentation may say nothing about dependence; 
explaining alcohol dependence may say next to nothing about heroin dependence; 
subcultural and biological processes may operate alongside psychodynamics, and so 
on (Goode, 2011).  
 
Therefore, it is accepted that no theory or model in a single sphere can 
comprehensively explain addiction and that any understanding of addiction comes 
from looking at the interaction between the biological, psychological and social 
spheres (Mitcheson et al., 2010). Accordingly, there is general consensus, also shared 
by the present thesis, that addiction is a biopsychosocial phenomenon (Wanigaratne, 
2006).  
 
 
I.6. Psychosocial, Pharmacological and Abstinence-Oriented 
Interventions to Crack Cocaine Use 
 
I.6.1. Current UK Treatments for Crack Cocaine Use  
 
Psychosocial approaches to the treatment of drug misuse have been the subject of 
much research and debate over the years (Wanigaratne, Davis, Pryce & Brotchie, 
2005). Such approaches vary depending on the theoretical model underpinning them 
but are broadly based on the use of the interaction between therapist and client to 
elicit changes in the client’s behaviour (for example, drug use), as well as other 
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related factors including cognition and emotion (NICE, 2008). Despite the recent 
increase in research on psychosocial treatments, current UK practice is not 
underpinned by a strong evidence base and there is wide variation in the uptake and 
implementation of psychosocial approaches to treatment across services (ibid). A 
number of factors may contribute to this situation. First, the emphasis in many 
community based opiate treatment services is based on pharmacological management 
and supportive case coordination, with practice tending to be influenced more by the 
background and training of those delivering treatment within services than what 
research has shown to be effective. Second, a considerable amount of the evidence is 
extrapolated from other substance misuse problems (predominantly alcohol misuse) 
or other healthcare systems, for example, the US or Australia and, inevitably, this 
raises questions about the applicability of the evidence to UK drug misuse services. 
Third, there has been weak dissemination of the evidence base concerning 
psychosocial interventions until recently (Wanigaratne et al., 2005; NICE, 2008). 
Fourth, the limited availability of appropriately trained therapists also contributes 
significantly to variable access to such services in the UK (Lovell, Richards & 
Bower, 2003; NICE, 2008).  
 
The National Institute for Health and Clinical Excellence published one technology 
appraisal (NICE, 2007a) and one national clinical practice guideline (NICE, 2008) on 
a range of drug treatment interventions, which endorse much of the mainstream 
psychosocial drug treatment provided in the UK as evidence based. These guidelines 
recommend (unstructured and structured) psychosocial interventions as the mainstay 
of treatment for crack cocaine use.  
In the US, the ‘National Institute on Drug Abuse’ (NIDA) also discusses 
pharmacotherapies as possible treatment options, several medications (e.g. modafinil, 
dexamphetamine, topiramate) have been reported to reduce cocaine use in controlled 
clinical trials (Castells et al., 2010; Nuijten et al., 2011). Furthermore, NIDA is 
funding research endeavours to identify and test new medications, including a 
vaccination to treat cocaine dependence safely and effectively (NIDA: Research 
Report Series, 2010). These interventions are not recommended by the NICE 
guidelines. However, there are trials underway, for example, the multi-site trials, 
‘Cocaine Dependence Treatment with Modafinil & Voucher-based Reinforcement 
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Therapy’ (COMBAT), in NHS drug treatment services, to test the effectiveness of 
modafinil with crack misuse within the opiate maintained population. Hence, for the 
sake of rigour and completeness, a section on pharmacotherapies is provided in this 
review.  
 
The forthcoming section outlines psychosocial, pharmacological and abstinence-
oriented interventions and its evidence base, which are endorsed by the NICE 
guidelines. These include the following: motivational interviewing and the model of 
change, cognitive behavioural therapies (including relapse prevention therapy), 
family based interventions, self-help groups (i.e. 12 step approaches), 
pharmacological treatments, detoxification and residential rehabilitation. Although 
non-residential 12 step programs are not considered to be a form of treatment per se, 
elements of the 12 step approaches are frequently incorporated in individual and 
group psychosocial interventions, residential rehabilitation and many health workers 
recommend the simultaneous attendance of self-help groups (Williams, 2007). Hence 
a short outline is included in this section. Additionally, it should be mentioned that 
the NICE guidelines (NICE, 2007) recommend the implementation of contingency 
management for stimulant drug use in UK treatment services, this will be covered in 
detail in section I. 7 Contingency Management. 
 
I.6.2. Motivational Interviewing and Model of Change 
 
Until the 1980s, the usual therapeutic way of dealing with ‘unmotivated’ clients was 
a confrontational approach, which was thought to be necessary to overcome the 
resistance of the client, the ‘pathological denial’ of substance use, and the perceived 
inherent lack of motivation about changing substance use. These characteristics were 
often seen as inherent qualities of the clients themselves (Davies & Petersen, 2007). 
Around 1980, a new style of interviewing substance misusing people who were 
ambivalent about change emerged (Miller, 1983). In Miller’s view, the interaction 
between the client and the therapist is critical in changing the ambivalence of 
changing substance abuse: the way clients are addressed by their therapists can either 
enhance or reduce motivation to change (ibid). 
 
 52 
Ambivalence about changing drug use behaviour is a common reason for treatment 
failure, which may be particularly salient for psychostimulant users who have 
difficulty entering and remaining in treatment. Motivational interviewing (MI) is a 
technique that was developed when William Miller applied the principles of the 
Rogerian client-centred approach to alcohol-dependent clients (Miller, Benefield & 
Tonigan, 1993). Miller and Rollnick (2002) define MI as “a client-centred, directive 
method for enhancing intrinsic motivation to change by exploring and resolving 
ambivalence” (p. 25). MI involves the application of four basic principles: (1) 
expressing empathy through techniques such as reflective listening, (2) developing 
discrepancy between the client's self-image as a drug user and other preferred non-
drug-using self-images, (3) ‘rolling with resistance’ and avoiding argumentation, and 
(4) supporting self-efficacy or the client's personal sense of ability to change (Miller 
& Rollnick, 2002). MI relies upon counselling microskills, described in Rogers' 
client-centred approach, including open-ended questions, reflective listening, 
affirmations, and summarising (Egan, 1998). Various strategies may be used, 
depending on the client's circumstances (Jarvis, Tebbutt, Mattick & Shand, 2005). 
These include exploring the positive and the negative points about drug use, 
exploring the client's concerns, and looking back to past expectations and looking 
forward to future hopes. MI can be delivered in two phases; the first builds the 
client's motivation to enter treatment, and the second seeks to strengthen treatment 
adherence including compliance to prescribed medication (Zweben & Zuckoff, 
2002). 
 
A useful model for understanding motivation and, specifically, how behaviour 
change occurs is Prochaska & DiClemente’s (1982) stages of change model, which 
has become known as the transtheoretical model of change. This stages of change 
model postulates that people progress through five stages when changing behaviours. 
The continuum includes the stages of ‘precontemplation,’ in which a person does not 
recognise a behaviour as problematic; ‘contemplation,’ in which a person begins to 
consider that a behaviour pattern might be problematic; ‘determination’ or 
‘preparation,’ during which the individual resolves to change; and ‘action,’ in which 
a person initiates active behaviours to deal with the problem. Following ‘action’ is 
‘maintenance’, if the behavioural change was successful, or ‘relapse’, if the person 
returns to the problematic behaviour. In the words of Prochaska and DiClemente 
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(1984): “Therapy with addictive behaviours can progress most smoothly, if both the 
client and the therapist are focusing on the same stage of change” (p. 6). For 
example, for persons at the precontemplative stage, motivational enhancement 
therapies or contingency management approaches promote therapeutic engagement, 
increased readiness, and movement toward the action stage. Offering active 
treatments (that is, those directed at achieving and stabilizing abstinence) at this 
juncture is premature, poorly received, and likely to be met with noncompliance 
(Chaney, O'Leary & Marlatt, 1978; Prochaska & DiClemente, 1986; Prochaska & 
Norcross, 2006). 
  
The stages of change model is an extremely popular concept in addiction research 
and has been widely adapted in clinical settings as a heuristic for understanding 
motivation and, more specifically, readiness for change (Emmelkamp & Vedel, 
2006). MI was found to be a useful adjunct to methadone treatment in opiate users 
(Saunders et al., 1995). Drug users (N = 122) received either motivational 
interviewing or psychoeducation. At six months follow-up, the clients who had 
received motivational interviewing showed less relapse than the clients in the control 
condition. Since then, another 15 randomised controlled trials demonstrated the 
feasibility of motivational interviewing for the drug dependent population, including 
cocaine dependent adults (Rohsenow et al., 2004; Secades-Villa et al., 2004). Most 
studies found that motivational interviewing led to better adherence and increased 
motivation, but only a few studies found that motivational interviewing led to 
decreased drug use or abstinence. However, not all studies supported the incremental 
value of motivational interviewing. In four studies the addition of motivational 
interviewing did not enhance treatment effectiveness in polydrug users (Booth, Corsi 
& Mikulich-Gilbertson, 1998; Schneider et al., 2000; Miller et al., 2003) and in 
cocaine dependent clients (Donovan et al., 2001). With drug use, there is some 
evidence that motivational interviewing is more effective for those who are 
ambivalent or not yet motivated to change substance use than for those already 
motivated. Two studies among cocaine dependent populations have supported the 
view that MI conveys the greatest benefit to clients with low initial motivation to 
change (Stotts et al., 2001; Rohsenow et al., 2005). These studies also suggested that 
MI could be counter-productive among more committed clients, whose drug use and 
treatment compliance outcomes actually appeared to deteriorate. As noted by the 
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authors, “It might be that the more permissive message used in Motivational 
Enhancement Therapy is maladaptive for the more motivated who may be impatient 
for a more directive approach” (Rohsenow et al., 2004, p. 872). 
 
Two meta-analyses (Burke et al., 2002; Hettema et al., 2005) analysed the data of 
clinical trials into the effects of motivational interviewing, not only on substance 
misuse but also on health behaviour. MI was equivalent to active treatments and 
superior to no-treatment or placebo controls for problems involving alcohol and drug 
use, and overeating. MI resulted in a medium effect size in studies with drug 
dependence and in small to medium effect size in the area of alcohol addiction. 
 
A large multi-site randomised clinical trial by Carroll et al. (2006) examined the 
effectiveness of integrating MI into the intake procedures of community drug 
treatment programmes (Carroll et al., 2006). Although MI significantly improved 
programme retention 1 month post enrolment compared with standard intake 
counselling, there were no differences in drug use across conditions. Primary cocaine 
and methamphetamine users comprised around a quarter of the sample (half of the 
subjects were primary alcohol users), and no detailed analyses for the stimulant 
subgroups were available. The lack of effect on substance use outcomes and longer 
term retention should be viewed in the overall context of high retention and good 
outcomes achieved at participating treatment centres.  
 
I.6.3. Cognitive Behavioural Therapy 
 
The application of cognitive-behavioural theory to substance misuse is relatively 
recent. For most of the 20th century until the mid-1980s, the field of psychotherapy 
and psychological counselling largely ignored drug use, viewing it as a superficial 
symptom of more important underlying problems. As substance misuse became more 
widely recognised, interest in developing effective treatments increased 
(Emmelkamp & Vedel, 2006).  
 
A wide diversity of treatment approaches fall under the umbrella of cognitive 
behavioural therapies (CBT), including relapse prevention techniques (see Marlatt & 
Gordon, 1985). All variants of CBT are grounded on social learning theories 
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(Bandura, 1986) and principles of classical and operant conditioning (Mitcheson et 
al., 2010). Cognitive behavioural therapy has developed from Aaron Beck’s (1963, 
1964, 2005) research and is an ‘active, directive, time-limited treatment’ that focuses 
on identifying a person’s thoughts, beliefs, attitudes and assumptions that may be 
impeding positive behavioural change. Beliefs and assumptions that the person holds 
may be distorted (during childhood and learning experiences as an adult) and, as a 
result, the person may have negative beliefs which predispose, for example, towards 
low self-esteem or the continued use of substances. Not all thoughts or beliefs may 
support substance misuse. The individual may at times experience a degree of 
conflict between beliefs that support continued consumption and those that support 
abstinence. The number and strength of thoughts from each side of the argument will 
determine the individual’s behaviour at any one time. Ironically, these conflicts may, 
in themselves, make the individual feel uncomfortable and increase the risk of 
substance misuse (Bennett, 2007).  
 
Among psychostimulant users, CBT aims to help clients recognise and understand 
drug related problems and assists them to restructure or modify dysfunctional 
cognitions that may be perpetuating the problem behaviour (Baker, Gowing, Lee & 
Proudfoot, 2004; Mitcheson et al., 2010). The key active ingredients of CBT include 
(1) functional analysis; which explores the patient's4 thoughts, feelings, and 
understanding of drug use within the context of its antecedents and consequences; (2) 
individually tailored training in relapse prevention skills; (3) monitoring thoughts 
about drugs; (4) identifying high-risk situations for relapse; (5) extra-session skills 
implementation (‘homework’); and (6) within-session skills practice (Carroll, 1998). 
Putting these various elements together, substance use is initiated by the presence of 
either external or internal cues. These trigger both core and addictive beliefs. When 
the preponderance of thoughts supports consumption, these instigate cravings to use 
a substance. This is then maintained or ceased either by physical incapacity or further 
cognitive processes (Caroll & Onken, 2005).  
 
                                                
4 It is recognised that there are real and important arguments about the relative merits of the terms 
‘client’ or ‘patient’ in psychotherapy. However, for simplicity, patient and client will be used 
throughout this portfolio interchangeably. 
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With respect to empirical evidence, investigators have not made clear distinctions 
between the different cognitive behavioural approaches in substance misuse. Hence 
meta-analyses frequently summarise the outcome of different therapeutic approaches 
including relapse prevention, which makes it difficult to ascertain the key active 
components. Yet, it seems clear from reviews that the effectiveness of CBT in the 
case of substance dependence and misuse appears to be substance-specific 
(Mitcheson et al., 2010). This means that CBT is differentially effective in the 
treatment of different substances. Reviews such as by Morgenstern and Longabaugh 
(2000) and Miller and Wilbourne (2002) investigating alcohol misuse, Carroll et al. 
(2004) studying disulfiram and CBT, and finally, Wanigaratne et al. (2005) and Irvin 
et al. (1999) researching alcohol and drug misuses are all illustrative examples. In 
terms of stimulant misuse, CBT has not been shown to be better than any other form 
of psychosocial intervention in initiating abstinence (Gowing et al., 2001; Rawson et 
al., 2006; Mitcheson et al., 2010). Furthermore, randomised controlled efficacy trials 
of cognitive behavioural therapies for stimulant misuse have not, so far, indicated 
strong effects compared to control groups at follow-up (Gossop, Stewart, Browne & 
Marsden, 2003). 
 
A meta-analysis of 26 clinical trials found CBT to be generally effective in reducing 
drug use and improving psychosocial functioning, although results were significantly 
better for alcohol and polydrug use than cocaine or tobacco (Irvin et al., 1999). CBT 
was also more effective when combined with medication, although this finding was 
based on only four trials (three in alcohol, one in cocaine) (ibid). A subsequent 
promising report of combined CBT and naltrexone in cocaine dependence was not 
replicated in dual dependence on cocaine and alcohol (Schmitz et al., 2001; Schmitz 
et al., 2004). An earlier qualitative meta-review of 24 RCTs found CBT to be more 
effective than no treatment but equally as effective as other treatment approaches 
(Carroll, 1996). In contrast to the meta-analysis published by Irvin et al., Carroll did 
not find that efficacy varied by drug type, although both reviews used the same three 
cocaine studies. Closer examination of these three studies showed only selective and 
modest support for the effectiveness of CBT. In the first study by Carroll, 
Rounsaville and Gawin (1991), the benefit of CBT over Interpersonal Psychotherapy 
(IPT) did not reach significance except in a subgroup of more severe users. Their 
second study (Carroll, Rounsaville, Nich et al., 1994) found improved outcomes for 
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CBT over case management only at 1-year follow-up, and this would not have been 
included in the meta-analysis by Irvin et al. The third study (Wells, Peterson, Gainey, 
Hawkins & Catalano, 1994) was a negative report when CBT was compared with 12 
step based counselling where no difference was found in either treatment retention or 
cocaine use. Subsequent comparisons of individualised CBT with standard group 
counselling found no additional benefit for CBT except in patients already 
committed to complete abstinence (McKay et al., 1997; 1999). 
 
In brief, cognitive behavioural approaches do not appear to be effective treatment 
options for stimulant users undergoing methadone maintenance treatment. The 
majority of trials found no benefit in comparison with control groups for abstinence 
and reduction in illicit stimulant use in opiate maintenance clients (NICE, 2008). 
Thus the NICE clinical guidelines (2008) do not recommend CBT as the first line of 
treatment for stimulant use. However, there was some evidence that standard CBT 
may be beneficial for a sub-sample who experienced high levels of psychiatric 
comorbidity (NICE, 2008).  
 
I.6.4. Behavioural Couples and Family Therapy 
 
Historically, the treatment community and the public at large have viewed alcohol 
and drug misuse as individual problems most effectively treated on an individual 
basis. However, during the last three decades, professionals and the public have 
come to recognize family members’ potentially crucial roles in the origins and 
maintenance of addictive behaviour (Fals-Stewart, O’Farrell & Birchler, 2004; 
O’Farrell & Fals-Stewart, 2006). Treatment providers and researchers alike have 
begun conceptualizing substance misuse from a family systems perspective and 
treating the family as a way to address an individual’s substance misuse (Fals-
Stewart, O’Farrell & Birchler, 2004; O’Farrell & Fals-Stewart, 2006). 
 
The defining feature of couples and family therapy is that drug users are being 
treated in the context of family and social systems in which substance use may 
develop or be maintained. Behavioural couples therapy (BCT) can be seen as a 
variant of family therapy, used for clients who have an established relationship with 
a drug-free partner (Velleman & Templeton, 2007; Ruff et al., 2010). Three 
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theoretical perspectives have come to dominate family based conceptualisations of 
substance misuse and thus provide the foundation for the treatment strategies most 
often used with substance users (for a more detailed review of these approaches, see 
Fals-Stewart, O’Farrell & Birchler, 2003). 
 
• The family disease approach, the best known model, views substance misuse as 
illnesses of the family, suffered not only by the substance abuser, but also by family 
members, who are seen as co-dependent. Treatment consists of encouraging the 
substance misusing client and family members to address their respective disease 
processes individually; formal family treatment is not the emphasis (Fals-Stewart, 
O’Farrell, & Birchler, 2004). 
 
• The family systems approach, the second widely used model, applies the principles 
of general systems theory to families, paying particular attention to the ways in 
which family interactions become organised around alcohol or drug use and maintain 
a dynamic balance between substance use and family functioning (Emmelkamp & 
Vedel, 2006). Family therapy based on this model seeks to understand the role of 
substance use in the functioning of the family system, with the goal of modifying 
family dynamics and interactions to eliminate the family’s need for the substance 
misusing client to drink or use drugs (Emmelkamp & Vedel, 2006). 
 
• A third set of models, a cluster of behavioural approaches (for example, 
behavioural couples therapy), assumes that family interactions reinforce substance 
misusing behaviour. Therapy attempts to break this deleterious reinforcement and 
instead foster behaviours conducive to abstinence (Fals-Stewart, O’Farrell & 
Birchler, 2004; Ruff et al., 2010). 
 
Behavioural Couples Therapy (BCT) is typically used with substance using clients 
and their partners. The causal connections between substance use and relationship 
discord are complex and reciprocal. Couples in which one partner abuses drugs or 
alcohol usually also have extensive relationship problems, often with high levels of 
relationship dissatisfaction, instability (for example, situations where one or both 
partners are taking significant steps toward separation or divorce), and verbal and 
physical aggression (Fals-Stewart, Birchler, & O’Farrell, 1999; O’Farrell & Fals-
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Stewart, 2006). Relationship dysfunction in turn is associated with increased 
problematic substance use and post-treatment relapse among alcohol and drug users 
(Maisto et al., 1988). Thus, substance use and marital problems generate a 
‘destructive cycle’ in which each induces the other. 
 
In the perpetuation of this cycle, marital and family problems (for example, poor 
communication and problem solving, habitual arguing, and financial stressors) often 
set the stage for excessive drinking or drug use. There are many ways in which 
family responses to the substance misuse may then inadvertently promote subsequent 
use (Fals-Stewart, O’Farrell & Birchler, 2004; O’Farrell & Fals-Stewart, 2006). In 
many instances, for example, substance misuse serves relationship needs (at least in 
the short term), as when it facilitates the expression of emotion and affection through 
caretaking of a partner suffering from a hangover. Recognising these 
interrelationships, BCT and family-based treatments for substance misuse in general 
have three primary objectives (Fals-Stewart, O’Farrell & Birchler, 2004; Ruff et al., 
2010): 
• To eliminate alcohol and drug misuse 
• To engage the family’s support for the client’s efforts to change 
• To restructure couple and family interaction patterns in ways conducive to 
long-term, stable abstinence 
Its main components are focused on current behaviour. In BCT, the drug user states 
each day her/his intention not to use illicit drugs, and the partner expresses daily their 
support for their partner’s efforts to stay abstinent (Emmelkamp & Vedel, 2006). It 
also aims to teach more effective communication skills, such as active listening and 
expressing feelings directly, and increases positive behavioural exchanges between 
partners by encouraging them to acknowledge positive behaviours and engage in 
shared recreational activities (Emmelkamp & Vedel, 2006; Ruff et al., 2010).  
BCT attempts to create a constructive cycle between substance use recovery and 
improved relationship functioning through interventions that address both sets of 
issues concurrently (Fals-Stewart et al., 1996, 2000). BCT can be conducted in 
several formats and delivered either as a stand alone intervention or as an adjunct to 
individual substance misuse counselling. In standard BCT, the therapist sees the 
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substance misusing client and his or her partner together, typically for 15 to 20 
outpatient couple sessions over 5 to 6 months. However, under some circumstances, 
therapists may administer group behavioural couples therapy (GBCT), treating three 
or four couples together, usually over 9 to 12 weeks (Fals-Stewart, O’Farrell & 
Birchler, 2004; Ruff et al., 2010).  
 
In regard to the research evidence, comparing behavioural couples therapy 
(consisting of group, individual and behavioural couples therapy sessions) with an 
equally intensive individual based treatment condition, those couples receiving 
behavioural couples therapy reported less substance use, longer periods of 
abstinence, and higher relationship satisfaction. However, differences disappeared 
during follow-up and were no longer significant one year after treatment (Fals-
Stewart et al., 1996, 2000; O’Farrell & Fals-Stewart, 2006).  
 
In the treatment of substance using clients entering methadone maintenance 
treatment, Fals-Stewart et al. (2001) compared methadone maintenance with CBT or 
in combination with BCT among 36 substance abusing men. Clients in the BCT 
treatment condition had fewer opiate- and cocaine-positive urine samples during 
treatment when compared to clients in the standard treatment condition and at post-
treatment, reported higher levels of dyadic adjustment and a greater reduction in drug 
use severity (Fals-Stewart et al., 2001; Ruff et al., 2010). 
 
A possible disadvantage of behavioural couple therapy is that it is best applied by a 
relatively highly skilled clinician who not only has a clear understanding of the 
cognitive behavioural conceptualisation of substance use, but also has skills in 
working with couples and is able to move partners toward productive behavioural 
change (Fals-Stewart & Birchler, 2002). Comparing master’s level counsellors 
versus bachelor’s level counsellors in the treatment of BCT, Fals-Stewart and 
Birchler (2002) found adherence ratings among counsellors to be similar, but 
competence of treatment delivery to be superior from master’s level counsellors.  
 
The National Clinical Practice Guidelines (NICE, 2008) for psychosocial 
interventions recommend that behavioural couples therapy should be considered for 
people who are in close contact with a non-drug misusing partner and who present 
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for treatment of stimulant or opiate misuse (including those who continue to use 
illicit drugs while receiving opiate maintenance treatment or after completing opiate 
detoxification).  
 
I.6.5. Self-Help Groups: Twelve Step Approaches 
 
The concept of self-help, in the sense of mutual help within a community, is a 
traditional and valued approach to many problems. With the changing structure of 
society, due to increased mobility and the loosening of family ties, this type of 
community support seems to occur less easily and more rarely, and more formal self-
help groups (SHG) have emerged to fill the void (Ghodse, 2010).  
 
A self-help group is a group of individuals with similar problems who meet together 
voluntarily to help each other to help themselves. In the field of substance 
dependence, the best known SHG is Alcoholic Anonymous (AA; was founded in the 
US in 1935 and 1947 in the UK), followed by Narcotics Anonymous (NA; US in 
1953 and UK in 1980) (White, 1980 see NICE full guidelines) and Cocaine 
Anonymous (CA; US in 1982 and UK in 1992) (Cocaine Anonymous UK, 2013). 
These are international fellowships or societies for recovering addicts who meet 
regularly to help each other to stay abstinent from drugs or alcohol. Non-residential 
12 step programmes are not considered to be a form of treatment per se but may 
assist treatment maintenance (Jarvis et al., 2005). 
 
Alcoholic Anonymous was founded by Bill Wilson and Bob Smith. They formulated 
the 12 steps and principles of AA from their own experiences of maintaining sobriety 
by sharing with others when they had not managed to do this alone (Williams, 2007). 
The book describing all this, Alcoholic Anonymous, published in 1939 is the core text 
of AA, affectionately known by members, as the ‘the Big Book’ (Sussman & Ames, 
2001). The fellowships or societies for recovering addicts meet regularly to help each 
other to stay abstinent from drugs or alcohol. They are open to anyone with any type 
of drug/alcohol problem, and the only requirement for membership is the desire to 
stop using drug/alcohol. The approach is grounded in the concept of addiction as a 
spiritual and medical disease, a disease that, according to this approach, can be 
controlled but never cured (Yoder, 1990).  
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The movement is abstinence based but because addiction is viewed as a pattern of 
thinking and behaviour, recovery is not only about abstinence from a substance 
(Sussman & Ames, 2001). ‘Sobriety’ is seen as the development of a healthier 
attitude to oneself and others. In AA the state of ‘abstinence’ without ‘sobriety’ is 
often called being ‘dry drunk’ (Yoder, 1990). As relapse commonly occurs as a 
response to painful emotions (fear, anger, guilt, etc.) and emphasis is placed on 
learning to cope with these feelings and on lessening these by changing thinking in 
ways that enhance feelings of acceptance and wellbeing or ‘serenity’ (Sussman & 
Ames, 2001). Recovery is achieved by attendance at meetings and ‘working the 
programme’ with the mutual support of others who are trying to do the same. 
 
The 12 step approach has elements common to other approaches. The belief that 
changed attitudes aid recovery may be seen as analogous with the principles of 
cognitive behavioural therapy (Williams, 2007). Similarly the use of slogans, short 
soundbites which aim to provide the individual with reassurance and a reminder of 
their goals, is similar to some techniques used in CBT. The non-judgmental 
philosophy is akin to the person centred approach of Carl Rogers (1951). Social 
learning theory (Bandura, 1977) suggests that behaviour is guided by expected 
consequences. Vicarious learning can influence the individual. The use of a sponsor 
as a role model is a form of positive learning (Sussman & Ames, 2001). Efficacy 
expectations are as important as outcome expectations. The structured building of 
esteem in the 12 steps includes the regular contact with others who are also 
‘succeeding’ and may generate a belief that success is possible. Azjen and Fishbein 
(1980) claim that behaviour is influenced by the belief a person has about that 
behaviour and how strongly they feel that belief to be true, as well as the individuals’ 
perceptions of what other people (that they value) will think of their behaviour. 
Where the individual values the members of the group, s/he will want to behave in 
ways that make her/him be accepted (Williams, 2007).  
 
The Minnesota Model is an adaption of the 12 step programme used in some 
specialist treatment settings. This treatment model uses the principles and tools of the 
12 step movement in a professional treatment context, alongside other treatment 
methods (Williams, 2007). Most treatment centres are residential. They have some 
overlap with broader therapeutic community approaches in that everyone is 
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encouraged to be part of the practical running of the house and decision making. 
Members are encouraged to use the support of others in the community to seek 
feedback and challenge unhealthy attitudes and behaviours, with staff help as 
necessary. Programmes typically involve a combination of group therapy, 
counselling, lectures and video-audio material (Williams, 2007). There may be ‘share 
sessions’ from recovering ex-residents and participants are encouraged to attend 
relevant local 12 step meetings. 
 
Research data in relation to 12 step programmes has historically been notoriously 
difficult to obtain (Williams, 2007). Although it is appearing more often in 
contemporary literature, methodological challenges still remain, the main difficulties 
being the anonymity of group members and self-selecting nature of the organisation. 
While 12 step self-help groups are typically recommended for drug dependent clients 
as well, few studies separate individuals dependent on alcohol alone from those with 
drug dependence as their primary problem (Sussman & Ames, 2001). Benefits of 12 
step affiliation have been reported among samples of alcohol and/or drug users 
combined (Christo & Franey, 1995; Miller & Hoffmann, 1995; Ouimette, Moos & 
Finney, 1998; Toumbourou, Hamilton, U'ren, Stevens-Jones & Storey, 2002; Moos 
& Timko, 2008) and drug users (Fiorentine & Hillhouse, 2000; Moos & Timko, 
2008). In the Collaborative Cocaine Treatment Study (Crits-Christoph et al., 1999; 
Crits-Christoph et al. 2003), nearly five hundred clients were randomised to 12 step 
oriented individual therapy, individual cognitive-behaviour therapy, individual 
emotional-supportive therapy, or group drug counselling. In terms of drug use at one-
year follow-up, the 12 step individual therapy was the most effective. In one large 
study (Moos, Finney, Ouimette, Suchinsky, 1999), the effectiveness of cognitive 
behaviour therapy and 12 step approaches was compared in over two thousand male 
veterans treated as inpatients for their substance use (36% for alcohol, 13% for drugs, 
51% for both alcohol and drugs). Both treatments were found to be equally effective 
at one-year follow-up after discharge, the only notable exception being percentage of 
abstinence (Moos et al., 1999). At one-year follow-up, 45% of the 12 step clients 
reported being abstinent from alcohol and drugs, as compared to 36% of clients in 
the cognitive-behaviour therapy programmes. 
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A study by Wells and colleagues (1994) found 12 step counselling equally effective 
as relapse prevention (Wells et al., 1994). In 2005, a study by Weiss and colleagues 
examined treatment for individuals with cocaine dependence and found that active 12 
step involvement in a given month predicted less cocaine use in the next month. 
Clients who received counselling and increased their 12 step SHG participation in 
the first 3 months of treatment had the best drug use outcomes at the end of treatment 
(Weiss et al., 2005). Moreover, the study showed that participation in treatment and 
participation in SHGs have independent effects on substance use outcomes and tend 
to augment each other. Clients who regularly engaged in 12 step activities but 
attended meetings inconsistently had better drug use outcomes than did patients who 
attended consistently but did not regularly engage in 12 step activities. Similarly, 
longer episodes of treatment and weekly or more frequent SHG attendance during 
and after treatment were each independently associated with 6 months abstinence 
(Fiorentine & Hillhouse, 2000a). Maintaining passive attendance may indicate 
reluctance to fully embrace 12 step group ideology and the goal of abstinence. 
Individuals who attend SHGs but are unable to embrace key aspects of the 
programmes are less likely to benefit from it (Shearer, 2007). 
 
I.6.6. Pharmacological Treatment 
 
The modest results of psychosocial treatments and the increasing knowledge about 
the neurobiology of cocaine dependence have led to an increasing number of studies 
searching for effective pharmacological agents that influence the neurochemistry of 
cocaine, including antipsychotics, anticonvulsants, antidepressants, psychostimulants 
and (other) dopamine agonists (Preti, 2007; Karila et al., 2008; Castells et al., 2010; 
Nuijten et al., 2011). Despite the considerable efforts in this field, there are no 
proven effective pharmacotherapies for cocaine dependence to date, and the testing 
of new medications for cocaine dependence continues to be high on the research 
agenda. Basically, the research efforts are focused on two pharmacological strategies 
(APA, 2007): one directed at abstinence from - or at least substantial reduction of - 
cocaine use and the other directed at minimizing cocaine-related harm by replacing 
short-acting, illicit cocaine by a long acting, legal stimulant that can be taken orally 
(Shearer et al., 2004; Ross et al., 2009; Herin et al., 2010). Concerning the first 
strategy, from the wide range of medications tested, topiramate and modafinil are 
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examples of new medications that are currently only registered for indications other 
than cocaine dependence, but have shown some beneficial effects in several studies 
in cocaine dependent populations in terms of abstinence or stimulant use reduction 
(Ballon et al., 2006; Castells et al., 2007; Alvarez et al., 2010).  
 
With respect to the second strategy, harm reduction or drug use reduction oriented 
treatment, a growing number of pre-clinical and human studies suggest that the 
monoamine releaser dexamphetamine, used for the treatment of attention deficit 
hyperactivity disorder (ADHD) and narcolepsy, is an important candidate for 
replacement therapy (Castells et al., 2007; Castells et al., 2010). The basic rationale 
for substitution treatment for cocaine dependence is similar to that for other 
addictions (nicotine replacement therapy in nicotine dependence, methadone and 
buprenorphine in opiate dependence): it aims to replace uncontrolled and harmful 
drug use with regulated and safer use, in terms of dose, route of administration and 
adverse effects, and to facilitate engagement with health care services by attracting 
and retaining addicted individuals in treatment (Shearer & Gowing, 2004; Shearer, 
2008). In addition, the regular supervised prescription regimen may by itself help 
patients to structure their daily life. In cocaine dependent clients, several controlled 
studies have shown significant improvements associated with the administration of 
sustained-release (SR) dexamphetamine without serious adverse events (including no 
serious cardiovascular complications). Shearer and colleagues (2003) reported 
positive results of dexamphetamine SR in a placebo-controlled study of cocaine 
dependent clients in terms of reduced cocaine use, craving, severity of dependence 
and delinquent behaviour, and dexamphetamine SR was found to attenuate cocaine 
use and improve treatment retention in combined cocaine and heroin dependent 
patients in controlled studies of Greenwald et al. (2010) and Grabowski et al. (2001, 
2004). 
 
In summary, a wide range of pharmacological agents has been tested for efficacy in 
cocaine dependence, but generally with disappointing or, at best, modest results. 
From the investigated candidate medications, topiramate, modafinil and 
dexamphetamine SR have shown the most promising results. The vast majority of 
these studies were conducted in the US, however, and therefore these study findings 
need to be confirmed in research outside the US (Nuijten et al., 2011). 
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I.6.7. Detoxification 
 
Crack cocaine users that consume large quantities and who are severely dependent 
may require inpatient detoxification. This is indicated if there have been repeated 
attempts at outpatient detoxification, or if drug withdrawal leads to severe depression 
or prolonged psychotic symptoms (Ghodse, 2010). Admission enables complete 
dissociation from sources of drugs and from drug using situations and also permits 
more attention to be paid to the patient’s general health and nutritional status, which 
may have suffered neglect (ibid). However, this can only provide a temporary 
respite, and the high relapse rate after discharge from hospital emphasises the 
extreme importance of all the general measures of intervention outlined in this 
section, including contingency management.  
 
I.6.8. Residential Rehabilitation 
 
Therapeutic communities offer detoxified/abstinent clients the opportunity for longer 
term maintenance of abstinence within a structured residential programme sometimes 
based on 12 step principles. The therapeutic community simulates a family model to 
act as a change agent for individual behaviour. Elements include strictly enforced 
behavioural norms, group and individual therapy, and clearly defined hierarchical 
roles and responsibilities with associated rewards and punishments (Platt, 1997). A 
randomised clinical trial (RCT) of a 90-day shelter based drug treatment programme 
in homeless cocaine-using men found significant declines in cocaine use compared 
with usual care after 21 months (Lam et al., 1995). Generally, however, there are 
logistic and ethical impediments in conducting RCTs in residential facilities, and 
most available evidence is from long-term treatment cohort studies (Shearer, 2007). 
Primary stimulant users enrolled in a UK drug treatment cohort study who received 
treatment in residential rehabilitation services significantly reduced drug use and 
associated problems at 1-year follow-up (Gossop, Marsden & Stewart, 2000). Drug 
Abuse Treatment Outcome Studies (DATOS), a US drug treatment cohort study, 
found that residential rehabilitation, outpatient programmes, and short-term inpatient 
programmes were all effective in improving treatment outcomes for cocaine 
dependence with higher problem severity and short treatment duration associated 
with higher cocaine relapses (Simpson, Joe, Fletcher, Hubbard & Anglin, 1999). A 
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longer term (5-year) follow-up of the DATOS cohort, however, found that clients in 
longer term residential rehabilitation reported significantly reduced cocaine 
consumption compared with those from outpatient methadone and outpatient drug 
free groups (Hubbard, Craddock & Anderson, 2003), although this result was 
influenced by significant attrition favouring treatment completers. These results were 
supported by the Australian Treatment Outcome Study, which found that residential 
rehabilitation was significantly more effective than methadone or detoxification in 
reducing cocaine use in heroin dependent individuals after 3 months of follow-up 
(Williamson, Darke, Ross & Teesson, 2006). The authors attributed this success to 
the broader aims of residential rehabilitation to help clients cease all drug use, 
whereas the other interventions were more narrowly focused on heroin use. 
 
 
I.7. Treatment Outcome Profile and Christo Inventory for Substance 
Misuse  
 
Monitoring outcomes assess the effectiveness of treatment interventions as they are 
delivered in practice (Affholter, 1994). The Treatment Outcome Profile (TOP) was 
conceived and implemented by the National Treatment Agency (NTA) in 2007 to 
monitor the demand and delivery of structured substance misuse services in the 
National Health Service (NHS) and non-governmental sector (Marsden et al., 2008). 
All service providers of structured treatment services for drug users (excluding 
primary alcohol users) are required to use it and submit regular data (NTA, 2010a).  
The TOP is a brief, health worker administered interview which is used in structured 
drug misuse treatment interventions as part of the care planning and review process. 
The TOP contains a set of questions based on the four domains established 
internationally and described in the NTA’s guidance on care planning and review 
(NTA, 2007). These are drug and alcohol use, physical and psychological health, 
offending and criminal involvement, and social functioning. The TOP allows health 
workers and service users to track progress on measures within these domains, and 
compare pre-treatment behaviour with behaviour at stages in (and even beyond) 
treatment (Marsden et al., 2008).  
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The Christo Inventory for Substance-Misuse Services (CISS) is a standardised, 
validated tool (Christo, Spurrell & Alcorn, 2000; Christo, 2000a) commonly used in 
Scotland (Effective Interventions Unit, 2001), England & Wales (Christo,1999a,b,c; 
Christo, 2000b,c,d,e,f; Christo, 2001; Audit Commission, 2002), and abroad (Christo 
& Da Silva, 2002). It is completed by the health worker with the client present or 
from case notes. It covers the domains; substance use, health and risk behaviours, 
psychological wellbeing, occupation, criminal activity, social functioning, social 
support, treatment compliance (i.e. adherence and reliability to treatment 
requirements, which is an indirect measure of the motivation to engage with 
treatment) and therapeutic alliance (i.e. working relationship between client and 
drug/alcohol worker). The last two items are not captured by the TOP but have 
shown to be good predictors for many different drug treatment outcomes (Simpson et 
al., 1997). The therapeutic alliance refers to the quality of the relationship between 
the client and her/his care providers and is the ‘non-specific factor’ that predicts 
successful therapy outcomes across a variety of different therapies (Luborsky et al., 
1985, Orlinsky et al., 2004). The nature of the therapeutic alliance depends on both 
staff and client. For example, the practitioner’s expertise and competence instils 
confidence in the treatment and strengthens the therapeutic alliance (Roth & Pilling, 
2007), while the client’s readiness to change also predicts a positive therapeutic 
alliance (Connors et al., 2000). In short, therapeutic relationships, pretreatment 
motivation and programme engagement have demonstrated to be central attributes of 
effective treatment (Simpson et al., 1997).   
 
In other respects, there is considerable overlap between the TOP and CISS. Both 
instruments are completed by clinicians following an interview with the client, both 
have good psychometric properties (with correlation coefficients exceeding 0.70 
between different indices) and have been validated in samples of several hundred 
clients (Marsden et al., 2008; Christo, Spurrell & Alcorn, 2000). There are several 
considerations for employing the TOP and CISS as outcome measures. The 
instruments are brief, easily administered and scored, pantheoretical, 
psychometrically sound, sensitive to change over a medium period of time, and have 
been developed and assessed in the National Health System in the UK (Marsden et 
al., 2008; Christo, Spurrell & Alcorn, 2000). The measures are in the public domain 
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and therefore can be used without cost but with due acknowledgement of its source 
(Marsden et al., 2008; Christo, Spurrell & Alcorn, 2000).  
 
 
I.8. Opiate  Substitution Treatment in the United States and United 
Kingdom 
Methadone maintenance treatment is the most prominent form of pharmacotherapy 
treatment for illicit opiate dependence throughout the world, originally pioneered by 
Dole and Nyswander (1965) as a treatment for heroin dependence. Less commonly 
prescribed is buprenorphine, which is a partial opiate agonist but an accepted 
maintenance treatment for opiate misuse (NICE, 2006d). The rationale for 
maintenance treatment is that, by using a synthetic opiate, cravings are relieved and 
by substituting heroin for a controlled drug, risks and harms associated with illicit 
drug use can be reduced (for example; illegal activities associated with obtaining 
drugs) and stability can be increased (Zaric, Barnett & Brandeau, 2000; Wechsberg 
& Kasten, 2007; Center for Substance Abuse Treatment, 2009). The implementation 
of opiate maintenance programmes varies internationally with respect to structures, 
procedures and practice. Differences include: payment for opiate substitution 
treatment (substitution treatments are free of charge at the point of delivery in the 
NHS), the number of clients treated, type and qualifications of staff, the amount and 
type of counselling and medical services provided, methadone doses, policies about 
urine testing, take-home methadone and many other aspects of treatment (Gossop & 
Grant, 1991; Ball & Ross, 1991; Stewart, Gossop, Marsden & Rolfe, 2000). 
Therefore it seems imperative to highlight some of the salient and relevant 
differences in the implementation of opiate substitution programmes in the US and 
UK. These factors may vicariously affect the process and results of the current 
research project. 
 
I.8.1. United States  
 
The following is an outline of the structure of the opiate maintenance services until 
2014, before the health care reform ‘The Affordable Care Act of 2010’ took effect. 
Besides the provision of substitute prescribing, maintenance treatment services in the 
United States were categorised into two groups: core and ancillary. Core services 
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include medical care (general medical and AIDS related medical care), psychological 
services and treatment for drugs other than heroin (detoxification from a substance 
other than heroin; treatment for dependence to alcohol, cocaine or other illicit drugs) 
(Wechsberg & Kasten, 2007). Ancillary services include educational, vocational, 
financial, legal, family, housing/shelter, acupuncture, transportation and child care 
services (ibid).  
 
The American Society of Addiction Medicine (ASAM, 2001) has defined standard 
outpatient treatment in the US as organised, non-residential services with designated 
drug misuse professionals providing regular treatment sessions totalling fewer than 9 
contact hours per week. Treatment might typically consist of weekly individual 
and/or group counselling, which would aim to address not only the drug misuse but 
also wider medical, psychological and social needs. ‘Treatment as usual’ in recent 
US-based multi-site clinical trials reflects this characterisation (for example, Rawson 
et al., 2004; Peirce et al., 2006). Timko and colleagues (2003) surveyed all 176 
Veterans Affairs substance misuse treatment programmes across the US and found 
that nearly all (99%) provided some form of drug or alcohol counselling or 
psychotherapy as part of standard outpatient care, with correspondingly high (90%) 
utilisation by service users. Additionally, the National Survey of Substance Abuse 
Treatment Services report (SAMHSA, 2009) indicated that a range of therapeutic 
approaches were used by treatment facilities. The frequency with which the facilities 
used these different approaches varied substantially. The majority of substance 
misuse treatment facilities always or often used substance misuse counselling, 
relapse prevention, cognitive behavioural therapy, 12 step approaches, and 
motivational interviewing. Nearly half sometimes used anger management, brief 
intervention, and trauma related counselling. The types of therapeutic approaches 
used by substance misuse treatment facilities depended upon the characteristics of 
both, the facility and the clients served by the facility (SAMHSA, 2009).  
 
Maintenance services may be covered by Medicaid, Medicare, Civilian Health, 
Medical Program of the Uniformed Services, private insurance, state and local 
governments or other sources (ASAM, 2012). In practice, they are usually financed 
from a combination of public and private sources and client self-payment, and the 
combination varies by state and by treatment service. However, many ‘cash-only’ 
 71 
clinics do not accept insurance, forcing clients to pay upfront and then seek 
reimbursement from their carrier, a process which is fraught with difficulty and a 
long history of denied claims (ASAM, 2012). Clients’ inability to pay may limit both 
treatment entry and retention, especially in States where opiate maintenance is not 
covered by Medicaid, State funds, or private insurance (CSAT, 2012). One study 
found that randomly offering prospective clients either cost-free treatment or 
moderate fee rates significantly increased treatment entry and retention for the cost-
free clients (Kwiatkowski et al., 2000). Consequently, CSAT recommended that 
clients’ resources to cover treatment costs should be determined during screening and 
assessment. Frequently clients are uninsured or have not explored their eligibility for 
payment assistance. The consensus panel in the guidelines for ‘Medication-Assisted 
Treatment for Opioid Addiction in Opioid Treatment Programs - a Treatment 
Improvement Protocol’ (CSAT, 2012) stated that services are responsible for helping 
clients to explore payment options so that they have access to a full range of 
treatment services, including medical care, while ensuring payment to the methadone 
clinic. In situations of inadequate funding or client ineligibility for funds, another 
source of payment should be identified (ibid). 
 
However, the Addiction Treatment Forum published figures showing that of the 
286,000 clients in opiate substitution treatment in 2008, approximately half attended 
private for-profit programmes, and paid for their treatment out-of-pocket, at posted 
fees ranging from $13 to $43 a day (Addiction Treatment Forum, 2011). The 
Director of the National Association of State Alcohol and Drug Abuse highlighted 
that the information on client fees and the funding of such treatments are not 
transparent (ibid). In fact, he points out that the exact figures are unknown, since the 
information is not routinely collected, “It’s disappointing, because this is an 
important and understudied topic” (ibid). 
 
On a positive note, this has supposedly changed in 2014 as the health care reform 
‘The Affordable Care Act of 2010’ took effect. SAMHSA (2013) reports that every 
citizen in the US will be eligible to be covered by Medicaid, Medicare or private 
insurance, and more people will have substance misuse medication coverage. 
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I.8.2. United Kingdom  
 
Standard care with substitute opiate medication typically consists of key working 
(Knight, 2006) which, as a matter of good practice, involves the building of a 
therapeutic relationship with the service user. A specified keyworker – sometimes a 
physician or psychologist, but usually a psychiatric nurse, social worker, or trained 
non-medical drugs worker – takes the lead role in the coordination of the client’s 
care which includes: 
 
● an initial care plan to address immediate needs (for example, providing 
information and advice on drug and alcohol misuse) 
● harm-reduction interventions (for example, better management of drug use, 
learning safer drug-using practices and being informed about dose limits and 
overdose risk) 
● motivational interventions to enhance retention in treatment 
● developing and agreeing the care plan with the client and implementation of the 
care plan – with interventions relevant to each stage of the treatment journey and 
regular care plan reviews (NICE, 2008). 
 
The NTA guidelines ‘A framework and toolkit for implementing NICE-
recommended treatment interventions’ (Pilling, Hesketh & Mitcheson, 2010) was 
designed to support drug treatment services in the effective delivery of evidence 
based psychosocial interventions, both for drug misuse and for common co-morbid 
mental health problems. It focuses on evidence based treatment interventions 
recommended by the National Institute for Health and Clinical Excellence, and 
categorises them as either low-intensity or high-intensity structured psychosocial 
interventions, consistent with their likely place in any ‘stepped care’ framework of 
provision, and with reference to Models of Care: Update 2006 (NTA, 2006b). 
 
Low-intensity interventions are generally delivered by keyworkers (i.e., drug 
workers), as their work already utilises components from motivational interviewing 
along with components drawn from other interventions such as relapse prevention, to 
reduce substance misuse (NTA, 2010a). Through regular clinic appointments, 
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keyworkers also organise access to community services (Department of Health, 
2006). These interventions are particularly suited to engage service users in treatment 
and to support early changes in drug using behaviour as well as achieving harm 
reduction goals. 
 
High-intensity interventions are defined as formal psychological therapies delivered 
by a specialist psychological therapist, offering interpersonal, motivational, or 
cognitive-behavioural therapies, or a combination, with no specific medication 
component (NTA, 2010a). During 3 to 20 sessions tailored to the client’s needs, the 
interaction between therapist and client aims to elicit changes in the client’s 
behaviour (for example, drug use), as well as other related factors including 
cognition and emotion (NICE, 2008).  
 
Additionally, a few services offer increased intensity treatment, sometimes with 
educational and life-skills training, which is delivered as a 12-week programme with 
3–5 days’ attendance per week. These treatments are provided by trained 
practitioners on an individual or group basis, and in some services the client’s partner 
or family can also participate (Marsden et al., 2009). These interventions are suited 
to service users with a sufficient degree of stability and those who may be working 
towards being drug-free (NTA, 2010a). In most cases, it is important to deliver low- 
and high-intensity interventions in the context of an agreed care plan, co-ordinated 
by a keyworker. 
 
To summarise, there were at least two vital distinctions between US and UK opiate 
substitution programmes. First, many clients in the US were liable to self-fund some 
portion of their maintenance treatment, depending on their insurance status, the state 
they were seeking the treatment and whether there were some alternative funds 
available, whereas treatment in the UK is free of charge. Second, US services 
seemed to provide higher levels of social care, support and regular counselling, 
which was expressed in the categorisation of core and ancillary services (CSAT, 
2012) and this has usually surpassed the available care in the UK (NICE, 2008). As 
mentioned above, the US contingency management evidence base that we consider 
to date was collected in the health system that existed until the changes took place in 
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2014. Hence, the above mentioned differences could inter alia effect the treatment 
outcome of the present voucher based reinforcement programmes. 
 
I.9. Contingency Management  
 
I.9.1.  Historical Roots and Conceptual Foundations of Contingency 
Management  
 
As discussed above, available treatment options for crack cocaine dependent people 
are limited, and a substantial part of the crack cocaine dependent population is not 
reached by the addiction treatment system (Nuijten et al., 2011). Psychosocial 
interventions for crack cocaine dependence generally show modest results, and there 
are no registered pharmacological treatments to date, despite the wide range of 
medications tested for this type of dependence (Mitcheson et al., 2007; Nuijten et al., 
2011). Study data and practice-based experiences indicate that poor compliance is a 
major complicating factor in these treatments (Magura, Nsakeze & Demsky, 1998; 
DeMaria et al., 2000; Rowan-Szal et al., 2000; Mitcheson et al., 2007). One of the 
more promising psychosocial treatments for cocaine dependence to date is 
contingency management, which has shown positive results in terms of improved 
treatment retention and reduction of substance use in a series of studies in the US 
(Lussier et al., 2006; Prendergast et al., 2006; Knapp et al., 2007; Dutra et al., 2008; 
Van Horn et al., 2010), and preliminary results from some studies in a community 
setting in Spain, using a behavioural approach and vouchers (Garcia-Rodriguez et al., 
2007; Secades-Villa, Garcia-Rodriguez, Higgins, Fernandez-Hermida, & Carballo, 
2008). CM is recommended as a key treatment intervention for stimulant drug users 
in the UK by the NICE guidelines (2008).  
 
The contingency management approach to drug misuse treatment is derived from an 
extensive theoretical, laboratory, and clinical history (Higgins, Budney & Bickel, 
1994). The historical roots of contingency management treatments for drug misuse 
lie in two general areas; the more general of these areas is the operant behaviour 
pharmacology conceptualization of drug use and drug self-administration; the more 
specific of these areas is work on the behavioural analysis and treatment of 
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alcoholism (Bigelow & Silverman, 1999). Work in each of these two areas originated 
relatively independently, with the themes joining only later. The behavioural 
pharmacology theme developed in the animal laboratory as a basic behavioural 
science strategy for developing experimental models of substance misuse and 
dependence. In contrast, the behaviour analysis and treatment theme began with the 
clinical phenomena of alcohol misuse and dependence and applied behavioural 
science principles to understanding and altering these clinical problems (ibid). It is 
interesting to note that both approaches derived from the same general theoretical 
and conceptual orientation of operant psychology, which has viewed substance use 
problems as instances of reinforced operant behaviour that are amenable to control 
by environmental consequences (i.e., behavioural contingencies) (ibid).  
 
This operant behaviour perspective does not hold that drug reinforcement is the only 
mechanism involved in the development of drug misuse problems (Bigelow & 
Silverman, 1999). It recognizes that vulnerability to drug misuse can be influenced 
by a broad range of psychological, biological and environmental variables. However, 
one of the strengths of this perspective is that it suggests mechanisms for 
intervention-alteration of behavioural contingencies that are independent of specific 
etiologic factors.  
 
In order to provide an accessible and logical structure to the present CM chapter, it is 
divided into four sections; (1) outlines the theoretical foundations of the operant 
behaviour conceptualisation and the brain mechanisms underpinning instrumental 
learning, (2) serves as an introduction of the implementation of CM, (3) this section 
reviews the empirical developments of CM in the field of crack cocaine misuse in 
outpatient psychosocial counselling programmes, and methadone maintenance 
programmes, (4) finally, an evaluation of the empirically examined CM intervention 
parameters.  
 
I.9.2. Theoretical Foundations and Biological Mechanisms  
 
The principle aims of behaviourism are to elucidate the conditions of human learning 
and to develop a technology for behaviour change (Skinner, 1938, 1972). 
Behaviourists believe that most or all human behaviour is learned, including not only 
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adaptive but also maladaptive behaviour (for example, addiction) (Thombs, 2006). In 
terms of frequency of occurrence, addictive behaviours are presumed to lie along a 
continuum of use, rather than being defined in terms of discrete or fixed categories 
such as excessive use (loss of control) or total abstinence. All points along this 
continuum of frequency of occurrence are assumed to be governed by similar 
processes of learning (Marlatt, 1985). Thus, substance use is considered a behaviour 
subject to the same principles of learning as driving a car, typing a letter or building a 
house. One of the major premises, then, is that certain fundamental laws (known and 
unknown) govern the initiation, maintenance, and cessation of human behaviour 
(Thombs, 1994).  
 
In the behavioural framework, addiction to substances arises from the operation of 
reward and punishment (West & Brown, 2013). There are many different variants of 
this approach and this section will examine the instrumental learning approach in 
quite general terms. Learned behaviour is usually classified according to whether it is 
the result of ‘respondent conditioning’ or ‘operant conditioning.’ This distinction is 
an important one. The two types of conditioning do not represent different kinds of 
learning but, instead, different types of behaviour (McKim, 1997). Respondent 
behaviour (classical conditioning) is under the control of a well-defined stimulus, 
whereas operant behaviour (instrumental learning) appears voluntary and is not 
directly elicited by a stimulus situation. Most human behaviour falls into the latter 
category (West & Brown, 2013).  
 
The central tenets of this operant behaviour conceptualization are that similar 
learning processes occur in animals and humans, that behaviour is often controlled 
by its consequences, and that behaviour can be changed by changing its 
consequences (Higgins & Petry, 1999). Drug self-administration behaviour is seen as 
the behavioural core of drug abuse problems (Higgins & Silverman, 2008). Drugs of 
abuse function as positive reinforcers that strengthen and maintain drug self-
administration behaviour (Higgins & Silverman, 2008). Drug use behaviour is 
considered abusive when it becomes excessively controlled by the reinforcing effects 
of drugs and inadequately controlled by the potential reinforcing effects of other 
activities and events. In this conceptualisation, the ability of drugs of abuse to 
reinforce behaviour is biologically normal, and drug abuse behaviour problems result 
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from inadequacies in the environmental contingencies of reinforcement rather than 
from defects within the individual (Skinner, 1975). An extensive scientific literature 
supports the view of drug reinforcement as biologically normal. Major elements of 
that literature include evidence of widespread vulnerability to drug reinforcement; 
laboratory experimental models involving drug self-administration by animals; and 
extensive cross-species commonalities in drugs that are self-administered, patterns of 
self-administration, and variables influencing self-administration (Griffiths, Bigelow 
& Henningfield, 1980). This is best demonstrated in a laboratory situation where an 
animal (usually a rat or a monkey) obtains a dose of a drug, such as cocaine, by 
pressing a lever. Thereafter the animal will press the lever repeatedly to obtain more 
cocaine and, as it receives more, will press the lever more and more rapidly. In other 
words, cocaine increases – or reinforces – behaviour resulting in its own 
administration, and is said to be a primary reinforcer and to have primary reinforcing 
properties (Miczek & Mutschler, 1996; Marrow et. al., 1999). Thus within the CM 
framework, operant behaviour is maintained in part by the reinforcing biochemical 
effects of the abused substance and by reinforcing environmental influences 
(respondent conditioning). Respondent conditioning, comes into effect when an 
environmental stimulus (person, place or thing) reliably predicts drug availability and 
administration (e.g., Schindler, Panlilio & Goldberg, 2002). Previously neutral 
environmental events that predict drug availability and use eventually acquire 
discriminative stimulus functions (i.e., they become occasion setters) for urges to use 
drugs as well as drug seeking and use (Higgins & Silverman, 2008). Not all drugs 
possess this property; those that do and which are administered by animals in a 
laboratory situation are the same as those commonly abused by humans (Deneau, 
Yanagita & Seevers, 1969). They include stimulants (e.g. amphetamines and 
cocaine), opiates (e.g. heroin), sedative hypnotics (e.g. sleep remedies), alcohol and 
some, but not all, hallucinogens (e.g. phencyclidine). Of these, cocaine and heroin 
stand out as the most powerful reinforcers, as defined by the rapidity of acquisition 
of self-administration (Ghodse, 2010). 
 
Addictive behaviours become entrenched and difficult to stop through a process that 
can occur without the individual being aware, it does not even require the individual 
to feel positive pleasure from the behaviour (West & Brown, 2013). It seems that the 
process, reinforcement, involves a part of the brain that evolved many millions of 
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years ago because it ‘trained’ animals to engage in behaviours such as obtaining 
food, water, warmth and shelter – all essential to survival and reproduction (Ghodse, 
2010). This could postulate that part of the motivation to take addictive drugs 
involves a learning mechanism that predates in evolutionary terms the development 
of conscious decision-making. Thus addiction involves the development of a habitual 
behaviour pattern that is independent of any conscious evaluation that might be 
taking place about the costs and benefits of the behaviour (West & Brown, 2013). 
The impulses to engage in dependence behaviour that are generated by this 
mechanism can be so strong that they overwhelm the desire of the dependent person 
to restrain themselves. 
 
Animal research, supported by ever more sophisticated neuroimaging techniques in 
humans, now suggests that there is indeed a neural circuitry underpinning positive 
reinforcement (Nestler, 2004). It is believed that whatever the drug or activity, 
ultimately the final common pathway through which reinforcement operates is the 
medial forebrain bundle and an important part of that is the mesolimbic pathway, 
specifically the dopamine pathway extending from the ventral tegmental area to the 
nucleus accumbens (Tomkins & Sellers, 2000). The nucleus accumbens lies towards 
the front of the brain and receives major input from the midbrain called the ventral 
tegmental area (VTA) (Robbins et al., 2007). There are many variations on the 
Dopamine Theory of Positive Reinforcement, but they all propose that the action of 
dopamine on receptors in the nucleus accumbens plays a critical role (West & 
Brown, 2013). This particular theory focuses on the mechanism by which addictive 
drugs exert their rewarding effects. The understanding of the circuitry is developing 
rapidly, but at its simplest it states that drugs with addictive potential increase the 
concentration of the neurotransmitter dopamine in a part of the brain known as the 
nucleus accumbens (NAcc). They further state that this increase in dopamine is 
necessary for addiction to occur.  
 
Stimulation of NAcc dopamine transmission by addictive drugs is shared by a natural 
reward like food but lacks its adaptive properties (habituation and inhibition by 
predictive stimuli) (Robbins et al., 2007). Thus it is suggested that the 'high’ which is 
associated with the drug intake experience might be correlated with an increase in 
dopamine levels in the NAcc. Conversely, whenever the blood levels of the index 
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drug (i.e. cocaine, opiate, nicotine, etc) fall, the NAcc becomes depleted of 
dopamine, which is interpreted by the frontal lobe as ‘craving’ (i.e. desire to ingest 
the drug again) (Robbins et al., 2007). In plain words, one could refer to these 
neurochemical modifications as the ‘biological background’ of the so-called 
‘psychological dependence/craving’ (Ghodse, 2010). Different types of dopamine 
receptors have now been identified and it appears that, initially, different drugs may 
act on receptors in different parts of the reward pathway which in turn influences the 
nucleus accumbens (DiChiara et al., 2004). Some scientists assume, therefore, that 
psychological dependence, which is central to any concept of drug dependence, is the 
real-life manifestation in humans of the reinforcing property of a drug, demonstrable 
in laboratory animals, and that reinforcement may be mediated via an identifiable 
pathway within the brain (Ghodse, 2010).  
 
Clearly, there is a difference between a rat or a mouse pressing a lever to get a dose 
of a drug and an individual’s overwhelming craving for it. Moreover, the above 
description paints a picture that is relatively clear cut, but in fact, there is still a great 
amount of uncertainty about these mechanisms, not least because it is not clear how 
far humans share the same kinds of response as rats and mice, bearing in mind that 
rats and mice are different from each other in some important respects (West & 
Brown, 2013). There are, however, certain similarities between the two conditions: 
the rat will press the lever thousands of times just to get a dose of a powerfully 
reinforcing drug and, given unlimited access to it, may stop eating food and drinking 
water altogether, and will increase its intake of the drug to the point of starvation, 
dehydration, severe toxicity and death. There are obvious parallels with human drug-
seeking behaviour so intense that it disrupts all normal activities, and sometimes so 
self-destructive that the individual dies as consequence (Ghodse, 2010).  
 
Instrumental learning offers a very powerful and attractive explanation for many 
aspects of substance addiction (Higgins, Budney & Bickel, 1994).  According to a 
simple instrumental learning model, drug use or another addictive activity not only 
becomes a deeply entrenched behavioural pattern ultimately under the control of the 
rewarding or punishing stimulus but also intricately tied into behavioural and social 
forces, and under impaired voluntary control (West & Brown, 2013). This can help 
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to explain how a conflict might occur between conscious desire to exercise restraint 
and motivational forces impelling the behaviour (ibid).  
 
The therapeutic task in the operant behaviour conceptualisation is seen as that of 
bringing behaviour under the control of other alternative behavioural contingencies 
that selectively reinforce and promote drug abstinence or other non-drug-related 
prosocial behaviours (Bigelow, Brooner & Silverman, 1998; Silverman, 2004). As 
such, the likelihood of substance use should be influenced by the context in which 
use occurs. More specifically, alternative non-drug reinforcers should decrease 
substance use if they are available in sufficient magnitude and according to a 
schedule that is incompatible with drug use (Petry, 2000; Silverman, 2004).  
 
I.9.3. Contingency Management Implementation  
 
The primary goal of drug misuse treatment in general, and of CM in particular, is to 
reduce or eliminate drug use behaviours (Stitzer & Petry, 2006). Behavioural analytic 
theory and the empirical literature on behaviour change suggests that the efficacy of 
CM interventions is influenced by 5 variables: the choice of the target behaviour, the 
monitoring of the target behaviour, the selection of the type of consequence 
(reinforcer), the magnitude of the reinforcer and the schedule used to deliver the 
reinforcers (Sulzer-Azaroff & Meyer, 1991; Stanger & Budney, 2010).  
 
Reinforcement of drug abstinence  
Abstinence is a primary behavioural outcome in drug misuse treatment, since periods 
of abstinence are associated with positive benefits both to the individual and to 
society (Stitzer & Petry, 2006). Controlled research reviewed below shows that CM 
procedures providing external reinforcement for evidence of drug abstinence can be 
highly effective for promoting sustained periods of abstinence, particularly while the 
interventions are in place (Petry & Simic, 2002). Natural recovery processes that take 
place during periods of sustained abstinence, including gradual diminution of 
response to drug-related cues and lifestyle changes that provide alternative 
competing reinforcers, may then form the mechanisms for longer-term recovery of 
dependent individuals (Stitzer & Petry, 2006). 
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Additionally, clients with substance misuse behaviours experience a variety of 
psychosocial problems that can also be modified via contingency management 
procedures (Petry & Simic, 2002). Some clinicians have found adaptations of the 
approach useful for altering other problematic behaviours and encouraging lifestyle 
changes. Reinforcement can be provided for attendance at therapy sessions (Stevens-
Simon et al., 1997), for prosocial behaviours within the clinic (Petry, Bickel & 
Arnett, 1998), or for compliance with goal-related activities. In terms of this latter 
category, clients decided upon three discrete activities each week that are related to 
their treatment goals, such as attending a medical appointment if the goal is to 
improve health, going to the library with their child if the goal is to improve 
parenting, or filling out a job application if the goal is to obtain employment (Iguchi 
et al., 1997; Bickel et al., 1997; Petry, Martin, Cooney & Kranzler, 2000).  
 
Monitoring of the target behaviour 
In CM interventions, the behaviour targeted for change must be measured frequently, 
and only reports that are objective, as opposed to subjective, can be usefully 
considered. Effective monitoring of the targeted behaviour is essential because 
reinforcement must be applied systematically (Petry, 2000). With substance users, 
this typically involves some form of biochemical verification of drug abstinence, 
usually via urinalysis testing (Stanger & Budney, 2010). Thus, when abstinence is 
the target behaviour for reinforcement, drug use is generally monitored several times 
(e.g., three times) weekly because most urine monitoring systems can detect only 
drug use that has occurred over the prior 48–72 hours (Petry, 2000). Frequent testing 
is ideal because it provides little opportunity for clients to use drugs without the test 
denoting a positive sample, while at the same time, it provides clients with frequent 
opportunities to earn reinforcement if they are able to refrain from substance use for 
a relatively short, 2–3 day period (Stitzer & Petry, 2006).  
 
Selection of the type of reinforcer  
Each time a client tests negative for the targeted substance, the clinician provides the 
client with the reinforcer. The type of reinforcers used in a CM programme can be 
critical to its success (Stanger & Budney, 2010). Individuals vary greatly in terms of 
the types of goods and services that will serve as reinforcers. For example, a specific 
reinforcer (e.g., pizza or movie theatre passes) that serves as an effective incentive 
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for one client may not be reinforcing for another. Use of a range of incentives or 
allowing clients to choose their incentive can increase the probability that the 
incentive will serve as a reinforcer and facilitate the desired target behaviour 
(Stanger & Budney, 2010). The reinforcers used in CM interventions have varied 
from money (Shaner et al. 1997), to vouchers exchangeable for retail goods and 
services (Higgins et al. 1994), to the opportunity to win prizes of different 
magnitudes (Petry et al. 2000). In some settings, desirable clinic privileges (such as 
take-home doses of methadone) (Stitzer, Iguchi & Felch, 1992), employment or 
housing opportunities, and refunds on treatment service fees, have been provided 
(Higgins, Silverman & Heil, 2008) 
 
Magnitude of the reinforcer 
The magnitude of reinforcement is also an important factor that can affect the 
efficacy of CM interventions. For example, if the goal is drug abstinence, a $10 
incentive for each negative drug test is likely to be more effective in increasing 
abstinence than one worth $2.00 (Stanger & Budney, 2010). Given the resilience of 
substance use, strong reinforcers may be necessary to compete with the 
reinforcement derived from well-established use patterns. Multiple studies have 
demonstrated that greater magnitude schedules of reinforcement have resulted in 
better abstinence outcomes than lower magnitude (Lussier et al., 2006). Creative use 
of relatively low magnitude reinforcers and variable or intermittent schedules can 
successfully modify target behaviours among drug users (Petry & Martin, 2002). 
However, the larger the incentives the higher the probability of motivating behaviour 
change in a greater proportion of individuals. In addition, larger magnitude 
incentives have been shown to be more cost effective than lower magnitude 
incentives (Sindelar, Elbel & Petry, 2007; Olmstead, Sindelar, Easton & Carroll, 
2007). 
 
The schedule used to deliver the reinforcer 
The schedule of reinforcement refers to the temporal relation between the target 
behaviour and the delivery of the consequence. Generally, efficacy is likely to 
improve as the temporal delay between the occurrence of the target behaviour and 
delivery of the consequence decreases (Stanger & Budney, 2010). For example, all 
else being equal, providing positive reinforcement for drug abstinence five minutes 
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after a client submits a negative urine specimen would likely engender greater rates 
of abstinence than waiting a week before reinforcement is delivered (Petry, 2000). 
Similarly, more frequent schedules of reinforcement are usually preferable to less 
frequent schedules in establishing an initial target behaviour like drug abstinence or 
regular attendance at counselling sessions. Frequent schedules allow multiple 
opportunities to reinforce and thereby strengthen the target behaviour. Once a target 
behaviour is established, less frequent schedules are typically considered for 
maintenance of behaviour change (Stanger & Budney, 2010). Research in behaviour 
analysis demonstrates that behaviours that are ultimately reinforced under variable 
schedules are less likely to extinguish if reinforcement is omitted. Descriptions of 
rats lever-pressing thousands of times without reinforcement, for example, are noted 
(Ferster & Skinner, 1957), as are descriptions of humans working for many hours for 
a single drug reinforcer (McLeod & Griffiths, 1983). In CM interventions for 
substance users, the situation becomes a bit more complicated because reinforcement 
may not be provided for a behaviour per se, but instead for the lack of one (non-drug 
use). The submission of drug-negative specimens is reinforced, as a proxy for 
refraining from drug use for a several-day period (Stitzer & Petry, 2006). 
 
Reinforcement principles have been applied both in outpatient psychosocial 
counselling programmes that treat alcohol, marijuana, and stimulant users, and in 
methadone maintenance programmes that treat opiate users. The following sections 
review relevant studies that have targeted abstinence from cocaine in these two types 
of settings. The last section discusses the research evidence of the common 
intervention parameters in CM.   
 
 
I.9.4. Contingency Management in Psychosocial Counselling 
Programmes and Methadone Maintenance Programmes 
 
Psychosocial Counselling Programmes 
Psychosocial counselling programmes refer to clinics providing counselling and 
psychotherapy without methadone or other agonist pharmacotherapies. They 
typically offer individual and group counselling of either a structured format (e.g., 
cognitive-behavioural therapy) or an eclectic approach. 
 84 
Cocaine abstinence  - voucher reinforcers 
Psychosocial counselling programmes have been the focus of a number of CM 
studies, including one of the first voucher CM studies conducted at the University of 
Vermont (Stitzer & Petry, 2006). Higgins et al. (1994) randomly assigned forty 
cocaine dependent adults to a behavioural treatment with or without an added 
incentive programme. The behavioural treatment was provided to both groups and 
was based on the community reinforcement approach (CRA), an individualised and 
intensive intervention in which therapists may go out into the community to engage 
clients in treatment and facilitate expansion of their non-drug using networks (for 
details please see Higgins et al., 1994; Smith, Meyers & Miller, 2010). All clients left 
urine samples twice weekly, which were screened for the presence of cocaine. Half 
of the clients (n = 20) were randomly assigned to receive CRA alone, and the other 
half (n = 20) received CRA plus vouchers for every specimen that tested cocaine 
negative. Voucher amounts escalated for each consecutive negative specimen, such 
that the first negative sample resulted in $2.50 in vouchers, the next sample $3.75, 
then $5.00 and so on. Over a 12-week period, clients could earn about $1.000 if they 
provided all negative specimens. Vouchers could be spent upon retail goods and 
services that were consistent with a drug-free lifestyle, and were typically used for 
gift certificates, clothing, electronics, etc. Clients who were assigned to the voucher 
+ CRA condition remained in treatment significantly longer and achieved greater 
durations of abstinence from cocaine than did those assigned to receive CRA alone 
(Higgins et al. 1994). Three-quarters of clients receiving CM completed the study, 
compared with 40% receiving CRA alone. Over half of those in the CM condition 
achieved at least two months of continuous cocaine abstinence versus only 15% in 
the non-CM condition. At 24-weeks after treatment entry, the voucher group 
evidenced significantly greater improvement than the no-voucher group on the Drug 
scale of the Addiction Severity Index (ASI). Combined with a behavioural 
counselling intervention, this voucher intervention produced some of the most 
impressive published results in the treatment of primary cocaine dependent clients 
(Higgins et al., 1991, 1993, 1994).  
 
Higgins et al. (2000) subsequently found that it was not just the availability of 
vouchers, but rather the contingent delivery of them, that improved outcomes. In that 
study, all cocaine dependent clients again received CRA as the platform therapy and 
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they also all received up to $1.000 in vouchers. In one condition, the vouchers were 
contingent upon cocaine abstinence (n = 36), but in the other (non-contingent) 
condition (n = 34), clients received vouchers regardless of the outcomes of their 
sample results. Provision of non-contingent vouchers resulted in similar proportions 
of clients remaining in treatment for six months (56% versus 53% in contingent and 
non-contingent, respectively). However, a higher proportion of those in the 
contingent (38%) versus the non-contingent (10%) condition achieved 12-weeks of 
continuous abstinence during treatment. Thus, a longer period of sustained 
abstinence was seen when vouchers were contingent upon providing negative 
samples (Higgins et al., 2000).  
 
Higgins and colleagues also investigated the longer-term post-treatment effects of 
voucher reinforcement targeted on cocaine abstinence. In one study (Higgins et al., 
2000), the benefits of contingent versus non-contingent voucher reinforcement were 
apparent for up to 12 months after treatment ended, resulting in higher rates and 
longer durations of cocaine abstinence for those treated with contingent vouchers. 
Importantly, Higgins and colleagues  (Higgins, Badger & Budney, 2000) have shown 
that the likelihood of post-treatment abstinence is directly related to duration of 
abstinence achieved during treatment. This observation emphasizes the importance 
of during treatment abstinence as a primary treatment goal. It also supports the 
speculation that mechanisms for long-term beneficial effects of CM lie in natural 
recovery processes and lifestyle changes that take place during periods of prolonged 
abstinence (Petry & Simic, 2002). 
 
CM was also effective when it was implemented by other investigators and in 
different treatment models. Jones et al. (2004) tested the efficacy of abstinence-
contingent vouchers for preventing relapse to cocaine use. After a brief residential 
stay, cocaine dependent clients were randomly assigned to conditions in which they 
could earn up to $1.155 in abstinence-contingent (n = 103) or non-contingent (n = 
96) vouchers during a 12-week, once weekly outpatient phase. Statistically 
significant benefits of contingent vouchers were found for the number of cocaine 
negative samples submitted and days of continuous cocaine abstinence in this 
treatment model, in which detoxification was followed by aftercare (ibid). 
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Methadone Maintenance Programmes 
 
Cocaine abstinence  - voucher and prize reinforcers 
Some of the initial studies of voucher reinforcement were conducted within 
methadone clinics because many methadone clients misuse stimulants in addition to 
opiates. Silverman et al. (1996), for example, utilized a matched-control design 
similar to that of Higgins et al. (2000). In this seminal report on vouchers with opiate 
dependent cocaine users, 37 methadone maintenance clients who were regular 
cocaine users participated in a 12-week intervention (Silverman et al., 1996). Clients 
were randomly assigned to receive vouchers contingent on cocaine negative 
urinalysis results or independent of urinalysis results and according to a schedule that 
was matched to the contingent group. Under this schedule, urine samples are 
collected three times per week and clients received a voucher for each cocaine free 
urine sample provided. Voucher values began around $2.50 each and increased to 
around $50 each. Clients exposed to this intervention were able to earn 
approximately $1.156 in vouchers for providing cocaine free urine samples over a 
12-week period. Voucher value and schedule were largely identical to that used in 
study by Higgins et al. (1994). During baseline conditions, clients in both treatment 
conditions were positive for cocaine use throughout baseline monitoring. Following 
the introduction of the voucher intervention, abstinence levels increased substantially 
among those who received contingent vouchers but not those who received them 
non-contingently. Almost half of the clients in the abstinence reinforcement group (9 
of 19 patients) achieved between 7 and 12 weeks of abstinence during the 12-week 
period. In contrast, no client in the non-contingent control group achieved over 6 
weeks of abstinence (only 1 control client (6% of controls) achieved more than 2 
weeks of sustained cocaine abstinence).  
 
Similarly, robust effects of vouchers were noted in a subsequent trial by this group 
(Silverman et al., 1998). Even though vouchers were contingent only on cocaine 
abstinence in this latter trial, opiate abstinence also increased. These trials established 
the efficacy of the voucher intervention for increasing cocaine abstinence in 
methadone maintenance clinics (Higgins, Alessi & Dantona, 2002). In a field that 
had failed to find effective treatments for cocaine misuse in methadone clients, these 
effects were striking (Stitzer & Petry, 2006). 
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Other studies have added considerable weight to the evidence that CM is efficacious 
in reducing stimulant use during methadone treatment and also have tried to identify 
improved intervention parameters. One study (Silverman et al., 1998) replicated prior 
observations that vouchers could significantly reduce cocaine use during treatment, 
but found that adding up to twelve $50 bonuses during the first six weeks of 
treatment based on early abstinence initiation did not improve outcomes. More 
recently, Silverman and colleagues (2004) examined the additive benefits of 
abstinence contingent take-homes and voucher reinforcers in a study that extended 
the intervention duration to 52 weeks. Methadone clients (N = 78) with evidence of 
ongoing cocaine use were randomly assigned to conditions where they could (a) earn 
methadone take-homes (three per week) for providing opiate and cocaine free urine 
samples, (b) earn take homes as above and also vouchers (maximum of $5.500 over 
52 weeks) for cocaine free urine samples, or (c) participate in usual care without the 
opportunity to earn abstinence contingent incentives. The results were impressive, 
with statistically significant between group differences in overall rates of cocaine 
negative urine samples submitted (Silverman, 2004). In addition, 42% of participants 
were continuously abstinent from stimulants for six months or more in the take home 
plus voucher group as compared with 8% in the take-home only and 0% in the 
standard care groups. Further, initiation of long periods of sustained abstinence was 
observed across the first nine months of the trial. These data suggest a benefit of 
long-term implementation of CM with clients in methadone maintenance treatment 
(Stitzer & Petry, 2006).  
 
Other types of reinforcers have also been investigated for reducing stimulant use in 
methadone treatment programmes. This research extends beyond the university 
setting to community based clinics, with an aim of reducing costs of the vouchers. 
Rather than earning escalating amounts of vouchers for successive cocaine negative 
specimens, clients earn the chance to draw a slip of paper from an urn, and each draw 
is associated with the chance of winning a prize (Stitzer & Petry, 2006). 
Colloquially, this is referred to as the fishbowl method. Only about half the slips 
result in a prize, as about 50% state, “Good job!” When prize slips are drawn, they 
are associated with three prize categories, in decreasing probabilities: small $1 prizes 
(e.g., choice of fast food gift certificates, bus tokens), large $20 prizes (e.g., watches, 
Walkmans), and jumbo $100 prizes (e.g., TVs, DVD players, stereo equipment). The 
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overall cost of prizes per client using this technique ranges from approximately $240 
to $400 during a 12-week treatment period. 
 
The prize CM technique is also efficacious in cocaine using methadone clients (Petry 
et al., 2004; 2005; 2006). Petry and colleagues (2005) randomly assigned 77 cocaine 
using methadone clients to standard treatment or standard treatment plus prize CM. 
Clients receiving CM had about twice the rate of cocaine abstinence as those in the 
standard condition (35% versus 17%, respectively). A similar study was conducted in 
six methadone maintenance clinics throughout the US as part of the National Drug 
Abuse Treatment Clinical Trials Network. Peirce et al. (2006) randomly assigned 
388 cocaine using methadone clients to standard treatment alone or with prize CM. 
Clients could earn up to $400 during a 12-week study if their samples tested 
negative. The overall proportion of cocaine negative samples submitted in the CM 
group (54%) was statistically significantly greater than in the standard group (37%), 
and the odds that a stimulant negative sample would be submitted during treatment 
were doubled by the CM intervention (Peirce et al., 2006). 
 
I.9.5. Evaluation of the Contingency Management Intervention 
Parameters  
 
The preceding sections have documented that cocaine misuse can be modified using 
CM techniques and it was noted that a number of different reinforcers are efficacious 
in altering cocaine use. Several technical commonalities are noted in successful CM 
interventions, the forthcoming section outlines and evaluates the most vital 
commonalities. The last section briefly discusses predictors of CM treatment 
outcome. 
 
Schedules of reinforcement - escalating and reset features 
Both voucher and prize CM studies have applied escalating schedules of 
reinforcement with resets back to low levels of reinforcement following a lapse to 
inappropriate behaviour, a strategy designed to reinforce sustained behaviour change. 
Specifically, as clients achieve longer periods of abstinence, the value of the 
vouchers or number of draws increases. By the end of the 12-week treatment period 
in Higgins’s studies (1994, 2000, 2003), for example, clients could earn over $30 for 
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each drug-free urine specimen. Similarly, in the prize CM procedure, clients can earn 
up to 10–15 draws. If a sample is positive, refused, or missed (e.g., unexcused 
absence), the next negative sample provided results in a reset to $2.50 in vouchers or 
one draw from the fishbowl. 
 
Eliminating the escalation feature and delivering a constant rate of reinforcement 
may make the voucher system less expensive and easier to implement. A study by 
Roll, Higgins and Badger (1996) compared in cigarette smokers the escalating 
approach to one that provided a constant rate of reinforcement, with both procedures 
providing equivalent total amounts of reinforcement. Although both schedules 
engendered similar amounts of overall abstinence, the escalating system resulted in 
longer periods of continuous abstinence, which in turn have been associated with 
good long-term outcomes (Higgins, Badger & Budney, 2000; Petry et al., 2006). 
These results suggest that an escalating system may be necessary for inducing 
significant periods of sustained abstinence, at least initially. Once behaviour change 
has occurred, and sustained abstinence is ongoing, the value of the reinforcer may be 
reduced (e.g., $1 lottery ticket) without a detrimental impact on outcomes (Stitzer & 
Petry, 2006). 
 
The importance of engendering stable initial abstinence was highlighted in a study by 
Kirby et al. (1998), where few cocaine dependent clients initiated abstinence under a 
traditional escalating schedule. However, much better outcomes were achieved in 
this population with a schedule that provided higher-valued reinforcers initially for 
each negative sample and then tapered the density of reinforcement using a fixed 
ratio schedule (i.e., requiring an increasing number of consecutive negative urines to 
receive the reinforcer).  
 
Reinforcer immediacy and magnitude 
Learning occurs best when each time the target behaviour is exhibited it is followed 
by its consequence without delay (Zeiler, 1977). Voucher programmes use this 
behavioural principal by providing vouchers immediately after submission of a 
negative specimen. Moreover, samples are screened within minutes of collection, and 
data suggests that onsite testing systems engender greater abstinence than sending 
samples offsite for testing (Schwartz et al., 1987). Similarly, draws from the fishbowl 
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or exchange of vouchers for retail items occur with minimal delay, 2–3 days from 
request. Meta-analyses demonstrate that immediacy of reinforcement appears to be 
linked to effect sizes in CM studies (Griffith, Rowan-Szal, Roark & Simpson, 2000; 
Lussier et al., 2006; Prendergast et al., 2006).  
 
Behaviour is determined not only by the rate of reinforcement but also by its 
magnitude (Catania, 1966), and studies of CM likewise find that magnitude of 
reinforcement affects outcomes. Stitzer and Bigelow (1983, 1984) found that 
nicotine abstinence increased as a function of the magnitude of the reinforcer, 
ranging from $0 to $12 per day. Silverman et al. (1999) found that some cocaine 
using methadone clients who were ‘treatment resistant’ at standard voucher amounts 
achieved abstinence if amounts were increased threefold. Dallery, Silverman, 
Chutuape, Bigelow and Stitzer (2001) noted a direct relationship between voucher 
amounts and abstinence in another study of methadone clients. These studies all 
suggest that larger magnitude reinforcers may improve outcomes. Yet, some studies 
employing low magnitude reinforcers have demonstrated positive effects. Rowan-
Szal et al. (1994) found that stars exchangeable for $5 items reduced drug use. Petry 
et al. (2000, 2002, 2004, 2005, 2006) found that prize systems based on intermittent 
reinforcement reduced alcohol, cocaine, and opiate use despite relatively low overall 
cost. Thus, when principles associated with learning are applied, positive outcomes 
may be achieved with lower magnitude reinforcers (Stitzer & Petry, 2006). However, 
more research is needed to identify characteristics of clients who can benefit from 
low-magnitude reinforcers versus those that require higher-magnitude reinforcers for 
effective behaviour change. For example, there is currently no evidence to indicate 
that individuals with lower versus higher income levels differentially benefit from 
CM interventions. However, it may be the case that income status could influence the 
reinforcer magnitude that is effective with a given individual. 
 
Reinforcement of successive approximation (Shaping) 
All of the above discussed studies employed standard qualitative urinalysis testing. 
Under that testing method, urine samples are considered positive for cocaine if the 
concentration of the cocaine metabolite, benzoylecgonine, in the urine sample is at or 
above 300 ng/ml. However, toxicological studies in chronic cocaine users suggest 
that some individuals, many of whom achieve urinary benzoylecgonine 
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concentrations exceeding 100,000 ng/ml during active use, may continue to provide 
urine samples that exceed the standard 300 ng/ml threshold for several days after 
initiating abstinence (Preston et al., 2002). As a result, using standard qualitative 
testing, a participant may have to remain abstinent for several days before earning a 
voucher for a negative sample. To develop a more sensitive method of detecting 
recent cocaine abstinence, Preston, Silverman, Schuster, and Cone (1997) proposed 
rules for detecting recent abstinence based on amounts of decreases in 
benzoylecgonine concentrations across days. To implement these rules, the authors 
employed quantitative testing, which provided more continuous measures of the 
benzoylecgonine concentrations. This principle allows the reinforcement of 
successive approximations or shaping, to establish new behavioural patterns. In 
establishing a pattern of drug abstinence, substance use can be reinforced for 
approximations of abstinence. Preston et al. (2001) showed that an initial ‘shaping’ 
procedure that reinforced reductions in urinary cocaine metabolite during the first 
three weeks of an eight-week intervention led to higher rates of abstinence during a 
subsequent abstinence-based reinforcement phase, possibly because the shaping 
procedure allowed more participants to earn reinforcers and thus come into contact 
with the benefits of the incentive programme (Stitzer & Petry, 2006). 
 
Although the reinforcement of cocaine abstinence based on decreases in 
benzoylecgonine concentrations has been examined under limited conditions, its 
clinical utility has yet to be demonstrated (Katz et al., 2002; Sigmon et al., 2004). In 
general, it appears that this method can increase the percentage of people who can 
come into contact with the reinforcement contingency (Robles et al., 2000; Preston, 
Umbricht, Wong & Epstein, 2001), it can increase cocaine abstinence relative to a no 
reinforcement condition (Robles et al., 2000; Katz et al., 2002;), and there is some 
evidence that it can produce better outcomes than abstinence reinforcement based on 
qualitative urine testing (Preston et al., 2002).  
 
I.9.6. Predictors of Treatment Outcome: Individual, Psychosocial and 
Treatment-Related Aspects 
 
While CM outcome research continues to grow, relatively few studies have 
examined associations between individual-level characteristics and response to CM 
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treatments. Moreover current research findings are equivocal among different trials, 
making it difficult to identify robust predictors (Poling, Kosten & Sofuoglu, 2007; 
Sun, 2007; Garcia-Fernandez et al., 2011). 
 
However, some progress has been made in identifying predictors of cocaine 
treatment outcome, some of these factors include individual aspects, such as 
sociodemographic characteristics (Heinz, Wu, Witkiewitz, Epstein, & Preston, 
2009), concurrent mental health problems (McMahon, 2008; Messina, Farabee, & 
Rawson, 2003; Tate et al., 2008; Waldrop, Back, Verduin, & Brady, 2007), addiction 
severity (McCamant, Zani, McFarland, & Gabriel, 2007; Poling, Kosten, & 
Sofuoglu, 2007), low self-efficacy (Dolan, Martin & Rohsenow, 2008; Hser et al., 
2006), craving (Weiss et al., 2003; Lopez et al., 2010), alcohol use (Alterman et al., 
2000) or greater presence of psychosocial problems (Simpson, Joe, & Broone, 2002). 
It was also found that income does not affect CM efficacy (Rash, Olmstead, & Petry, 
2009), and that the effectiveness of abstinence-based incentives interacts with intake 
stimulant urinalysis results (Stitzer et al., 2007). 
 
Additionally, Dobkin, De Civita, Paraherakis & Gill (2002), demonstrated that social 
support is also important in predicting treatment retention. A comparison of the 
results from Buchanan & Latkin (2008) and Bohnert, German, Knowlton and Latkin 
(2010) suggest that social interactions, behaviour of drug consumption and treatment 
participation are related. Hence, it is possible to affirm that social operations are in 
direct relation to treatment success (Simpson et al., 2002). 
 
Recent studies investigated treatment-related variables that seem to be associated 
with better outcome, such as use of psychiatric services (Ray, Weisner & Mertens, 
2005), advice about legal matters (Hser, Joshi, Anglin & Fletcher, 1999), sustained 
self-help participation (McKay, Merikle, Mulvaney, Weiss & Koppenhaver, 2001) 
and greater service intensity and satisfaction (Grella, Hser & Hsieh, 2003; Hser, 
Evans, Huang & Anglin, 2004).  Some studies have demonstrated that the amount of 
services received by clients exerts a considerable impact on patient outcomes (e.g. 
McLellan, Alterman, Cacciola, Metzger & O’Brien, 1992; McLellan et al., 1995; 
Hoffmann et al., 1996; Hser, Polinsky, Maglione & Anglin, 1999). For example, 
McLellan and colleagues (1995) demonstrated that clients who received a broader 
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array and increased frequency of services stayed in treatment longer and showed 
15% better outcomes than clients who did not. Because longer duration of treatment 
has been the most consistent and important predictor of favourable treatment 
outcomes, Simpson (2000) conducted a series of studies that showed that greater 
programme participation was associated with better therapeutic relationships and that 
both of these factors promoted positive changes in treatment, which are related to 
longer retention. With some exceptions (McLellan, Hagan, Levine, Gould, Meyers, 
Bencivengo & Durell, 1998), several studies have found that clients who are engaged 
in and satisfied with their treatment experience tend to stay in treatment longer or 
have better treatment outcomes (Holcomb, Parker & Leong, 1997; Sanders, Trinh, 
Sherman & Banks, 1998; Kasprow, Frisman & Rosenheck, 1999;). 
 
A comparison of the results obtained from the previous investigations suggested that 
social interactions, behaviour of drug consumption and treatment participation are 
related (Buchanan & Latkin, 2008; Bohnert, German, Knowlton & Latkin, 2010). 
Hence, it is possible to affirm that social operations are in direct relation to treatment 
success (Simpson et al., 2002). 
 
 
I.10.   Background of the Study, Research Aims and Questions 
 
The current study was conducted at a service in Greater London, it was part of a 
nationwide multisite contingency management trial commissioned by the National 
Institute for Health and Clinical Excellence (NICE). It was implemented and funded 
by the National Treatment Agency for Substance Misuse (NTA)5 in 2008 and 2009. 
The research programme aimed to target substance misuse related behaviours to gain 
an understanding of the acceptability and external validity of contingency 
management to the UK substance misuse population. In 2007 the NTA approached 
potential sites to declare their interest to conduct a contingency management study at 
their service. A variety of treatment settings were addressed as possible 
demonstration sites, these included: community drug services, residential drug 
                                                
5 The National Treatment Agency for Substance Misuse (NTA) was established in 2001 by the 
government as a special health authority within the National Health Service, with the aim of 
improving the availability, capacity and effectiveness of treatment for drug misuse in England. In 
April 2013 the NTA became part of Public Health England, an executive agency of the 
Department of Health. 
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services and prison based drug services. The participation in the CM trial was 
optional for the drug services. The invitation letter stated a variety of drug using, 
health and attendance related behaviours that could be incentivised, such as the 
uptake of Hepatitis B vaccinations in previously reluctant clients or the collection of 
Hepatitis C test results by the clients, drug-free tests or attendance for primary crack 
users, elimination of usage of illicit drugs on top of the prescribed medication, 
reduction or elimination of injecting behaviour, increased attendance at drug worker 
and psychosocial interventions for those in optimised oral maintenance programmes. 
Interested services were asked to familiarise themselves with the NICE guidelines 
(2007) that described the behavioural principles underpinning contingency 
management and the key elements in the delivery of a programme in the NHS. 
Furthermore, the NTA also recommended reading a selection of research papers that 
highlighted the underlying principles of the effective delivery of CM in the US. 
Additionally, interested services were required to complete a proposal that outlined 
the nine general CM requirements, namely, the target behaviour the service wished 
to address (a single behaviour for e.g., crack cocaine use, marihuana use) and the 
target population, the incentive schedule, the nature of the incentive (e.g. voucher, 
bank account), value and scaling of the incentive, client non-compliance, length of 
programme (usually 12 weeks for an individual client), length of project (usually 6 
months), staff training for CM and staff ‘fidelity’ to the CM model, budgeting for 
CM programme and onsite research capacity. In order to define and formulate the 
aspects of the proposal, the NTA provided a guideline that accurately described the 
principles and general requirements for the contingency management demonstration 
projects. However because of brevity reasons these principles cannot be outlined 
here, suffice to say that the principles and general requirements of drug using, health 
and attendance related behaviours were addressed to guide the design and 
implementation of the incentive programmes. These were based on the principles 
that underlie the effective delivery of CM programmes. Within strict limits, services 
could negotiate individual specifications for the general requirements to better meet 
the needs of their client population. We devised a protocol that aimed to incentivise 
the abstinence of crack cocaine in opiate maintenance clients using retail vouchers, 
with an escalating incentive schedule over a 12-week period. In consideration of the 
specific and general requirements of the CM protocol, permissions were given by the 
NTA and the Expert Advisory Group (EAG). Final approval for the nationwide 
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multisite trial was given by the Department of Health. For a more detailed 
description of the individual specifications of our CM programme please see section, 
II.1. Study Setting and Research Design. 
 
As a result of the above highlighted considerations, the present study’s purpose was 
to determine whether voucher based contingency management reduces concurrent 
cocaine use among clients in opiate maintenance treatment, when implemented 
adjacent to standard care in a community drug and alcohol service in Greater 
London. We aimed to investigate how much and how many participants reduce their 
cocaine use over a course of a 12-week CM intervention period. The central tenets of 
the CM intervention were to (a) urine test clients on fixed intervals according to a 
standardised incentive protocol in a 12-weeks intervention period, (b) provide 
monetary based incentives when cocaine abstinence is demonstrated, (c) withhold the 
incentive when cocaine use is detected. The incentives consisted of monetary based 
vouchers. As will be detailed later, a natural unplanned comparison group developed 
from participants that initially agreed to participate in the CM intervention but did 
not attend any of the scheduled reinforcement sessions. These clients continued to 
receive standard treatment (ST), consisting of opiate maintenance treatment and 
psychosocial interventions. Frequency of crack cocaine use in the previous 28 days 
was be monitored by self-report and verified by weekly/fortnightly urine analysis. 
 
Briefly, four research questions were examined in the present study. The primary 
research question was whether abstinence from crack cocaine misuse can be 
increased among clients on opiate substitution treatment, using contingent positive 
reinforcement. The present voucher CM schedule was similar to that from Silverman 
et al., 1996, albeit for the first time systematically employed and documented in a 
European cultural context and in a community setting. The second question was 
connected to the first, which pattern will the abstinence curve exhibit? The meta-
analysis from Dutra et al., (2008) found that although CM interventions in cocaine 
using clients yielded the largest effect size, it also yielded the largest dropout rates, 
and this dichotomous finding may suggest that rather than pursuing stepwise gains, 
many clients make an early decision between targeting abstinence or dropping out of 
treatment. The third research question was whether treatment compliance (i.e., 
adherence and reliability to treatment requirements) and therapeutic alliance (i.e., 
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working relationship between client and drug worker) were associated with CM 
treatment outcome. Past research has shown that therapeutic relationships, pre-
treatment motivation and programme engagement have demonstrated to be central 
attributes of effective treatment (Simpson et al., 1997; Roth & Pilling, 2007). The 
last research question pertains to the comparison between the standard treatment and 
the voucher CM groups. Is there a difference in self-reported frequency of crack use 
in the previous 28 days between the standard and voucher CM groups at timepoints 2 
and 3. 
 
The project is of scientific importance because it aims to evaluate whether the US 
study findings in CM can be generalised to UK crack cocaine misusers that receive 
opiate substitution treatment. As discussed above, there were at least three important 
distinctions between US and UK opiate substitution programmes and the respective 
client groups. First, many clients in the US were liable to self-fund some portion of 
their maintenance treatment, depending on their insurance status, the state they are 
seeking the treatment and whether there were some alternative funds available 
(ASAM, 2012; CSAT, 2012). Second, US services seemed to provide higher levels 
of social care, support and regular counselling, which was expressed in the 
categorisation of core and ancillary services (CSAT, 2012) and this usually surpassed 
the available care in the UK (NICE, 2008). Third, US research has involved highly 
deprived urban populations from areas where crack cocaine misuse was endemic 
(NTA: 2002b). How this evidence relates to the UK context where crack cocaine 
misuse and urban deprivation are less entangled, less extreme and less entrenched is 
an open question.  
 
The study is of clinical importance because it emphasises the use of positive 
reinforcement as a means to shape behaviour with the goal of improving retention 
and outcomes for crack cocaine using clients who have not stopped their using while 
in opiate substitution treatment. Besides the value of achieving abstinence in this 
difficult to treat and often disenfranchised population, there is evidence that CM has 
a great potential to enhance the engagement of these clients with their drug workers 
and additional treatments, and therefore providing a more fertile basis for counselling 
based interventions, i.e. motivational interviewing, cognitive-behavioural therapy 
and relapse prevention (Weaver et al., 2007). Additionally, a clinically meaningful 
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period of abstinence allows individuals to make a more informed decision on their 
using behaviour and cognitive functioning improves after a few days of abstinence 
(Stitzer, Iguchi & Felch, 1992). Natural recovery processes that take place during 
periods of sustained abstinence, including gradual diminution of response to drug-
related cues and lifestyle changes that provide alternative competing reinforcers, may 
then form the mechanisms for longer-term recovery of dependent individuals (Stitzer 
& Petry, 2006). 
 
The objectives of the study are wholly consistent with the emerging field of practice-
based evidence research, which aims to examine what treatments or services are 
provided, and in what ways, to individuals within service systems, as well as to 
evaluate how to improve treatment or service delivery (Street, Niederehe & 
Lebowitz, 2000). Such a development would not only provide data to support good 
practice but also advance an agenda in which research effort is focused on activities 
that are designed to support decisions in the delivery of substance misuse services 
(Newman & Tejeda, 1996). 
 
A word of caution is imperative at this point. Although generalisability is usually 
high in practice-based evidence designs, the results from the present study should be 
seen as tentative, due to sample constraints i.e. small sample size in the contingency 
management group (n = 21) and the nature of the comparison group. Yet the sample 
size is in agreement with several other CM studies (see for example, Higgins et al., 
1994; Silverman, 1996; Silverman, 1998; Groß, Marsch, Badger & Bickel, 2006).  
     
 
II.  METHODOLOGY 
 
II.1. Study Setting and Research Design 
 
The study was conducted at a community drug and alcohol service in Greater 
London. The service operated from a harm minimisation model and hence focused 
on minimising the negative outcomes of continued substance misuse. It thereby 
aimed to address the conditions and context of substance use while addressing drug 
use itself. The team at the service was multidisciplinary, consisting of trained non-
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medical drug and alcohol workers (keyworker), nurses, psychologists, physicians and 
psychiatrists. 
 
The service provided clinical interventions such as substitute prescribing services or 
access to in-patient services. It incorporated a spectrum of strategies, ranging from a 
full assessment of treatment needs for drug and alcohol users, individual support, 
psychological counselling, psychotherapy, assessment for funding for detoxification 
and rehabilitation programmes, alternative therapies (for example, auricular 
acupuncture, shiatsu) and referral to other services. It also offered information and 
testing to clients on blood borne viruses like HIV and hepatitis, as well as sexual 
health advice. Referrals were accepted from any source including self-referrals and 
referrals from family members.  
 
The project leaders were a clinical psychologist and the aforementioned doctorate 
student. The CM programme was designed within the general requirements and 
principles that were set out by the NTA. The following will attempt to outline the 
contributions of the researchers to the pre-existing design features from the NTA. 
The target behaviour (abstinence from crack cocaine), the selection of the eligibility 
criterion (a minimum of twice weekly self-reported crack use), the voucher value and 
scaling of the incentives was defined by the researchers. For example, the magnitude 
of the reinforcement vouchers; starting with a monetary value of £5, rather than £2 as 
the NTA proposed, and increasing by increments of £5 to a maximum of £20. So was 
the decision to use vouchers from the retailers; Argos, Boots, JJB Sports, MK One, 
Shoe Express, Virgin Megastores, WH Smith and Woolworths. The specifications of 
these CM protocol features were achieved in discussions with the clinical 
psychologist and the doctorate student, and negotiations with the NTA. 
 
The incentive schedule was outlined by the NTA, so was the rule of ‘resetting’ the 
value of the incentive at the next appointment to the starting level if non-compliance 
occurred. Also, the recommended length of the programme was 12 weeks. The 
budget was calculated by Dr. Christo on the basis of the results of the random urine 
checks from the opiate maintenance clients that were on the caseload at the service, 
for more details please see section; III.3.3. Changes in the Planned Data Analyses. 
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Equally, the costs for the two research assistants were estimated and included in the 
budget.  
 
Regarding the staff training at the service; the project development was supported by 
the NTA with a template PowerPoint presentation and trainer’s notes. These 
resources were used by the clinical psychologist to train the staff at our service. 
Teaching of the material was spread over two conventional weekly team meetings. 
The two training events consisted of a mixture of didactic and participatory learning. 
Specific topics and clinical issues were addressed through role-play exercises, with 
theoretical background lectures as necessary. Drug and alcohol workers and two 
research assistants supported the implementation. Dr. Christo and myself attended 
the training session at the NTA.    
 
Monitoring of the data collection process and a minimum of weekly consultations 
with the research assistants were undertaken by myself. Additionally, the doctorate 
student performed data processing into Excel and SPSS spreadsheets, and the 
evaluation of the study independently and autonomously. The anonymised data set 
was supplied to the NTA, at several timepoints. Additionally, the doctorate student 
presented the results of the investigation at an NTA workshop in 2009.  
 
A quasi-experimental design with a convenience sampling method was employed to 
monitor client’s frequency of crack cocaine use. Clients on opiate maintenance that 
fulfilled the eligibility criteria (please see section; II.2 Participants) were asked if 
they were interested to participate in the CM programme. From this group of clients, 
a sample of clients agreed to participate and attended the scheduled reinforcement 
sessions. The remainder of clients agreed to participate but did not engage with the 
intervention. As a result, a natural unplanned comparison group (Standard treatment 
group; ST) developed from participants that initially agreed to participate in the CM 
intervention but did not attend any of the scheduled reinforcement sessions. These 
clients continued to receive standard treatment, including opiate maintenance 
treatment and key working.  
 
The central tenets of the intervention in the CM group were to (a) urine test clients at 
fixed intervals according to a standardised incentive protocol in a 12-weeks 
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intervention period (for the incentive protocol, please see section; II.4.2. Contingency 
Management Group), (b) provide monetary based incentives when cocaine 
abstinence was demonstrated, (c) withhold the incentive when cocaine use was 
detected. The incentive consisted of monetary based vouchers. Participants can earn 
a maximum of £240 in vouchers if they submit all 21 scheduled negative specimens. 
Two dependent outcome measures were employed; self-reported crack cocaine 
consumption (verified by a minimum of fortnightly urine analysis) and quantitative 
urinalysis results. 
 
The first part examined between-treatment group differences in the standard 
treatment and the voucher CM condition. The primary dependent measure was self-
reported crack cocaine use (responses extracted from the TOP questionnaire) at three 
time-points; at baseline (a four week period) – timepoint 1, 3 months + 1 week (i.e., 
on average 1 week after the CM programme intervention concluded) – timepoint 2, 
and at 6 months follow up (on average) – timepoint 3. We also explored the 
remaining relevant responses from the TOP and CISS questionnaire. 
 
The second part investigated within-group differences in the voucher CM group. The 
primary dependent outcome measure was crack cocaine abstinence measured by 
objective urinalysis results over the 12-weeks intervention period (for the incentive 
schedule, please see section II.4.2. Contingency Management Group), and responses 
from timepoint 1.  
 
The following measures of control were employed:  
 
1. Researchers were trained by the NTA and the research assistants were trained 
by one of the researchers, to assure accurate and reliable application of the 
CM protocol with clients. 
2. Researchers monitored study procedures weekly to ensure appropriate 
conduct.  
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II.2 Participants 
 
Participants were 42 outpatients receiving opiate substitution treatment between 
February and August 2008. Participants were eligible for the study if they had been 
enrolled with the NHS service, provided objective evidence of current opiate 
dependence and at least 1 year of opiate use and had been stabilised on an opiate 
substitute (i.e. methadone or buprenorphine) dose for at least 1 month. They also 
provided objective evidence of cocaine use and reported smoking crack cocaine a 
minimum of twice6 a week, were 21 years or older (the minimum required age at the 
service for opiate substitution treatment was 21 years), and spoke English. Except 
where otherwise indicated, the term cocaine misuse is used in this study in a generic 
sense and not according to the Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.; American Psychiatric Association, 1994).  
 
Participants were excluded from the study if they were unable to comprehend it, had 
a psychotic disorder (schizophrenia, bipolar disorder) that was not adequately 
controlled by medication, were currently suicidal or were affected by serious 
unstable medical illnesses. Further, clients who already participated in another 
research project were also excluded. Study criteria were not restrictive to increase 
generalisation of findings. Participation in the research project was voluntary, 
informed consent was obtained and confidentiality of the responses was assured by 
anonymising the data. For more details please see section, II.7. Ethical 
Considerations and Consent. 
 
A convenience sampling method was employed. Research assistants and drug and 
alcohol workers presented and discussed the study with 49 clients. Those not 
consented stated that they were not interested to participate in the study (n = 4), or 
did not meet the study criteria (n = 3). Twenty-one (50%) clients agreed to 
participate in the contingency management group and started to attend scheduled 
reinforcement sessions. A further twenty-one (50%) clients initially agreed to 
participate in the CM group but did not attend any of the scheduled reinforcement 
sessions. It was spontaneously decided that this group of clients could function as a 
                                                
6  Crack cocaine is often taken repeatedly over a period of time that may last hours or days, called a     
‘crack cocaine binge’, this count frequently refers to a binge. 
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comparison group (standard treatment group). Clearly, the nature of this group and 
the non-randomisation of the participants carry certain implications in terms of the 
conclusions that can be drawn from the study, please see section, IV. Discussion. 
Inspection of the data revealed that the 7 excluded patients were similar to the 42 
patients who represented the final sample, in terms of years of heroin and cocaine 
use, demographics, previous drug treatment attempts and opiate substitution dose 
(for more details regarding the final sample please see section, III.4. Demographic 
and Baseline Characteristic section, Table 1).  
 
Representativeness of the sample was examined by pertaining to the statistics from 
the National Drug Treatment Monitoring System (NDTMS: Annual Report, 
2008/09), regarding the following client characteristics; age, gender and ethnicity. 
First, the average age for the CM group was 42 years (SD = 10) and 42 years (SD = 
7) for the standard treatment group, this is comparable to the average age of 44 of 
opiate and crack cocaine users in the NDTMS report. Second, the NDTMS report did 
not provide any data on opiate and crack cocaine users in London compiled by 
gender. However, 30% of all clients seeking treatment in drug and alcohol services in 
London were female. This number was slightly higher in the CM group 48% (female 
participants) and slightly lower 24% (female participants) in the ST group. Third, 
according to the NDTMS report, 67% of all clients’ seeking treatment for drug and 
alcohol problems in London reported to be White and 33% belonged to other ethnic 
groups (i.e., ‘Mixed’, ‘Asian British’, ‘Black British’, ‘Other Ethnicity’ and ‘Not 
stated’). This was comparable to 76% and 86% of clients who reported to belong to a 
White ethnic group in the CM and standard treatment group, respectively. Moreover, 
the distribution of ethnicity was representative of the General Population census in 
London (2001) where 72% reported to be White British and 28% belonged to other 
ethnic groups. Equally, the distribution of ethnicity was representative of the 
population served by this Trust (Dr. N. Margerison, personal communication; April 
2008).  
 
II.3. Research Assistants and Drug and Alcohol Workers  
 
The team consisted of 9 drug and alcohol workers, 5 female and 4 male, and 2 
female research assistants. The drug and alcohol workers had a minimum of 1 year 
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work experience at the service. Their formal education ranged from no degree to a 
master’s degree in substance misuse. The research assistants held a bachelor degree 
in psychology. All had completed a minimum of 2 hours introductory behavioural 
modification training and were required to apply the NTA treatment guidelines. The 
drug and alcohol workers and research assistants were able to discuss any questions 
at weekly team meetings. 
 
II.4. Study Groups 
 
II.4.1. Standard Treatment Group (ST) 
 
Participants in both groups received the clinic’s standard treatment. This consisted of 
opiate substitution treatment and psychosocial interventions. Standard opiate 
substitution treatment was delivered by drug and alcohol workers, and included 
issuing fortnightly methadone or buprenorphine prescriptions. Methadone and 
buprenorphine are both long-acting, orally effective opiate medication that are used 
to treat opiate dependence. Standard treatment group participants (n = 21) presented 
their prescriptions to a pharmacy that dispensed the opiate substitute on a daily or 
weekly basis. Participants ingested an opiate substitute dose daily and attended 
individual drug and alcohol worker session, which included psycho-education, crisis 
intervention, HIV education, 12-step oriented treatment, relapse prevention treatment 
(including life skills training) and motivational interventions, which ranged from 2 
times per week to once fortnightly. This depended on the desired engagement of the 
client. Additionally, regular reviews of the adequacy of the medication dose 
(methadone or buprenorphine) and harm reduction advice was conducted by medical 
doctors.  
 
Clients’ frequency of cocaine, amphetamines, benzodiazepines, opiates, 
buprenorphine and methadone use was monitored by self-report (TOP questionnaire) 
and a minimum of fortnightly urinalysis by drug and alcohol worker. Participants 
received immediate feedback on their results. Staff congratulated participants when 
s/he tested negative for any of the above substances and encouraged them to stop 
using when they tested positive. This was part of the service protocol. 
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II.4.2. Contingency Management Group (CM) 
 
Contingency Management group participants (n = 21) received the standard 
treatment protocol and the behavioural intervention. For the arrangements of the 
standard treatment including the opiate substitution delivery, please see section, 
II.4.1. Standard Treatment Group. 
 
Cocaine use, as measured by urine analysis, was the principal dependent measure 
during treatment. Urine specimens were collected by staff according to a fixed 
monitoring schedule 3 days/week during weeks 1 – 3 (e.g., Monday, Wednesday and 
Friday), 2 days/week during weeks 4 – 6 (e.g., Monday and Friday) and 1 day/week 
during weeks 7 – 12 (usually Wednesday). In total, up to 21 specimens could be 
submitted over a 12-week treatment period. A negative urine sample for cocaine was 
required to earn a voucher. In week 7 of the incentive schedule, two participants 
submitted two urine samples instead of one and hence earned two vouchers worth 
£15. It was decided to continue with the incentive schedule as planned.  
 
Participants earned vouchers with a specified incentive value (please see below), 
exchangeable for retail goods, for each cocaine-negative sample they submitted. 
Voucher amounts started at £5 with submission of the first negative specimen up to a 
maximum of £20 per negative sample. Voucher amounts were reset to £5 with 
submission of a positive specimen, refusal to submit a specimen, or an unexcused 
absence (not approved by the research assistant at least 24 hrs in advance). The next 
consecutive negative specimen was reinstated stepping up from £5. There was no 
change to the incentive schedule. 
 
Participants could earn a maximum of £240 in vouchers if they submitted all 21 
scheduled negative specimens. Vouchers could be redeemed at the following retail 
stores: Argos, Boots, JJB Sports, MK One, Shoe Express, Virgin Megastores, WH 
Smith and Woolworths. Vouchers could be spent on virtually any item, except 
alcohol and cigarettes, and were usually used for food, clothing and electronic 
equipment. 
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Incentive schedule: 
Week 1    = 3 drug-free urine analyses      £5         £5         £5 
Week 2    = 3 drug-free urine analyses      £5         £5         £5 
Week 3    = 3 drug-free urine analyses      £10       £10       £10 
Week 4    = 2 drug-free urine analyses      £10       £10      
Week 5    = 2 drug-free urine analyses      £10       £10 
Week 6    = 2 drug-free urine analyses      £15       £15 
Week 7    = 1 drug-free urine analysis       £15      
Week 8    = 1 drug-free urine analysis       £15 
Week 9    = 1 drug-free urine analysis       £20 
Week 10  = 1 drug-free urine analysis       £20 
Week 11  = 1 drug-free urine analysis       £20 
Week 12  = 1 drug-free urine analysis       £20 
 
Travel fares were reimbursed on receipt of a valid bus / tube ticket from the home 
address or other evidence e.g. oyster card printout. Clients that had additional 
appointment/s at the service on the same day were only reimbursed once for their 
fares. The highest amount that was reimbursed was £4.80 where an off peak travel 
card had been purchased. Researchers monitored study procedures in both conditions 
at least weekly to ensure appropriate conduct. 
 
II.5.  Procedure 
 
All clients that fulfilled the above mentioned inclusion criteria received an Invitation 
letter of the CM trial (Appendix III), either at the service or via mail. A follow up 
phone call or in person contact at the service was made by the research assistant to 
establish whether the client was interested to participate. If the client declared her/his 
interest to participate in the study, the research assistant verbally explained the 
content of the Information letter (Appendix III) and highlighted what it would 
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involve to participate. The research assistants assured themselves that the client had 
understood the requirements and pointed out that s/he had 7 to 14 days to make a 
decision. If at the next scheduled psychosocial session with the drug worker, the 
client expressed her/his interest to participate in the study, the researcher verbally 
explained the content of the standardised NHS consent form (Appendix III) and had 
it signed by the client and a witness. The researcher completed the TOP and the CISS 
questionnaire with the client. It is common practice that clients are asked to complete 
the TOP and CISS questionnaire at regular intervals. Relevant demographic 
information was recorded by the researcher, from the clinical file of the clients, in 
order not to inundate the participants with further questions. An appointment was 
made to start the CM protocol, usually within the next two weeks of signing the 
consent form. At the first CM session the participants submitted a urine sample and 
thereby started the CM protocol (for the incentive schedule, see section II.4.2. 
Contingency Management Group). If the client decided not to attend the scheduled 
CM appointment but continued to attend standard treatment, s/he was assigned to the 
comparison group receiving the usual standard opiate substitution treatment at the 
service, for more information please see section II.4.1. Standard Treatment Group. 
However, in first six months of the CM programme it was possible for a client in the 
comparison group to change her/his mind and join the programme if s/he wished to 
do so. None of the clients in the comparison group made use of this option. 
 
For both groups, the responses from the questionnaires (TOP and CISS) were used as 
the baseline (timepoint 1), including the response for the crack consumed in the past 
28 days and were cross-checked with the routine weekly/fortnightly urinalysis 
results. There were no discrepancies regarding the self-reported cocaine consumed in 
relation to the urinalysis results in either group.  
 
All urine samples were tested immediately using an onsite testing system EZ-Split 
Key Cup (Quantum Diagnostics, Waltham Abbey, U.K.) that detected cocaine, 
amphetamines, benzodiazepines, opiates, buprenorphine and methadone (for the 
urine sample collection and testing, see section II.6.1. Urine Toxicology). In the CM 
group, a negative urine sample for cocaine was required to earn a voucher. 
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Study participation did not impact standard care services. The service placed no 
systematic contingencies on drug use, as long as clients did not attend the service 
grossly intoxicated. Overt intoxication would result in no clinic services that day. 
However, no instances of gross intoxication occurred with any study participants 
during the course of the study. The NHS service operates from a harm minimisation 
model and hence the emphasis is on treatment retention and no sanctions are applied 
for illicit drug use. Participants could continue receiving standard treatment without 
continuing in the study and after study completion. Although the information letter 
stated that the participant could ask the drug and alcohol worker and/or the 
researcher (telephone number and email address were provided) for further 
information, none of the participants made use of these options. Finally, the 
debriefing letter (Appendix III) was either presented by the researcher at the last 
scheduled contingency session or by the drug and alcohol worker if the client did not 
attend CM sessions.  
 
Follow-up evaluations were scheduled for both groups at: Timepoint 2, one week 
after completion of the intervention period (12 weeks + 1 week) and timepoint 3, (6 
months after the CM intervention concluded). Research assistants completed the 
TOP and the CISS with the participants present, and urine samples were collected 
within 1 – 2 weeks.  
 
No clients refused participation in the follow-up evaluation, not even those who had 
withdrawn from the urine collection portion of the study. The decision to withdraw 
from the urine collection portion was made at the discretion of the participant. 
Follow-up participation rates did not differ significantly by group. One participant in 
the CM group lost his life tragically in a drug related crime and hence no follow-up 
data could be collected. 
 
II.6.  Outcome Measures and Assessments 
 
II.6.1. Urine Toxicology 
 
All urine samples were tested immediately using an onsite testing system EZ-Split 
Key Cup (Quantum Diagnostics) that detected cocaine, amphetamines, 
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benzodiazepines, opiates, buprenorphine and methadone (for further information and 
instructions, please see Appendix IV). Attention was paid to sample veracity. 
Participants were asked to leave their coats / jackets / bags etc. outside of the toilet 
cubicle. Samples were provided directly into a plastic, disposable receptacle. Validity 
checks included the use of an external temperature strip, the range for a unadultered 
specimen is 32–38˚Celsius (Quantum Diagnostics, 2007). A minimum sample size of 
25mls was required for the urine test to be effective. Among other substances, valid 
samples were qualitatively tested for the metabolites of cocaine (benzoylecgonine). 
The test identifies specimens as positive if metabolite concentrations are greater than 
or equal to 300ng/ml. The approximate cut-off detection time for benzoylecgonine is 
2 – 7 days. For the cut-off levels and times for the other substances, please refer to 
Appendix IV. Urine samples that failed the validity check were discarded and 
participants were asked to provide another sample. If a concern remained that the 
provided urine sample was not genuine, the test was invalid and a positive result was 
assumed (please see, Appendix III – Information Letter). This did not occur in the 
study.  
 
II.6.2. Treatment Outcome Profile 
 
The Treatment Outcomes Profile (TOP) is a multidimensional structured interview 
for the evaluation of substance misuse treatment and has been developed by the 
National Treatment Agency for Substance Misuse (Marsden et al., 2008). It is one of 
the most commonly used standardised assessment instruments to evaluate the 
effectiveness of drug treatments in the field of substance use in the UK (for the 
questionnaire, please see Appendix IV). It is used at the start of treatment, in care 
plan reviews and is reported through the National Drug Treatment Monitoring 
System (NDTMS). The TOP is partially based on the Maudsley Addiction Profile 
(Marsden et al., 1998) and was developed as a brief alternative. The TOP comprises 
20 items representing the following four key drug treatment outcomes, targeting the 
past four weeks: 
 
• Substance use  
• Injecting risk behaviour  
• Offending and criminal involvement  
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• Health and social functioning  
 
The TOP features three types of responses: (a) Timeline, the participants are invited 
to recall the number of days in each of the past four weeks in which they engaged in 
the behaviour stated in the question, for example, the number of days they used 
opiates and the number of days they attended college. A total score is calculated 
which can range from 0 – 28 days. (b) Yes and no, a simple tick for yes or no. (c) 
Rating scale, a 20 – point scale, where a score of 0 = poor and a score of 20 = good.    
 
Psychometric properties of the TOP have been reported in detail elsewhere (Marsden 
et al., 2008) and results will only be summarised here. A prospective cohort study of 
1021 service users, aged between 16 – 62 years, were recruited from 63 treatment 
agencies in England. These drug and alcohol treatment agencies provided the 
following services; opiate substitution treatment, psychosocial interventions, in-
patient detoxification and residential rehabilitation. The personal interviews were 
conducted by 163 drug and alcohol workers. The test-retest stability was moderate to 
high, using a 1-week and 1-month interval (Marsden et al., 2008). The twenty 
outcome measures met inter-rater reliability criteria: days used alcohol, opiate, crack 
cocaine, cocaine powder, amphetamines, cannabis and one other named substance; 
days injected and period prevalence of direct or indirect needle/syringe sharing; 
subjective rating of physical and psychological health; days committed shop theft 
and drug selling, period prevalence of vehicle, property, fraud/forgery and 
assault/violence offences; rating of quality of life; days worked and attended for 
education/training; and period prevalence of acute housing problems and risk of 
eviction. Intraclass correlation coefficients for scale measures and Cohen's kappa for 
dichotomous measures reached or exceeded 0.75 and 0.61, respectively (Marsden et 
al., 2008). Convergent validity was assessed with other instruments in the field, for 
example, the Life Stressors and Social Resources Inventory (Moos, Fenn & Billings, 
1988), the Addiction Severity Index (McLellan, Luborsky, Woody, & O'Brien, 1980; 
McLellan et al., 1992) and self-reported behaviours, and items were found to be in 
the range of moderate to good. There were satisfactory validity assessments and 
change sensitivity of scale items judged by effect size and smallest detectable 
difference. In conclusion, the TOP is a reliable and valid 20-item instrument for 
treatment outcomes monitoring (Marsden et al., 2008). The TOP is in the public 
 110 
domain and therefore can be used without cost but with due acknowledgement of its 
source (Marsden et al., 2008).  
 
II.6.3.  Christo Inventory for Substance Misuse Services 
 
The Christo Inventory for Substance-Misuse Services (CISS) is a standardised, 
validated tool (Christo, Spurrell & Alcorn, 2000; Christo, 2000a) now commonly 
used in Scotland (Effective Interventions Unit, 2001), England & Wales 
(Christo,1999a,b,c; Christo, 2000b,c,d,e,f; Christo, 2001; Audit Commission, 2002), 
and abroad (Christo & Da Silva, 2002). The CISS is a single page outcome 
evaluation tool completed by drug and alcohol service workers, either from direct 
client interviews or from personal experience of their client supplemented by existing 
assessment notes (for the questionnaire, please see Appendix IV). Its purpose is to 
elicit workers’ impressions of their clients in the past 30 days in a quick, quantitative, 
standardised and reliable way. The 0 to 20 unidimensional scale consists of 10 items 
reflecting clients’ problems with: 
 
Drug / alcohol use      General health 
Psychological functioning     Social functioning        
Sexual / injecting risk behaviour     Occupation                
Criminal involvement     Ongoing support   
Compliance       Working relationships 
       
These outcome areas are scored on a three point scale of problem severity (0 = none, 
1 = moderate, 2 = severe), each point is illustrated with relevant examples for 
guidance. To avoid the use of the number 0 in the data analysis, the scale was 
transformed to 1 = none, 2 = moderate, 3 = severe. Thus, a CISS score of 10 would 
indicate no problems and a score of 30 would indicate severe problems in all 
outcome areas. Use of a single outcome measure produces a simple and readable 
report. The process is further simplified because the CISS outcome score can be 
reduced to two or three categories, e.g., 'good/poor' outcome or 'low/average/high' 
problem severity. For abstinence-oriented treatment, a score of 6 (transformed score 
= 12) or less is indicative of a good outcome. For drug services based on harm 
minimisation, a score of 0 (5) to 5 (10) = low problem severity, 6 (12) to 12 (24) = 
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average, 13 (26) to 20 (40) = high problem severity. For outpatient alcohol services, 
the score distribution is similar but shifted down one point less than drug users. 
Alcohol users are less likely to score on problems of social functioning, HIV risk 
behaviour and criminal involvement, but they are more likely to score on 
psychological problems. The spread of CISS scores cover the entire range, and there 
are no restricted variance, floor or ceiling effects in the score distribution (Christo, 
Spurrell & Alcorn, 2000). 
 
Psychometric properties of the CISS have been reported in detail elsewhere (Christo, 
Spurrell & Alcorn, 2000) and results will only be summarised here. In a validation 
study (Christo, Spurrell & Alcorn, 2000), comparison scores indicating low, average 
or high problem severity were produced by 243 drug users attending a harm 
minimisation outpatient service and 102 alcohol users at an outpatient alcohol 
service. Means and cut-off scores for abstinence oriented treatments were derived 
from a 6-month follow-up of 90 treated drug users. The item alpha coefficient of 
internal consistency was 0.74, thus indicating that scale items were sufficiently 
different to avoid redundancy, yet sufficiently related to form an acceptable 
unidimensional scale. The test-retest coefficient was 0.82, and the inter-rater 
coefficient was 0.82. The inter-rater coefficient increased to 0.91 when re-tests were 
conducted the same day. These figures indicated the scale to be of satisfactory 
reliability. The CISS demonstrated good face validity as its items were acceptable to 
drug and alcohol workers, and clients. Clients generally preferred face to face 
interviews that did not require self-completion (Christo, Spurrell & Alcorn, 2000). 
Given that the CISS was developed from relevant outcome research and existing 
multidimensional instruments, all CISS items addressed areas considered relevant to 
substance misuse outcome, thus content validity is good. 
 
The concurrent validity of the CISS was satisfactory, its scores correlated well with 
other measures of treatment outcome. Among the abstinence oriented treatment 
sample, the CISS produced correlations ranging from 0.43 to 0.99 with the Opiate 
Treatment Index (Darke et al., 1991, 1992), Spielberger trait anxiety inventory 
(Spielberger et al., 1984), the Rosenberg self-esteem inventory (Rosenberg, 1965), 
and the custom scales; unpleasant life events (Christo, Spurrell & Alcorn, 2000) and 
quality of life (Christo, Spurrell & Alcorn, 2000).  
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The simplicity, flexibility and brevity of the CISS make it a useful tool allowing 
comparison of clients within and between many different service settings (Audit 
Commission, 2002). The tool is freely distributed via the internet (Christo, 2008), the 
conditions for use being that it is not sold for profit and the title, instructions and 
item wording are not altered. 
 
For the purpose of the present study, only two items from the client-support 
interaction were extracted from the CISS; Compliance – measuring client 
compliance and reliability with treatment requirements. This is a clinician observed 
measure of reliability, the absence of which is one of the first indicators of an 
addiction problem. Many clients will have lost jobs through being late or absent. The 
ability to turn up on time and co-operate with requirements of others is a critical 
indicator of recovery and re-integration with society (Christo, 2000a). Working 
Relationship – measuring the quality of the working relationship between worker and 
client. This is a directly observed measure of the client’s ability to interact with 
others. While the item pertains to interaction with the clinician, the behaviours 
usually generalise to all individuals the client may have contact with. For example, it 
has been found in clinical practice that clients that present with a dual-diagnosis of 
severe depression, personality disorder or psychosis score particularly highly on the 
'compliance' and 'working relationships' items (Christo, 2000a). Yet, if these 
symptoms decrease, the individual becomes more able to engage in social 
interactions and relationships (Christo, 2008). 
 
These items are not captured by the TOP but have shown to be good predictors for 
many different drug treatment outcomes. Specifically, therapeutic relationships, pre-
treatment motivation and programmes engagement have demonstrated to be central 
attributes of effective treatment (Simpson et al., 1997). Given that we aimed to 
identify client characteristics that are predictors of CM treatment outcome, it seemed 
important to complement the four outcome variables from the TOP with the two 
client-support interaction items from the CISS. This was discussed in detail and 
supported by the author from the CISS (Dr. G. Christo, personal communication; 
February 2008). All other questionnaire items from the CISS are very similar to the 
TOP. 
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II.7.  Ethical Considerations and Consent 
 
The National Treatment Agency for Substance Misuse (NTA) commissioned a 
nationwide trial of contingency management at drug and alcohol NHS services, in 
the UK, in 2008 - 2009. The trials were in accordance with the guidelines for ‘Drug 
Misuse: Psychosocial Interventions’ published by the National Institute for Health 
and Clinical Excellence (NICE, 2007) and these guidelines have been developed by 
the ‘The British Psychological Society’ and ‘The Royal College of Psychiatrists’.  
 
General approval for the trial was sought by the NTA from the Department of 
Health. The regional approval from the Trust’s Clinical Director and Clinical 
Governance Committee was sought by the service manager. For a letter stating that 
these permissions were granted please see, Appendix II. The study adhered to the 
British Psychological Society’s Code of Ethics and Conduct (2009) and the Ethical 
Principles for Conducting Research with Human Participants (2010). The ethics 
release form from City University was completed (Appendix I).  
 
Informed Consent – Clients received an invitation letter (Appendix III) that outlined 
the nature of the study and what it involved to participate. If the client declared 
her/his interest after reading the invitation letter, the participant was given the client 
information letter (Appendix III) which explained in detail the aims of the study, a 
short summary explaining the motivations of the research, and reasons they were 
chosen to participate. The information letter stated the rules of the CM trial and the 
incentive schedule with the escalating voucher earnings for each submitted cocaine 
negative urine sample. The drug and alcohol worker also explained that participation 
is voluntary and that s/he can withdraw at any time, without giving any reason, 
without the participant’s medical care or legal rights being affected. The information 
letter also stated that travel expenses were reimbursed. It also provided the telephone 
numbers and addresses of the researchers. The client kept a copy of both, the 
information letter and the consent form. 
 
Regarding the allocation of the clients to the standard treatment group, clients that 
had signed the informed consent form but did not attend any of the scheduled CM 
sessions were asked verbally by the drug worker/research assistant, if we could 
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continue to collect their data for the study. Only data that was gathered through 
routine clinical treatment evaluation (i.e., TOP and CISS questionnaires) was 
congregated from the case notes. Importantly, all clients in the study had signed ‘the 
consent to share information’ in the initial assessment form from our service, which 
is the formal; ‘Substance misuse services initial assessment form’. Specifically, 
consent was given to share information with staff at the service, National Drug 
Treatment Monitoring System (NDTMS), and in some cases a related drug and 
alcohol service in the area, the client’s GP and other involved organisations. Thus 
clients in the standard treatment group were not burdened with any further questions 
or demands, and continued to receive standard treatment including maintenance 
prescription of methadone or buprenorphine, and key working sessions from drug 
workers who acted as case co-ordinators for their care. However, in the first six 
months of the CM programme drug workers occasionally reminded clients that the 
CM programme was running and that it was possible for a client in the standard 
treatment group to change her/his mind and join the programme if s/he wished to do 
so. If a client declared her/his interest, clients were informed that they could arrange 
an appointment for a CM session and thereby start the CM programme. None of the 
clients in the comparison group made use of this option. 
 
It should be noted that the idea to proceed to gather the data from the clients that had 
not attended the CM sessions was spontaneous. The realisation was that important 
baseline information had been collected and that it was likely that these clients would 
continue to visit our service. Thus a decision was made that we would try to continue 
to collect this valuable information in order to create a comparison group.  
 
When the 12-week CM programme concluded, we implemented a similar 
behavioural model, whereby drug workers and psychologists tailored incentives to 
individual clients. In accordance with the harm minimisation model we embraced 
rehabilitation, recovery and self-sufficiency as primary treatment goals in 
collaboration with the client. All opiate maintenance clients were offered incentives 
as a possible intervention if they wished to attain objective treatment plan goals they 
had not mastered so far. Setting of the treatment plan goals was established in 
collaboration with the client and drug worker/psychologist.  
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The content of the invitation letter, information letter, consent form and debriefing 
letter were verbally explained to the participants. Given that the current participants 
were substance users, it was particularly important to clarify that rejecting or 
withdrawing from participation, at any point would not have any impact on their 
standard care treatment. Moreover, the information and debriefing letter stated that 
the participants could ask the drug and alcohol workers and/or the researchers if they 
wished to receive any further information about the study. The research assistants 
made an effort to invite participants to ask questions. A standardised NHS consent 
form (Appendix III) was signed by the individuals prior to participation. A debriefing 
letter (Appendix III) was handed to each participant either by the research assistant at 
the last contingency session or by a drug and alcohol worker if the client did not 
return for further contingencies.  
 
Confidentiality and anonymity – The names of the participants were not used in the 
study and the questionnaires are not identifiable. The research assistants held a list of 
identification numbers which were assigned to clients immediately after consent 
forms were signed, and were used on recording sheets to preserve client anonymity. 
For the duration of the study, the research assistants were required to keep the list in 
their possession so as to correctly assign the collected urine specimen at each 
contingent. At the conclusion of the study, the list was handed over to the lead 
researcher. All clients were made aware and consented to staff being privy to her/his 
notes.  
 
Ownership of data and conclusions – The data is owned by service and will be 
destroyed one year after submitting the research. It will be kept securely in a locked 
filing cabinet. The conclusions will be given to theservice and are its intellectual 
property. In the debriefing letter, the client is offered the opportunity to contact us at 
the service in person or via the telephone if s/he wants to know the results of the 
research or for further questions. 
 
 
III.  RESULTS 
 
 116 
III.1. Software for the Statistical Analyses 
 
The statistical analysis was conducted with the software SPSS 20.0 for Apple Mac 
Personal Computer 2012 and Microsoft Office Excel 2007 for Microsoft Windows 
XP 2002.  
 
III.2. Statistics for the Measured Variables 
 
The assumption of univariate and multivariate normality were evaluated for both 
groups separately (Appendix VI). The continuous variables: age, years of cocaine 
use, years of heroin use, methadone and buprenorphine dose, mean number of 
previous treatment attempts, and the continuous variables from the TOP 
questionnaire; crack, cocaine, opiates, alcohol, cannabis use, days attended work 
and/or college, psychological health, physical health and overall quality of life, 
criminal involvement, and the ordinal variables from the CISS questionnaire; 
working relationship and compliance and reliability with treatment requirements 
were examined through various SPSS programmes for accuracy of data entry, 
missing values, and fit between their distributions and the assumptions of 
multivariate analysis.   
 
The mean, standard deviation, skewness and kurtosis for the standard and 
contingency management groups were inspected. The Shapiro-Wilk test was used to 
assess numerically if the variables were normally distributed (the test is 
recommended for sample sizes < 50) (Bortz & Lienert, 2008). The convention is that 
a p-value of ≥.05 for a variable indicates that the distribution is significantly different 
from a normal distribution (Backhaus, Erichson, Plinke & Weiber, 2006). This was 
observed on the majority of the variables. Additionally, visual examination of the 
histograms confirmed this conclusion, showing skewness and kurtosis of the 
variables.  
 
The conservative convention of the interquartile range (IQR) was used to define 
outliers from the normal distribution. IQR is defined as the range of the middle 50% 
of the observations, or the difference between the 25th percentile and the 75th 
percentile (Aitken & Cardinal, 2006). An observation is called an outlier if it exceeds 
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the IQR by 1.5 times and an observation is deemed extreme if it differs 3 times 
(ibid). Inspection of the boxplots showed outliers on the majority of variables and a 
few extreme cases were also observed.  
 
Thus, considering the results from the diagnostic analyses outlined above and the 
small sample size, non-parametric statistical methods are recommended for all 
variables, for the purpose of rigour and consistency.  
 
The procedure of the Mahalanobis distances score was used to identify multivariate 
outliers (Tabachnik & Fidell, 2001). The procedure calculates the distance of 
particular scores from the centre cluster of the remaining cases and produces a z 
score. The z score for each participant is calculated and is considered an outlier if it 
exceeds a critical value. No cases were identified as multivariate outliers, that is, no 
variable was in excess of a z score of 56.892 (df  = 28; p < .001) (Tabachnik & 
Fidell, 2001). 
 
A missing data analysis was conducted, which showed that the missing values were 
randomly distributed and each variable had less than 5% missing values (Tabachnik 
& Fidell, 2001). In fact, a visual inspection of the data revealed that the responses of 
only one participant in the CM group at timepoint 3 were missing. Therefore, 
analyses that involved data from timepoint 3 was calculated by applying the SPSS 
default command – ‘listwise deletion’, otherwise N = 42 out of 42 cases were 
available for data analysis. All the analyses were performed on raw data, provided in 
Appendix V. 
 
III.3. Statistical Methods 
 
The results section is composed of two parts; the first part is concerned with the 
between-groups analysis, i.e. the comparison between the CM and ST groups, and 
the second part is dedicated to detailed within-group analyses of the CM group.  
 
 
III.3.1. Between-Group Analyses  
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Data analyses of the demographic and baseline characteristics for the standard 
treatment and the contingency management groups were conducted using Mann-
Whitney U tests for continuous and ordinal variables, and chi-square for categorical 
variables (Appendix VI). 
 
The data for the three measured timepoints 1, 2 and 3 were examined using Mann-
Whitney U tests for between group differences, and Friedman tests to compare the 
three timepoints for the standard treatment and contingency management groups 
separately (Appendix VI). Where appropriate, post-hoc analyses with Wilcoxon 
signed-rank tests were conducted with a Bonferroni correction applied. That is, 
pairwise contrasts between timepoints were conducted with χ2 tests using α levels 
determined by dividing the conventional α of .05 by the number of pairwise 
comparison made. For the three timepoints, the following outcome variables from the 
TOP questionnaires were examined; crack, cocaine, alcohol, opiates, cannabis use, 
days attended work and/or college, criminal involvement, psychological health, 
physical health, quality of life, and the two extracted outcome variables from the 
CISS questionnaire; measured quality of the working relationship between drug 
worker and client, and compliance and reliability with treatment requirements.  
 
The following outcome measures of the TOP will not be presented in the results 
section, due to no or too few responses: (a) None of the participants reported any 
cocaine use (b) Acute housing problem and/or at risk of eviction; two participants 
reported problems with their accommodation at timepoint 2. (c) Injecting risk 
behaviour; three participants reported high-risk injection practices. (d) One person 
reported using amphetamines twice a month and two participants reported the use of 
illicit diazepam 1 – 3 times a month at timepoint 2. Regarding the questionnaire 
items ‘days paid work’ and ‘days attended college or school’, the responses to these 
two separate, but related measures were consolidated to one category because there 
were too few participants responding positively to either of the questions.  
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III.3.2. Within-Group Analyses  
 
Conditional Probabilities of Change and Clinical Improvement 
Regarding the within-group analyses for the CM group, study results were 
investigated for evidence of clinically meaningful changes on an individual 
participant level. We operationalised the statistical method of conditional 
probabilities of change and the criteria of clinically meaningful change to assess 
outcome. These conventions were also used by Gawin et al., (1989), Stitzer et al., 
(1992) and Iguchi et al. (1997) to evaluate CM programme outcome. The definition 
of conditional probabilities of change is as follows; participants who could improve 
were defined as those whose baseline rate of cocaine free urines was 90% or less; 
these participants were classified as improved if their rate of cocaine free urines 
increased by 10% or more during the intervention. Participants who could deteriorate 
were defined as those whose baseline cocaine free urine rate was 10% or more; these 
participants were classified as deteriorated if their rate of cocaine free urines 
decreased by 10% or more during the intervention. Clients whose cocaine positive 
urine test rate for baseline versus intervention period remained within ±10% were 
classified as unchanged. The 10% urine improvement criterion was selected to 
eliminate small changes based on chance fluctuations (Gawin et al., 1989; Higgins et 
al., 1991; Carroll, Rounsaville & Gawin, 1991; Stitzer et al., 1992; Iguchi et al., 
1997).  
 
In order to apply an even more stringent definition of clinical improvement, a further 
standardised evaluation of treatment for crack cocaine misusing clients, namely the 
requirement of 3 consecutive cocaine free weeks was employed. The rationale for the 
3 week requirement of cocaine free urines was that this represented a clinically 
meaningful period of abstinence and, at the same time, constituted an achievable goal 
for the population of chronic supplemental users of cocaine in a 12 week intervention 
period (Stitzer et al., 1992; Iguchi et a., 1997).  
 
To give equal weight to urine results of early dropouts and those retained throughout 
the evaluation, data analyses were based on the overall percentage of cocaine 
positive urine samples given by each participant during baseline and during the 
portion of the intervention in which s/he participated. In this way, data from each 
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client contributed equally to the analysis whether or not the client stayed through the 
entire intervention period (Stitzer et al., 1992). Therefore, urine specimens not 
collected from participants leaving treatment prior to the end of the intervention 
period were counted as cocaine positive and missing urine samples were considered 
positive samples, which is predicated on a widely used approach in CM trials (for 
example, Silverman et al., 1996; Budney et al., 2000). 
 
Baseline and Crack Use During CM Intervention 
A non-parametric procedure, the Spearman’s rank order correlation coefficient (i.e., 
Spearman's rho) was performed to address the question whether self-reported 
baseline cocaine consume (timepoint 1) was associated with crack cocaine 
abstinence during the CM intervention period (Appendix VI).  
 
Survival Analysis  
A survival analysis Kaplan-Meier product-limit procedure (non-parametric) was 
employed to estimate time-to-event models and to examine the distribution of the 
time-to-event variables (Appendix VI). A great advantage and a unique characteristic 
of this method is that it accounts for censored observations, i.e. cases where the 
critical event (event of interest) has not occurred in the observed intervention period, 
and cases that are lost to analysis because of participants leaving treatment prior to 
the end of the intervention period. The latter are so-called ‘right censored cases’, of 
which the present sample comprised a fair amount. 
 
Two modelling strategies for retention data were used. For the first model, the 
outcome (‘event’) was determined as time to study dropout. The event was defined 
as the second consecutive occasion a scheduled reinforcement session was not 
attended and the absence was not authorised prior to the appointment. The second 
non-attendance was selected because several participants missed one scheduled 
reinforcement session but did not dropout of the study at that point. 
 
For the second model, outcome was specified as time to first positive cocaine 
urinalysis or second consecutive unexcused non-attendance (see first model). The 
event was specified as occurring when the first positive cocaine urinalysis or second 
unexcused non-attendance was produced (whichever occurred first).  
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For both models, the event (i.e. time to dropout or first positive cocaine urinalysis) 
was calculated from the first day of the study. If the event did not occur during the 
12-week period, data were censored at the last day of the intervention (usually Day 
84). Retention analyses are reported using the estimated survival function, mean, 
median and 95% confidence intervals (CIs). 
 
III.3.3. Changes in the Planned Data Analyses 
 
At the time of the proposal for the study (in 2008), the drug and alcohol service held 
a caseload of 270 opiate maintenance clients. In order to qualify for opiate 
substitution treatment, the policy at the service required weekly or fortnightly urine 
tests. An examination of 52 random urine samples revealed that 32 tests were 
positive for cocaine, that is 62%. It was extrapolated that approximately 167 clients 
(62% from 270 clients) consume cocaine or crack cocaine. Thus, the assumption was 
that approximately 50 clients use crack cocaine on a regular basis, have a desire to 
abstain from crack use and are interested to participate in a CM intervention.  
 
Within the realm of the (methodological) restrictions from the NTA, the study was 
designed. One of the aims was to investigate predictors of CM treatment outcome 
(please see section, I.10. Background of the Study, Research Aims and Questions), 
for example the two implemented measures from the CISS; treatment compliance 
and working relationship. To investigate these treatment outcome predictors, the 
statistical method of a logistic regression would have been indicated. However, the 
small sample size and the relatively few participants that remained abstinent for 
extended durations of time prevented the application of this method. Advanced 
statistical methods, such as logistic regression models, require greater sample sizes. 
Bergtold, Yeager, Jason and Featherstone (2011) established that sample size can 
affect parameter estimates and hence, the robustness of the inferences from logistic 
regression analysis. Equally, using a survival analysis model (for example, a Log 
rank (Mantel Cox test)) to establish whether gender differences can be observed with 
regard to treatment response was not feasible.  
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III.4. Demographics and Baseline Characteristics 
 
Table 1 shows demographic characteristics collected at intake for participants in 
standard treatment (n = 21) and contingency management (n = 21) groups. Data 
analyses were conducted using Mann-Whitney U tests for continuous and ordinal, 
and chi-square for categorical variables. Of the 23 baseline variables tested, only 2 
differed significantly between the two groups; self-reported years of cocaine use and 
the rated working relationship between the client and the drug worker, extracted from 
the CISS questionnaire. A Mann-Whitney U test revealed a statistically significant 
difference of the self-reported years of crack use between the standard treatment 
(median = 10; IQR = 10) and the contingency management groups (median = 15; 
IQR = 13), (U = 138.5; N1 = 21; N2 = 21; p = 0.039). Additionally, the working 
relationship between the client and the drug worker, as rated by the drug worker, 
showed a significant difference between the standard treatment (median = 3; IQR = 
0) and the contingency management groups (median = 2; IQR = 1), (U = 144.5; N1 = 
21; N2 = 21; p = 0.024). No differences were evident across groups on any other 
demographic variables. 
 
During the 28 days baseline phase (timepoint 1), the median numbers of self-reported 
crack use (verified with weekly or fortnightly drug tests) were 12 (IQR= 22) for the 
standard treatment group and 14 (IQR = 20) for the contingency management group. 
These numbers of crack use did not differ significantly across groups (U = 207.5; N1 
= 21; N2 = 21; p = 0.739). This result seems to indicate that the initial frequency of 
cocaine consumption was very similar in both groups. 
 
The maintenance dose of methadone for clients in the standard treatment and 
contingency management groups was not significantly different (U = 139.5; N1 = 21; 
N2 = 18; p = 0.160) and the median was 60 mg/day (IQR = 28) and 70 mg/day (IQR 
= 39), respectively. This average daily dose is comparable to a study by Silverman et 
al. (1998). Additionally, the recommended methadone maintenance dose range in the 
UK is 60–120 mg/day (NICE, 2007b).   
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Table 1 
Baseline Characteristics and Demographics of Study Participants (N = 42) 
 
Variable Standard 
Treatment 
Group 
(n=21) 
Contingency 
Management 
Group 
(n=21) 
Statistical  
Test 
Value of  
Test Statistic 
P-Value 
 
Age in years, Median [IQR] (n) 
 44 [11] (21) 40 [16] (21) MWU-Test 
(N=42) 
U=199 0.588 
 
Gender, % (n) 
Male 76.2 (16) 52.4 (11) Χ²-Test (N=42)  
 
Χ²=2.59;df=1 0.107 
Female 23.8 (5) 47.6 (10) 
 
Ethnicity, % (n) 
White British 76.2 (16) 85.7 (18) Χ²-Test (N=42)  
Fisher's exact test 
 0.697 a 
Other 23.8 (5) 14.3 (3) 
 
Marital status, % (n) 
Married/Cohabiting 42.9 (9) 42.9 (9) Χ²-Test (N=42) 
 
Χ²=0.00;df=1 1.000 
Single 57.1 (12) 57.1 (12) 
   
Employment status, % (n) 
Employed 14.3 (3) 4.8 (1) Χ²-Test (N=42) 
Fisher's exact test 
 0.606 a 
Unemployed 85.7 (18) 95.2 (20) 
 
Social income support, % (n) 
Yes 81.0 (17) 95.2 (20) Χ²-Test (N=42) 
Fisher's exact test 
 0.343 a 
No 19.0 (4) 4.8 (1) 
 
Years of cocaine use, Median, [IQR] (n) 
 10 [10] (21) 15 [13] (21) MWU-Test 
(N=42) 
U=138.5 0.039* 
 
Years of heroin use, Median, [IQR] (n) 
 17 [16] (21) 20 [7] (21) MWU-Test 
(N=42) 
U=212 0.830 
 
Methadone dose, mg/day, Median, [IQR] (n) 
 60 [28] (21) 70 [39] (18) MWU-Test 
(N=42) 
U=139.5 0.160 
 
Buprenorphine dose, mg/day, Median (n) 
  12   (3) b    
 
Median number of previous treatment attempts, Median, [IQR] (n) 
 1 [1] (21) 1  [2] (21) MWU-Test 
(N=42) 
U=-213.5 0.848 
 
Psychiatric diagnosis and/or current involvement with Mental Health services, % (n) 
No Diagnosis 61.9 (13) 47.6 (10) Χ²-Test (n=42)  
 
Χ²=0.865;df=1 0.352 
Diagnosis 38.1 (8) 52.4 (11) 
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Table 1 
Baseline Characteristics and Demographics of Study Participants (N = 42), 
continued 
 
Variable Standard 
Treatment 
Group 
(n=21) 
Contingency 
Management 
Group 
(n=21) 
Statistical  
Test 
Value of  
Test Statistic 
P-Value 
Treatment Outcome Profile 
 
Days of substance use in past 28 days – Crack
 c
, Median, [IQR] (n) 
  12  [22] (21) 14  [20] (21) MWU-Test 
(N=42) 
U=207.5 0.739 
 
Days of substance use in past 28 days – Opiates
 c
, Median, [IQR] (n) 
  12 [24] (21) 11 [28] (21) MWU-Test 
(N=42) 
U=190 0.433 
 
Days of substance use in past 28 days – Alcohol
 c
, Median, [IQR] (n) 
  3  [28] (21) 0  [17] (21) MWU-Test 
(N=42) 
U=165.5 0.127 
 
Days of substance use in past 28 days – Cannabis
 c
, Median, [IQR] (n) 
  0  [0] (21) 0  [2] (21) MWU-Test 
(N=42) 
U=174 0.088 
 
Days attended work and/or college in past 28 days
 c
, Median, [IQR] (n) 
  0  [0]  (21) 0  [0] (21) MWU-Test 
(N=42) 
U=208.5 0.591 
 
Criminal involvement in past 28 days
 c
, Median, [IQR] (n) 
  0 [0]  (21) 0 [10] (21) MWU-Test 
(N=42)) 
U=162 0.057 
 
Psychological health in past 28 days
 d
, Median, [IQR] (n) 
  10 [7]  (21) 10 [5] (21) MWU-Test 
(N=42) 
U=192.5 0.476 
 
Physical health in past 28 days
 d
, Median, [IQR] (n) 
  10 [10] (21) 10 [5] (21) MWU-Test 
(N=42) 
U=214 0.869 
Overall Quality of Life in past 28 days
 d
, Median, [IQR] (n) 
  10 [9] (21) 10 [8] (21) MWU-Test 
(N=42) 
U=209.5 0.781 
Christo Inventory for Substance Misuse Services
 e 
 
 
Compliance with treatment requirements, Median, [IQR] (n) 
  2 [1]  (21) 2 [2] (21) MWU-Test 
(N=42) 
U=175.5 0.227 
 
Quality of working relationship, Median, [IQR] (n) 
  3  [0]  (21) 2  [1]  (21) MWU-Test 
(N=42) 
U=144.5 0.024* 
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Note. All p values are for two-tailed test and significance value is set at p <.05. Only relevant 
responses from the questionnaires were reported and items with more than one positive response.  
 
a The analysis showed that 2 cells had an expected count less than 5, in this case SPSS does not 
provide a Fisher’s Exact value. 
 
b Only 3 participants in the CM group received buprenorphine. Hence, no IQR could be calculated and 
no between-group test could be performed.  
 
c The responses to these items from the TOP are scored on a timeline response, the participants were 
invited to recall the number of days in the past four weeks in which they engaged in the behaviour 
stated in the question, for example, the number of days they used opiates and the number of days they 
attended college. A total score was calculated which could range from 0 – 28 days. 
 
d The responses to these items from the TOP are scored on a rating scale, a 20 – point scale, where a 
score of 0 = poor and a score of 20 = good. 
 
e The responses to these two items from the CISS are scored on a three point scale of problem severity 
(1 = none, 2 = moderate, 3 = severe). Thus, an item score of 1 would indicate no problems and a score 
of 3 would indicate severe problems. 
 
 
III.5. Between-Group Analyses for the CM and ST Group 
 
III.5.1. Self-Reported Crack Cocaine Consume  
 
There was no statistically significant difference between the standard treatment and 
CM groups on self-reported crack consume (in the past 28 days) at timepoint 1, as 
reported above (please see section, III.4. Demographics and Baseline 
Characteristics) and timepoint 2 (U = 194.5, N1 = 21, N2 = 20, p = 0.684). There 
was, however, a statistically significant difference between the two groups at 
timepoint 3 (U = 130.5, N1 = 21, N2 = 20, p = 0.036). The median crack cocaine 
consume at timepoint 3, was 8 (IQR = 16) for the standard treatment and notably 
lower for the CM group 4 (IQR = 8).  
 
A Friedman test was used to examine the differences between the three timepoints 
within the standard treatment and the CM groups separately. Median crack cocaine 
consume for timepoint 1, 2 and 3 in the standard treatment group were 12 (IQR = 
22), 8 (IQR = 13) and 8 (IQR = 16), respectively. There was no statistically 
significant difference between the timepoints 1, 2 and 3 in the standard treatment 
group, (χ2 = 0.909; df = 2; p = 0.635), yet there was a reduction in self-reported 
 
 
 
126 
crack cocaine use from baseline to timepoint 2. Therefore, no post-hoc test was 
conducted.  
 
There was a statistically significant difference between the timepoints 1, 2 and 3 in 
the CM group, (χ2 = 12.265; df = 2; p = 0.002). Post-hoc analysis with Wilcoxon 
signed-rank tests was conducted with a Bonferroni correction applied, resulting in a 
significance level set at p < 0.017 (α = 0.05/3). Median crack cocaine consume for 
timepoint 1, timepoint 2 and timepoint 3 in the CM group were 14 (IQR = 20), 7 
(IQR = 11) and 4 (IQR = 8), respectively. These numbers differed significantly 
between timepoint 1 to timepoint 2 (Z = -2.693; n = 20; p = 0.007) and timepoint 1 to 
timepoint 3 (Z = -3.242; n = 20; p = 0.001), showing a reduction in crack cocaine use 
over time. Although there was a reduction in crack cocaine use between timepoint 2 
and 3, this reduction was not statistically significant (Z = -1.819; n = 20; p = 0.069). 
 
 
 
Figure 1. Median self-reported crack cocaine consumption (in the past 28 days) at timepoint 
1 (baseline), timepoint 2 (1 week after the CM intervention) and timepoint 3 (6 months after 
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the CM intervention concluded), for the standard treatment (ST; n = 21) and contingency 
management groups (CM; n = 21).    
 
 
 
III.5.2. Treatment Outcome Profile and Christo Inventory for 
Substance Misuse Services 
 
Mann Whitney U tests of the TOP and the CISS questionnaire responses showed the 
following results; there were no statistically significant differences between the ST 
and the CM groups at timepoints 1, 2 and 3 on the following measured variables: 
alcohol, opiates, cannabis use, days attended work and/or college, criminal 
involvement, psychological health, physical health and quality of life, and the 
variable compliance and reliability with treatment requirements from the CISS 
questionnaire.  
 
Regarding the measured quality of the working relationship between drug worker 
and client (derived from the CISS questionnaire), there was a statistically significant 
difference between the ST and CM groups at timepoint 1, as reported above (please 
see, III.4. Demographics and Baseline Characteristics section), and timepoint 3 (U = 
142, N1 = 21, N2 = 20, p = 0.034). There was no statistically significant difference 
between the two groups at timepoint 2 (U = 152.5, N1 = 21, N2 = 20, p = 0.078), 
median 3 (IQR = 1) and median 2 (IQR = 1) for the ST and CM groups respectively. 
The median of the rated quality of the working relationship at timepoint 1, was 3 
(IQR = 0) for the standard treatment and 2 (IQR = 1) for the contingency 
management groups. At timepoint 3, the median was 3 (IQR = 0) for the ST group 
and 2.5 (IQR = 1) for the CM group. As can be postulated by the IQR, there was 
very little statistical variability in the data. The collected data at timepoint 1 and 3 
suggests that the measured quality of the working relationship between the drug 
worker and client was rated as marginally less functional for the participants in the 
ST group compared to the participants in the CM group. 
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A Friedman test was used to examine the differences between the three timepoints 
within the ST and the CM groups separately. There was no statistically significant 
difference between timepoints 1, 2 and 3 in the ST group, (χ2 = 2.000; df = 2; p = 
0.368) and the CM group (χ2 = 2.000; df = 2; p = 0.368); therefore, no post-hoc test 
was conducted. This result seems to indicate that there was no improvement in the 
measured quality of the working relationship between the client and the drug worker 
in the ST and CM groups over time. Thus, although the crack cocaine consume 
decreased over time in the CM group, this seemed to have no effect on the measured 
quality of the working relationship. However, the results regarding the working 
relationship should be interpreted with caution, for reasons that are outlined in 
section IV. Discussion. 
 
 
III.6. Within-Group Analyses for the CM Group 
 
III.6.1. Treatment Acceptability, Voucher Earnings, Voucher 
Delivery and Baseline Use 
 
Treatment acceptability was informally inferred from the number of participants who 
attended more than one contingency session. This method was employed by Higgins, 
Budney et al., (1994), evaluating CM treatment acceptability. In their study, high 
levels of treatment acceptability were detected, that is 100%. In the present study, 13 
participants (62% participants) attended more than one contingency session, 
indicating slightly more than an average level of initial client acceptance. 
 
Mean voucher earnings for the CM group was £63 (SD = 102) and the total was 
£1.315. Nine (43%) of the participants submitted their first positive cocaine urine 
sample at the first contingency session and 6 (29%) of participants in the CM group 
failed to earn a single voucher.  
 
In an attempt to examine whether baseline (timepoint 1) crack use was associated 
with in-treatment abstinence, a Spearman correlation coefficient was used. There was 
no statistically significant correlation between the number of days of self-reported 
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baseline crack cocaine use and the number of cocaine free urine samples during 
treatment, (rho = -0.047; n = 21; p = 0.839). Thus, baseline drug use severity was not 
related to the initiation of abstinence in that individuals with more heavy use were 
not less likely to initiate abstinence. Some studies have shown that individuals who 
are abstinent or who evidence infrequent use prior to CM treatment have better 
outcomes than those who are using cocaine heavily and provide positive samples at 
study initiation (Poling, Kosten, & Sofuoglu, 2007; Stitzer et al., 2007). 
 
 
III.6.2. Conditional Probabilities of Change and Clinical 
Improvement 
 
Figure 1 is a visual illustration of the clinical improvement status of the participants 
after CM intervention. Overall, 21 participants delivered less than 90% cocaine free 
urines during the baseline period and, therefore, could have shown clinically 
significant improvement according to the a priori criteria. Conversely, 14 participants 
delivered more than 10% cocaine free urine samples during baseline, therefore, 
having the potential to meet the a priori criteria for clinically significant deterioration 
during intervention.  
 
Five of the 21 participants who could improve did improve their percentage of 
cocaine free urine tests by 10% or more and met the a priori criteria for clinical 
improvement - 3 consecutive cocaine free weeks. Those 5 participants (24%) 
delivered 21 cocaine free samples and hence, were abstinent for the entire 
intervention period (12 weeks). 
 
Nine of the 14 participants who could deteriorate met the 10% criterion for 
statistically significant deterioration. That is, 43% of the participants delivered less 
cocaine free samples in the intervention period than in the baseline period. Overall, 7 
participants remained within the ±10% range of cocaine positive urine samples and 
hence, were classified as unchanged. It is worth noting again at this point that 
missing urine specimens were counted as cocaine positive. 
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Statistical and Clinical Improvment Status after CM Intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The green bar depicts the number of participants who improved their cocaine free 
urine test results by ≥10% or more, from baseline (timepoint 1) to intervention period and 
submitted at least 3 consecutive cocaine free weeks during the intervention period. The 
yellow bar shows the number of participants whose urine positive test rate for baseline 
versus intervention periods remained within the ±10% range, these participants were 
classified as unchanged. The number of participants that were classified as deteriorated are 
depicted in the red bar, these participants increased their crack cocaine use from baseline to 
intervention period by ≥10%.     
 
III.6.3.  Survival Analyses 
 
Model 1 
The first Kaplan Meier model was computed using time to study dropout, i.e. the 
event was defined as; second consecutive unexcused non-attendance. The median 
time until the second consecutive scheduled reinforcement session was not attended 
was 14 days (CI = 11 – 17), and mean time was 28 days among participants in the 
CM group. The large difference between the estimated mean and median survival 
time was due to the majority of participants failing to attend two consecutive 
 
 
 
 
131 
scheduled reinforcement sessions at the beginning rather than towards the middle or 
the end of the CM intervention.  
Survival Function  –  Study Dropout 
 
Figure 3. Observed cumulative survival rates in percent among CM participants (n = 21). 
The y-axis (vertical) shows the percentage of participants surviving, i.e. continuing to attend 
the CM programme, while the x-axis (horizontal) shows the time in days since the initiation 
of the CM programme. Please note that the calculations of survival analysis start at day 0 
which is equal to day 1 of the CM programme, i.e. first attended reinforcement session. The 
status variable is defined as dropout; second consecutive unexcused non-attendance. If the 
event did not occur during the 12 week period, data were censored at the last scheduled 
reinforcement session (usually at day 84). Horizontal lines with vertical steps correspond to 
censored cases. The survival curve shows that 19% of the participants had failed to attend 
two consecutive reinforcement sessions by day 4 of the intervention period, and at day 14 the 
percentage had increased to 57%. By day 42 of the programme only 24% of the participants 
continued to attend the reinforcement sessions until the end of the study.   
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Model 2 
For the second Kaplan Meier model, the outcome variable was defined as; first 
positive cocaine urinalysis or second consecutive unexcused non-attendance 
(whichever occurred first). The median time until the first positive cocaine urinalysis 
or second consecutive unexcused non-attendance was produced was 4 days (CI = 0 – 
8) and mean time was 21 days among participants in the CM group. Again, the large 
difference between the estimated mean and median survival time was due to the 
majority of participants either delivering a positive urinalysis or failing to attend two 
consecutive scheduled reinforcement sessions at the beginning rather than towards 
the middle or the end of the CM intervention. 
 
 
Survival Function  –  First Positive Urinalysis/Study Dropout 
 
 
 
Figure 4. Observed cumulative survival rates in percent among CM participants (n = 21). 
The y-axis (vertical) shows the percentage of participants surviving, i.e. submitting cocaine 
free urine samples or continuing to attend the CM programme, while the x-axis (horizontal) 
shows the time in days since the initiation of the CM programme. Please note that the 
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calculations of survival analysis start at day 0 which is equal to day 1 of the CM programme, 
i.e. first attended reinforcement session. The status variable is defined as first positive 
cocaine urinalysis or second consecutive unexcused non-attendance (whichever occurred 
first). If the event did not occur during the 12 week period, data were censored at the last 
scheduled reinforcement session (usually at day 84). Horizontal lines with vertical steps 
correspond to censored cases. The survival curve shows that 43% of the participants 
submitted their first positive cocaine urine sample at day 1 of the CM programme. At day 5, 
67% of the participants had delivered their first positive cocaine urine sample or failed to 
attend their second consecutive reinforcement session. By day 14 of the intervention period, 
only 24% of the participants continued to attend the reinforcement sessions and continued to 
deliver cocaine free urine samples.   
 
To summarise, the survival analyses investigated the period during which abstinence 
was initiated. Results from the above analyses combined with previous research 
suggest timeframes for decision making in the event that a client does not respond. If 
clients were to become abstinent during the intervention period, they most often 
ceased using during the first 1 to 4 weeks of treatment. Thus, continued application 
of CM beyond this time period is unlikely to benefit many clients, and alternate 
treatments may be warranted for this subpopulation (Weinstock et al., 2010). 
 
 
IV. DISCUSSION 
 
The purpose of this study was to investigate four research questions. The primary 
objective was to test the acceptability and feasibility of a voucher based contingency 
management programme that incentivises the abstinence of crack cocaine in opiate 
maintenance clients at a community drug service in the UK. The secondary aim was 
to determine whether the CM programme reduced concurrent crack cocaine use 
among clients in opiate maintenance treatment when implemented adjacent to 
standard treatment. The third purpose was to investigate the period during which 
abstinence from crack cocaine was initiated in the contingency management group. 
Lastly, the study examined whether the frequency of self-reported crack use differed 
for the ST and voucher CM groups at timepoint 2 and 3. 
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This study has illustrated that it is feasible both to apply the CM protocol at a UK 
community drug treatment service to target abstinence from crack cocaine in opiate 
maintenance clients and that it was possible to engage a number of participants for 
the entire 12-weeks of the programme. Furthermore, the present study showed that if 
clients were to become abstinent during the intervention period, they ceased using 
crack cocaine during the first two weeks of the intervention. 
 
The preliminary evaluation demonstrated a statistical significant reduction in crack 
cocaine use over time in the contingency management group. Furthermore, in 
comparison to the standard treatment group self-reported crack cocaine use was 
significantly lower in the CM group at 6 months follow-up. From a harm reduction 
point of view these changes are important. 
 
Clearly, it cannot be concluded that the observed changes were the result of the CM 
programme given the nature of the CM group (i.e. self-selection) and the allocation 
of the clients to the standard treatment group. This study however, was the first 
attempt to test the acceptability and feasibility of the intervention. There are currently 
large randomised controlled trials underway that investigate contingency 
management programmes with opiate maintenance clients.  
 
It could be argued that the sample used was not representative of those typically 
seeking treatment for crack cocaine use. Although we cannot prove that the sample 
was representative, the types of drug problems and drug taking severity presented by 
the sample were in many ways typical of the run of clients in the service. In addition, 
at this stage of evaluation the principal concern was to test the intervention with 
opiate maintenance clients targeting their concurrent crack cocaine misuse at a 
community service in order to establish its feasibility.  
 
Besides the presentation and discussion of the empirical findings of the study, there 
are some other aspects that stipulate further commenting, including a critical 
appraisal of the ethical and moral issues of the use of contingency management in 
health care. This will be covered in the section following the discussion.  
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Baseline Characteristics of the Standard Treatment and Contingency Management 
Groups  
Demographic and baseline characteristics may be associated with treatment outcome. 
In our study, two of the investigated baseline characteristics were statistically 
significant for the ST and CM groups; years of crack cocaine use and the working 
relationship between the client and the drug worker (measured by the CISS).  
 
There is a lack of studies that have investigated the effects of the duration of crack 
cocaine use on CM treatment outcome. A related topic of research that may assist the 
understanding of the present finding is the investigation into the differential 
responsiveness to CM treatments in clients that misuse crack by comparing 
individuals with no prior treatment attempts to individuals with 2 or more treatment 
attempts. Frequently, the number of reported prior treatment attempts are associated 
with clients that have more extensive and severe cocaine use histories (Hser et al., 
1999; Ferri, Gossop, Rabe-Hesketh & Lanrajeira, 2002). Rash and colleagues (2008) 
noted in their study that clients with multiple prior treatment attempts seemed to 
show a greater potential benefit of CM with respect to retention and longer durations 
of abstinence compared to clients with no prior treatment attempts. They 
hypothesised that multiple treatment opportunities may have provided clients with 
sufficient exposure and opportunities to practise skills that may eventually lead to 
treatment engagement and successful abstinence (ibid). 
 
Therefore, it is possible that the clients in the CM group decided to participate in the 
treatment because they had accumulated sufficient exposure to mechanisms of 
change in prior treatments and felt ready and motivated to make changes to their 
crack using behaviour. This hypothesis is further supported by the evidence that 
treatment for substance misuse is widely considered a long-term and multiple 
repeated event (McLellan et al., 2000; Scott, Dennis & Foss, 2005). Extraordinary 
studies that have tracked the individual life histories of heroin dependent people, for 
example, have shown that patterns of use, abstinence, and relapse repeat over periods 
as long as 30 to 50 years (Hser et al., 2001; Galai, Safaeian, Vlahov, Bolotin & 
Celentano, 2003; Vaillant, 1973). Furthermore, many people relapse after treatment 
is discontinued and they frequently require multiple treatment episodes (Simpson et 
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al., 1999), and the provision of a variety of different treatment modalities that may 
eventually lead to successful abstinence. Whether CM results in increased coping 
skill execution or otherwise contributes to treatment related change processes 
remains to be seen (Rash et al., 2008). This is a topic likely to receive attention in 
future CM studies as the field moves toward identifying mechanisms of change 
within specific treatments. 
 
Regarding the measurement of the working relationship at the three timepoints, it has 
been mentioned that there was very little statistical variability in the data set. 
Moreover, the CISS exhibits relatively low sensitivity to change (Burns, MacKeith & 
Graham, 2010). Sensitivity to change is defined as the ability of a tool to detect 
meaningful changes over time. It involves two issues; first, the measure must detect 
clinically meaningful change when it has occurred (sensitivity to change). Second, it 
must remain stable when no change has occurred (specificity to change). The issues 
of the little statistical variability in the data, and the low sensitivity to change of the 
CISS combined, have lead to a narrow spread with respect to the scores of the 
working relationship, allowing only a cautious interpretation of the between group 
differences, as provided in the result section. No further interpretation is feasible. 
 
Comparison of the Standard Treatment and Contingency Management Groups  
A comparison of the ST and CM groups showed that the number of days of self-
reported crack use differed significantly at 6 months follow up (timepoint 3) but not 
1 week after the CM intervention concluded (timepoint 2). Furthermore, the CM 
group showed a significant trend of an increase in the number of abstinence days 
over time. A weakness of these findings was that it rests on self-reported data. 
However, similar studies that recorded self-reports on drug use and objective 
urinalysis results have shown that these two different measures are significantly 
correlated (please see for example, Petry & Martin 2002). Furthermore, it is not 
uncommon to collect self-reported data in CM studies on drug use, particularly at 
baseline and follow up (Rawson et al., 2002; Epstein et al., 2003). A more detailed 
discussion on self-reported data is provided in the section outlining the limitations of 
the study. 
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The participants that were abstinent during the entire intervention period reported 
less crack use or abstinence at 6 months follow up compared to baseline. Thus, for 
some clients, the beneficial effects of the CM procedure persisted beyond the 
intervention phase. The research evidence regarding the sustainability of CM 
treatment effects after the discontinuation of the intervention is sparse. Until recently, 
most studies of CM did not include post-treatment follow ups. However, a number of 
newer studies have included post-treatment follow ups, usually up to 12 months. The 
results have been mixed, with some studies showing evidence of sustained voucher 
effects (Alessi, Hanson, Wieners & Petry, 2007; Epstein et al., 2003; Higgins et al., 
2003, 2006; Higgins, Wong, Badger, Ogden, & Dantona, 2000) and other studies 
showing no sustained effects (Milby et al., 2003; Petry et al., 2005, 2006; Rawson et 
al., 2002, 2006; Shoptaw et al., 2005).  
 
Petry and Martin (2002) investigating cocaine abstinence rates at 3 months follow up 
in a prize reinforcement programme found that participants in the standard treatment 
group reported an average of 21 days (out of 30 days) and the prize reinforcement 
group an average of 25 days. Similar abstinence rates were found in the CM group in 
the present study at 6 months follow up; participants reported an average of 23 days 
(out of 28 days). Yet, the self-reported abstinence rates in the ST group were lower, 
showing an average of 16 days. The high abstinence rates in the standard treatment 
group in the Petry and Martin study may have been due to the relatively low rate of 
baseline cocaine use compared to other studies, including the present. About half of 
the submitted cocaine samples were negative in the first weeks of the study, 
regardless of treatment group. On the other hand, Silverman et al. (1998) reported 
results from a 2 month follow up period which revealed substantial relapse, but also 
suggested that a subset of participants continued to exhibit reductions in cocaine use 
and cravings after the incentives were discontinued.   
 
A handful of other studies have examined treatment outcome follow ups at 12 weeks 
to 52 months (Farronato, Dürsteler-Macfarland & Wiesbeck, 2013). These research 
efforts frequently compared and combined CM with other psychosocial treatments, 
in particular cognitive behavioural therapy. Some investigators stipulate that the 
combination of CM and CBT may produce complementary effects (Rawson et al., 
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2002; Epstein et al., 2003; Rawson et al., 2006). The idea is that the onset of CM’s 
effect is rapid (Robles et al., 2000) and the effect of CBT is not always noted during 
active treatment (Rawson et al., 2006). However, in the follow up period of up to 1 
year after the end of treatment, sleeper effects (i.e., effects that occur with a delay 
after active treatment) begin to manifest, indicating improvement in drug related 
outcomes in clients assigned to CBT (Carroll et al., 1994). In contrast, the effects of 
CM tend to diminish after its discontinuation (Rawson et al., 2006). Combining these 
two treatments might produce complementary effects. Reduction in cocaine use 
would not only be rapid but also enduring (Farronato et al., 2013). 
 
To examine this hypothesis Farronato et al. (2013), in their systematic review 
comparing cognitive behavioural therapy and contingency management for cocaine 
dependence, analysed potential beneficial effects of comparing the combination of 
CBT plus CM to CM or CBT alone. They concluded that positive, rapid and 
enduring effects on cocaine use are reliably seen with CM interventions (up to 52 
weeks), whereas measurable effects of CBT only emerge after treatment and do not 
occur as reliably as with CM. However, in the follow up period of up to 1 year after 
the end of treatment, sleeper effects begin to manifest, indicating improvement in 
drug related outcomes in clients assigned to CBT. Synergistic effects of the 
combination of CM plus CBT were demonstrated in 2 trials but another 3 trials found 
no additive effects (ibid). 
 
Future research could address variables that promote more enduring behavioural 
changes. Longer durations of contingent reinforcement, booster reinforcement 
sessions, or gradual reductions in the frequency of reinforcement may improve 
outcomes over longer timeframes (Farronato et al., 2013). In addition, future studies 
should try to detect predictors for the responsiveness of CM and CBT, as well as the 
influences on the effectiveness of the interventions, such as demographics status and 
other client attributes. 
 
To achieve a more reliable effect of the combination of CM plus CBT, a better 
integration of CM in CBT could be advantageous. In future studies, reinforcers 
should be given not only for cocaine abstinence but also for therapy attendance 
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(McKay et al., 2010) or compliance with treatment plan, such as achieving steps 
toward treatment goals. Furthermore, to improve the generalisability of the findings, 
it is important that research groups outside of the United States conduct trials 
comparing CM to CBT. 
 
Some participants had decreased their crack use or initiated abstinence at follow up, 
although that they did not fully engage with the CM intervention. One explanation 
for the improvements noted may be related to the sample electing to participate in the 
study (as mentioned above). It is possible that these clients had an initial desire to 
reduce their crack use and although that they only had a brief exposure to the CM 
intervention, this may have served as a further impetus to move the participants 
along the continuum of the ‘stages of change’ (Prochaska & Norcross, 2006). 
Although that CM is not explicitly concerned with internal change processes that 
may be occurring during a period of change, it is likely that it promotes reflection on 
drug use and consequences in the context of the individual’s goals and values. 
Motivational models suggest that individuals initiate change when the perceived 
costs of the behaviour outweigh the perceived benefits, and when they can anticipate 
some benefits from behaviour change (Cunningham et al., 1994; Burke, Arkowitz & 
Menchola, 2003). This is supported by a study that found that a salient trigger that 
immediately preceded the decision to quit cocaine use was a decisional process, 
which was described as an explicit re-evaluation of cocaine in the light of the 
negative consequences associated with its use (Toneatto et al., 1999).  
 
Motivation and treatment readiness should not be viewed as global, undifferentiated 
constructs (DeLeon, 2000). Other aspects of motivation and treatment readiness, 
besides the ones defined in the ‘stages of change model’, may have played a part in 
the decrease of crack cocaine use. These factors are more complex and include 
readiness to engage with the treatment programme, and with specific intervention 
activities. Readiness also includes client attributes, including skills and resources, 
confidence and self-efficacy related to change (Dansereau et al., 2003), and attitudes 
toward substance use, substance use expectancies, perceptions of social norms or 
other factors (Ledgerwood & Petry, 2006). 
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It is possible that motivation to change substance use is fluid and changing based on 
treatment processes and other factors, and CM may be an intervention that affects 
motivation. However, these answers are speculative and additional research is 
needed to further define the concept of motivation to change substance misuse and to 
identify factors that lead to changes in motivation during treatment. 
 
Conditional Probabilities of Change and Clinical Improvement 
This study found beneficial effects in reducing crack cocaine use among opiate 
maintained clients, yet not to the extent as other comparable US studies. In two 
studies by Silverman (Silverman et al., 1996a; Silverman et al., 1998), 47 – 60% of 
the participants that received vouchers were able to maintain 1 or more months of 
continuous cocaine abstinence. Both studies showed that the distribution of clients 
that achieved continuous abstinence ranged from 0 – 3 weeks for 50% of the 
participants and the remaining 50% of participants attained 5 – 12 weeks. However, a 
closer inspection of the results also revealed that only 2 and 3 participants, 
respectively, achieved continuous abstinence for the 12 week intervention period.  
 
Equally, in another study by Silverman et al. (1996b), 50% of clients assigned to a 
condition in which they received vouchers for submitting cocaine free samples failed 
to achieve 3 weeks or more of abstinence. In two other studies (Stitzer et al., 1992; 
Iguchi et al., 1997), more than 45% of the opiate maintained participants failed to 
earn a single voucher for the submission of a cocaine free sample. However, most of 
the studies with opiate methadone maintenance clients have shown abstinence rates 
ranging from 35% to 65% (Iguchi et al., 1997; Silverman, 2004). This is a moderate 
to high success rate, particularly considering the fact that these clients were selected 
(or self-selected) for the studies because they had failed to respond to conventional 
treatments and considering the very high baseline rates of cocaine use in the study 
populations. In addition, it is important to highlight that all major types of drug 
treatment consistently exhibit attrition rates of more than 50% and subsequent 
relapse (Simpson, Joe, Rowan-Szal & Greener, 1997). 
 
It has long been understood that retention in substance misuse treatment is important 
in achieving a successful outcome. Consistent attrition rates of more than 50% in all 
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major types of drug treatment and subsequent relapse (Simpson et al. 1997) have 
focused research on trying to predict which client and / or programme characteristics 
might improve client retention in treatment so that clients remain in treatment long 
enough to gain treatment benefits. 
 
In comparing the abstinence patterns of participants in the US studies and the present 
results, it is noticeable that a greater number of participants attained short to medium 
durations of continuous abstinence in the US studies. Examining the abstinence 
patterns of participants’ CM intervention attendance and urinalysis results allows 
identification of individuals who were and were not engaged by the intervention. 
Figure 2 shows that the CM intervention appeared effective in engaging 5 of the 21 
(24%) CM participants. These participants delivered 21 cocaine free samples in the 
12 week intervention period and, hence, were classified as clinically improved. Five 
other participants engaged with the intervention and exhibited the following patterns: 
one participant delivered 8 cocaine free urine samples but not consecutively. A 
further participant attended the CM intervention 15 times but submitted only 3 
cocaine free samples. The third participant submitted 5 urine samples and 2 of these 
urine samples were cocaine free. The fourth and the fifth participants attended 5 
times and delivered 3 and 4 cocaine free samples, respectively. Another four 
participants submitted only one cocaine free sample.  
 
Overall, 7 participants remained within the ±10% range of statistically significant 
change and were classified as unchanged as defined by the a priori criteria. Finally, 
nine participants delivered less cocaine free samples in the intervention than in the 
baseline period and, hence, were categorised as deteriorated. Although the results 
may be inflated by assuming the missing urine samples as cocaine positive during the 
intervention (which is predicated on a widely used approach in CM trials, for 
instance please see Silverman et al., 1996a and Budney et al., 2000), an important 
point to consider is that these participants did not fully engage with the CM 
intervention. For these participants, having had only contact with instructions about 
the available contingencies and no actual contact with earning or ‘consuming’ the 
voucher (not even once), the initial response requirement may have been too large or 
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stringent, and the reinforcement for abstinence and attendance too weak, to promote 
initial abstinence and engagement with the CM intervention.  
 
There are many possible solutions to the difficulties encountered in this study. These 
solutions do not need to involve radical departures from the use of abstinence 
reinforcement but, rather, need only help participants more readily come into contact 
with the available reinforcers. It seems probable that any method used to increase 
contact with the contingencies might also increase the likelihood of success in the 
treatment programme. Findings from reviews (Silverman, 2004; Stitzer & Petry, 
2006) and meta-analyses (Lussier et al., 2006; Prendergast et al., 2006; Dutra et al., 
2008) in contingency management seem to suggest that two modifications to the 
present approach may have beneficial effects.  
 
First, using quantitative urinalysis testing methods to detect and reinforce abstinence 
(Preston, et al., 1997) may be useful. Most studies, including the present, employed 
standard qualitative urinalysis testing. Under that testing method, urine samples are 
considered positive for cocaine if the concentration of the cocaine metabolite, 
benzoylecgonine, in the urine sample is at or above 300 ng/ml. However, 
toxicological studies in chronic crack cocaine users suggest that some individuals, 
many of whom achieve urinary benzoylecgonine concentrations exceeding 100,000 
ng/ml during active use, may continue to provide urine samples that exceed the 
standard 300 ng/ml threshold for 2 – 5 days after initiating abstinence (Preston et al., 
2002). As a result, using standard qualitative testing, a participant may have to 
remain abstinent for several days before earning a voucher for a negative sample and 
some individuals may not be able to attain this period of abstinence, especially early 
in treatment. Preston and colleagues (1997) proposed a more sensitive and 
continuous method of detecting recent cocaine abstinence – a quantitative measure of 
benzoylecgonine concentrations. Under these procedures, a participant is considered 
‘abstinent’ and eligible for reinforcement if the benzoylecgonine concentration in the 
participant’s urine sample decreases by a specified percentage per day. Using this 
method, cocaine abstinence might be shaped in participants by reinforcing observed 
decreases in benzoylecgonine concentration (Preston et al., 2001), and the 
reinforcement might occur more immediately relative to the behaviour of abstaining. 
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However, most urine testing systems, especially on-site systems which are better 
suited for CM procedures (Schwartz et al., 1987), are qualitative. These technical 
issues must be considered in designing CM procedures to reinforce abstinence 
(Petry, 2000).  
 
Second, an increase of the magnitude of the voucher value may be beneficial. This 
study provided low magnitude vouchers, with a maximum earning of £240 
(equivalent to ca. $468 in March 2008) for complete abstinence, compared with 
around $1,200 or higher in studies showing stronger beneficial effects with similar 
sample sizes (Silverman et al., 1996, 1999). Silverman et al. (1999) found that some 
cocaine using methadone clients who were ‘non-responsive’ at standard voucher 
amounts achieved abstinence if amounts were increased threefold. Dallery et al. 
(2001) noted a direct relationship between voucher amounts and abstinence in 
another study of methadone clients. Accordingly, numerous individual studies have 
shown that magnitude of voucher reinforcement affects efficacy (Silverman et al., 
1999; Dallery et al., 2001; Wong et al., 2003; Petry et al., 2004), and meta-analyses 
(Lussier et al., 2006; Prendergast et al., 2006; Dutra et al., 2008) have also found that 
magnitude of reinforcement impacts the effects sizes. However, more research is 
needed to identify characteristics of clients who can benefit from low magnitude 
reinforcers versus those that require higher magnitude reinforcers for effective 
behaviour change. For example, there is currently no evidence to indicate that 
individuals with lower versus higher income levels differentially benefit from CM 
interventions (Stitzer & Petry, 2006). However, it may be the case that income status 
could influence the reinforcer magnitude that is effective with a given individual 
(ibid).         
 
Survival Analysis  
Results from the survival analysis seem to indicate that if opiate maintenance clients 
with cocaine use are to become abstinent from crack, the onset of abstinence is 
proximal, rather than distal, to the start of the CM programme. The examination 
revealed that, after 14 days of the intervention, 57% of participants had withdrawn 
from the CM programme. Thus, a positive response (i.e. abstinence) to the CM 
treatment was likely to occur early in treatment or not at all, and this is consistent 
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with other clinical trials for crack cocaine use in which a positive response to 
treatment typically occurs within the first few weeks (2 – 4 weeks) of the 
intervention (Kampman et al., 2002; Dutra et al., 2008; Plebani, Kampman & Lynch, 
2009; Weinstock et al., 2010).  
 
For the second Kaplan Meier model, outcome was defined as either first positive 
urinalysis or drop out. This model showed that the median time until first crack use 
was 4 days in the CM group and 43% of the participants submitted their first positive 
cocaine urine sample at the first contingency session. In fact, six participants never 
earned a single voucher. Similar results were reported by Iguchi et al. (1997), they 
found that 10 of the 27 participants in the contingent group never earned a single 
voucher. They concluded that the reason for the low acceptability of the voucher CM 
intervention may be due to the low monetary value of the vouchers (total voucher 
value of $185 equivalent to ca. £280 in 1997) relative to earlier studies and the 
insufficiency of this reward as an incentive for abstinence (Iguchi et al., 1988; Iguchi 
et al.,1996).  
 
A potential practical implication of these results with respect to CM implementation 
in opiate maintenance services is that clients who do not respond fairly quickly to the 
CM procedures should not continue to be offered the same CM intervention, as most 
responders are early responders. Based on the results from this study, 2 weeks seems 
to be an appropriate timeframe to monitor initial client response to CM interventions. 
while Weinstock and colleagues (2010) recommended that 4 weeks may be a more 
appropriate timeframe. Clients demonstrating good treatment response can continue 
on with the intervention. If a client is unable to initiate abstinence within this 
timeframe, consideration of alternative treatment options is suggested. 
 
The present results and the results from Weinstock et al. (2010) of the proximal onset 
for cocaine abstinence are in contrast to Silverman et al. (2004). In their study, a 
portion of cocaine using opiate maintenance clients were randomised to a yearlong 
voucher CM intervention. A few clients, 4 of 26, continued to use cocaine and only 
after extended exposure (i.e., 2–3 months) to the CM procedures did they initiate 
long periods of sustained cocaine abstinence. However, the CM procedures in their 
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study differed from the CM procedures use in the current study (e.g., higher 
magnitude of rewards, contingencies for take home doses). 
 
In this study, clients were on stable opiate substitution doses for at least 1 month 
prior to starting the trial. The best timing for initiating a CM intervention in an opiate 
maintenance setting remains unaddressed. Further, the generalisability of these 
findings beyond the specific CM interventions employed and non-opiate 
maintenance settings are unclear. Different courses of initiating abstinence occur in 
non-opiate substitution settings, as the majority of clients in such settings test 
negative for substances throughout treatment (Petry et al., 2004; Petry et al., 2005).  
 
Psychosocial Functioning  
As in other CM studies in the United States (Petry & Martin, 2002), this study found 
beneficial effects in reducing crack cocaine use, but not in other areas of 
psychosocial functioning as assessed by the TOP scores. Achieving drug abstinence 
may be a necessary first step prior to improving outcomes in other domains. Once 
drug abstinence is achieved, clients may begin to work on other areas, such as 
alleviating depression, reducing family conflict, finding employment and improving 
legal problems. More extended treatment durations and larger sample sizes may be 
required to show changes in these areas because of the heterogeneous nature of 
psychosocial problems experienced. Some studies suggest that providing enhanced 
psychosocial services (McLellan et al., 1993) and reinforcing changes in other 
behavioural domains, such as employment (Silverman et al., 2001) and housing 
(Milby et al., 1996), may improve outcomes in other dimensions.   
 
Contingency Management Beyond the United States 
The difficulty of comparing the results of the present study with those obtained in 
previous North American studies should be stressed. Not only are the CM 
interventions applied in different cultures and contexts, but the implementation of the 
opiate substitution treatment nationally and internationally also varies, as outlined in 
the introduction, (please see section, I.8. Opiate Substitution Treatment in the United 
States and United Kingdom). The function of the present study was not to investigate 
the delivery of treatment services with respect to structures, procedures and practice. 
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Hence, it remains unresolved how these treatment aspects impacted on the 
implementation and outcome of the present research, and whether they played a part 
in the observed moderate acceptability and abstinence rates. However, there are two 
further issues that impede the comparability of the results and, thus, they deserve 
mentioning. The last section provides a brief discussion on the CM research 
undertakings of a team in Spain.  
 
First, Petry and colleagues (2005) identified an issue regarding the different research 
conditions in their CM study. They suggested that the lower retention and abstinence 
rates in their study may be reflective of variations in the nature and context of 
treatment in community settings relative to research clinics. In fact, the majority of 
CM trials that targeted crack cocaine use in opiate maintenance clients were 
conducted at research clinics with efficacy study designs (Petry, 2000). Differences 
in research conditions (i.e. efficacy and effectiveness studies) are well known 
confounders that could reveal differences in achieved treatment effects. Efficacy 
studies often produce larger effects than effectiveness studies which typically take 
place in a real-world setting (Curtis, Ronan & Borduin, 2004; Petrosino & Soydan, 
2005). Efficacy studies are often conducted by the researchers themselves, evaluate a 
method on a small scale and under optimal conditions, with a high degree of control 
over treatment adherence and research realisation.  
 
Second, Gossop (2006) highlighted the lack of transparency in published CM studies 
regarding the offered services. He stated that most studies failed to report whether 
social support services were provided or made accessible, or the extent to which they 
were provided, if available. 
 
Lastly, a group of researchers in Spain have published preliminary results regarding 
the generalisability of a specific CM programme. These studies, which are conducted 
by Garcia-Rodriguez, Secades-Villa, Higgins and colleagues (2007, 2008, 2009, 
2011), focused on the combination of the community reinforcement approach 
(CRA), plus CM. The manual guided CRA plus vouchers therapy (Budney & 
Higgins, 1998) focused on three general topics: first, drug avoidance skills where 
clients were trained in functional analysis to detect antecedents of cocaine use, 
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problem solving (pros and cons of cocaine use and refusal), and drug refusal training; 
second, lifestyle change components, where clients were counselled to develop new 
recreational activities and a healthy social network; and third, other substance 
misuse, where specific interventions were carried out with all those who reported 
alcohol problems or cannabis use. Their studies suggest the effectiveness of CRA 
plus voucher based contingency management for retaining outpatients in treatment 
and achieving cocaine abstinence in a community setting. They concluded that their 
studies indeed support the generalisability of a specific CM and psychological 
programme for cocaine addiction, the CRA plus vouchers approach, beyond the US 
and with similar levels of efficacy. However, at least two important points need to be 
considered.  
 
First, the CRA plus voucher CM approach is a specific and manual guided approach. 
This intervention was initially developed and implemented by Higgins and his 
colleagues (1991) for the treatment of cocaine addiction in outpatient contexts 
(mainly University research clinics). Second, Garcia-Rodriguez and colleagues 
pointed out the difficulty of comparing their results to the results obtained in 
previous studies with North American participants. They stated that their participants 
are, at least to some extent, different – especially with regards to the administrations 
route for the drug, which is preferentially smoked as crack in the US, whereas in 
Spain intranasal administration is more common. This means that the addiction 
severity of their clients may be lower than that of clients from other studies, so the 
outcomes are not fully comparable. 
 
Limitations 
It is worth noting, that the NTA imposed some methodological restrictions (please 
see Methodology and Result sections, II.1. Study Setting and Research Design and 
III.3.3. Changes in the Planned Data Analyses) and the study design needed to be 
approved. For instance, random assignment to the study groups was not allowed. 
Clearly, this sampling method would have evoked ethical issues but it would have 
increased the internal validity of the study. However, many efficacy studies have 
been conducted in the US. Therefore, the next step was to determine how well the 
intervention works in typical clinical practice outside of the US. Thus, the aim was to 
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examine the research question, “Does CM reduce crack cocaine use in opiate 
maintenance clients when implemented adjacent to standard treatment in a 
community service?”   
 
With regard to the comparison group, a natural unplanned comparison group 
emerged from the clients that initially agreed to participate in the CM group but did 
not attend the scheduled CM sessions. In the first few weeks of the study the 
doctorate student observed that there was a group of clients that initially agreed to 
participate in the CM intervention but did not attend any the scheduled reinforcement 
sessions. Given that this group of clients had given informed consent and the usual 
consent to share information, (for more details please see Methodology section, II.7. 
Ethical Considerations and Consent), it was considered that this group of clients 
could function as a comparison group similar to a TAU group (treatment-as-usual) 
and thereby potentially increase the validity and reliability of the study. In this way 
valuable data that had already been collected would not be lost.  
 
This research design could be vaguely compared to a TAU design. Recently, TAU 
designs have increased in popularity because it is a research design that can face the 
challenge to assess relative superiority of new treatments over current methods and 
still balance internal and external validity (Löfholm, Brännstroem, Olsson & 
Hansson, 2013). In the present study, we implemented a four week baseline period 
and a comparison group that received standard treatment. In this way, the 
contingency management group participants served as their own controls by 
collecting baseline data on the participants prior to the 12-weeks CM intervention 
period. The additional implementation of the standard treatment group should 
provide some assurance that history and maturation (both are extraneous variables) 
should have affected both groups equally. 
 
Although that the creation of the comparison group afforded the comparison between 
a group that continued to receive treatment-as-usual and a group undergoing the CM 
intervention, it is necessary to highlight that the clients in the standard treatment 
group consciously decided not to participate in the CM programme. Thus it must be 
assumed that these clients are different to the participants in the CM group for 
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instance in terms of client factors such as; motivation to change crack cocaine use, 
treatment readiness, personality characteristics. These factors are complex and 
include readiness to engage with the treatment programme, and with specific 
intervention activities. Readiness also includes client attributes, such as skills and 
resources, confidence and self-efficacy related to change (Dansereau et al., 2003), 
and attitudes toward substance use, substance use expectancies, perceptions of social 
norms or other factors (Ledgerwood & Petry, 2006). This study did not 
systematically investigate how theses two groups differed with respect to these 
factors. However efforts were made to compare the participants on relevant factors, 
as was demonstrated in section, III.4. Demographics and Baseline Characteristics. 
 
Next, a particular pertinent point to the present study was the constraint that it was 
not possible to introduce qualitative methods complementary to the quantitative 
methods. For instance, the use of individual semi-structured interviews or focus 
groups to examine how participants experienced the CM intervention; exploring 
questions regarding participants’ motives and reasons to engage or not engage in the 
intervention, and obstacles participants had to face during the intervention would 
have aided the understanding of the CM interventions goals and processes. 
Moreover, qualitative methods seek to understand the phenomenon under study in 
the context of the culture or the setting in which it has been studied, aiding in the 
development of new treatment approaches.  
 
There are several further limitations to the present study, which should be considered 
in interpreting the results. First, clients were self-selected in that they chose whether 
to participate in the CM programme or continue with the standard treatment. It is 
possible that those who entered the contract would have done well with any 
treatment. Thus, participation in CM treatment may simply be a behavioural 
indicator of high recovery motivation, and it is this high motivation rather than 
participation in treatment that accounts for the higher rates of abstinence. This cannot 
be empirically refuted if participation in CM treatment is viewed as measures of 
motivation. There is an abundance of research evidence demonstrating the 
importance of motivation and readiness to change amongst drug users in seeking, 
complying with and remaining in treatment (De Leon, 1993; Simpson et al., 1997). 
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Likewise, the importance of clients’ motivation for the choice of a particular 
therapeutic intervention has been recognised, and this is reflected in the large body of 
literature about enhancing treatment motivation (Miller & Rollnick 2002; Walitzer, 
Dermen & Connors, 1999; De Leon et al., 2000).  
 
Conclusions about the precise nature of motivation and its role in the process of 
seeking and engaging with treatment, and continuous behaviour change are at times 
inconsistent (Claus, Kindleberger & Dugan, 2002). The reasons for this may lie in 
the way that motivation is defined and measured. The variety of factors and 
influences that impact on change related decisions and behaviours of a diverse group, 
such as substance misusing populations, present an additional challenge to the 
endeavour of understanding and explaining motivational dynamics and identifying 
interventions to improve motivation, treatment retention and, ultimately, sustained 
recovery (Groshkova, 2010). 
 
Second, the total number of participants was relatively small and one of the outcome 
measures, 12-weeks of objectively verified abstinence from cocaine, was attained by 
only a small percentage of participants.  
 
Third, the programme appeared to be unacceptable to some clients. Implications and 
possible solutions to the second and the third limitations were discussed in section, 
‘Conditional Probabilities of Change and Clinical Improvement’.  
 
Fourth, the NTA stipulated the use of the TOP questionnaire to evaluate treatment 
outcomes. The CISS questionnaire was routinely used at the service until 2009, 
hence, it was possible to draw on the results of this instrument without burdening the 
clients. Although that the TOP and CISS demonstrated acceptable levels of validity 
and reliability, these instruments would not have been the first choice of the 
doctorate student. Essentially, both questionnaires were developed to assess 
treatment outcome in routine clinical practice rather than as a research tool. The 
following will briefly highlight some of the controversial aspects of the TOP and the 
CISS.  
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One point concerns the administration of the questionnaires. Interviewer based 
questionnaires have some disadvantages in comparison to self-completion 
instruments. For instance, interviewers can introduce bias, which will affect the 
reliability of responses. Such bias might emerge from the way in which questions are 
asked, or in the personal characteristics of the interviewer, or in the respondents’ 
wish to give socially desirable responses. Thus, the person who administers the 
instrument can have a dramatic impact on how participants respond to the measures. 
Researchers who administer a questionnaire to a particular group of respondents 
might have certain expectations (sometimes based on social stereotypes) about that 
group and how it should respond to the measures (Hurtado, 1994; See & Ryan, 
1998). An interviewer’s expectations of and behaviour toward a study participant can 
have a significant influence on how that participant responds to items in a 
questionnaire (Rosenthal, 1966). This may occur via two mechanisms: (1) the 
researcher might unintentionally treat different groups of participants differently 
(e.g., might emphasise certain words when reading instructions or smile more at one 
group than at another) depending on the group’s background and characteristics, or 
(2) if the interviewer is recording the participants’ responses, s/he might subtly 
interpret and then record their responses differently based on prior expectations. 
Interviewer expectancies can be communicated to participants both through verbal 
and nonverbal communication, potentially influencing participants’ responses to 
items in a study instrument (Duncan, Rosenberg & Finkelstein, 1969; Jones & 
Cooper, 1971).  
 
Even if the same interviewer does not inadvertently transmit potentially biasing cues 
to participants, many times questionnaires are administered to different groups of 
respondents by several different people (Richter & Johnson, 2001). This inevitably 
results in subtle (or not so subtle) variations in questionnaire administration that can 
have substantial effects on how different participants respond to questionnaire items. 
For example, one study found that social distance between the interviewer and 
respondent, a variable measured by the number of shared social identities (shared 
demographic characteristics) that each respondent and interviewer had in common, 
was a significant predictor of respondents’ reports of substance use behaviours 
(Johnson, Fendrich, Shaligram, Garcy & Gillespie, 2000). Specifically, respondents 
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in dyads with relatively low social distance (i.e., more shared demographic 
characteristics) were more likely to report drug use. Using self-completion 
questionnaires reduces biasing error caused by the characteristics of the interviewer 
and the variability in interviewers’ skills. The absence of an interviewer provides 
greater anonymity for the respondent. When the topic of the research is sensitive or 
personal it can increase the reliability of responses. 
 
Another common criticism of structured interviews and by extension interviewer 
based questionnaires is that their use may damage rapport or the therapeutic 
relationship (Segal, Maxfield & Coolidge, 2008). Perhaps most importantly, 
interviewer based questionnaires may impede the connection between client and drug 
worker because interviews are problem-centered rather than person-centered. There 
is a danger that interviewers may get so concerned with the questions of the 
instrument that they fail to demonstrate the warmth, empathy and genuine regard 
necessary to form or continue a therapeutic relationship. Indeed, the standardisation 
of the interview may play out as ‘routinisation’ (Rogers, 2003). In addition, drug 
workers who are overly focused on the questions that they must ‘get through’ when 
they complete the TOP for example may, as a consequence, miss important 
behavioural cues or other information that could prove essential to the case. 
 
Proponents of interviewer based questionnaires note that the problem of rapport-
building during an interview can be overcome with training, experience and 
flexibility (Rogers, 2003). Therefore, as emphasised by Rogers (2003), “rapid 
inquiries or monotonous questioning represents clear misuse of structured 
interviews” (p. 222). If interviewers make an effort to use their basic clinical skills, 
structured interviews can and should be conducted in such a way that establishes 
rapport and enhances understanding of the client. 
 
Regarding the subjective health measures (measurement items) ‘overall quality of 
life’, ‘physical health status’ and ‘psychological health status’ of the TOP. Self-rated 
health as one-item indicators have long been used in population surveys to measure 
health status, quality of life (QoL) and health related quality of life (Fayers & Hand, 
2002). The classic self-rated health status item consists of asking respondents to rate 
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their health as “excellent, good, fair, or poor”. Variations of this question have been 
used in surveys worldwide (Bowling, 2005). While the single item question can 
provide valuable information, has the advantage of simplicity, and can be reliable 
and valid, it is at the expense of detail. More information may be required on 
different dimensions of health or QoL, than a single item can provide. Classic 
measurement theory holds that single items are at a relative disadvantage to multi-
item measures because more items produce replies that are more consistent and less 
prone to distortion from sociopsychological biases, and this enables the random error 
of the measure to be cancelled out. Hence they are more stable, reliable, and precise 
(Bowling, 2005). 
 
Furthermore, variations between surveys and nations in the wording of the item, and 
in the number of response categories, do limit comparative analyses and 
interpretations. Analysis of data from the Australian National Health Survey has 
shown that it does have some response instability when repeated in the same 
questionnaire (before and after other questions about health), although this might 
also reflect the biasing effect of question order (Crossley & Kennedy, 2000). And 
interpretation of the item at an individual level varies, depending on the referent 
being used by the respondent. Some people refer to specific health problems and 
others refer to general physical functioning when replying to the question (Meurer, 
Layde & Guse, 2001).  
 
Hence, interpretation of these measures is complicated by incomparability when 
different people understand and respond to a given question in different ways. 
Paradoxical findings have been reported in many analyses of population health 
surveys, suggesting that single item self-report measures may be misleading without 
adjustment for these differences (Mathers & Douglas, 1998; Sen, 2002; Sadana, 
Mathers, Lopez et al., 2002). Distinguishing between differences in self-ratings due 
to actual health differences and differences due to varying norms or expectations for 
health is a key challenge in interpreting self reported measures of health (Freedman 
& Martin, 1998; Carr, Gibson & Robinson, 2001). We may conceptualise different 
dimensions of health— for example, mobility, cognition, vision—as continuous but 
unobserved scales. Each available response to a categorical question corresponds to a 
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range of values on the scale that may vary across individuals. Differing expectations 
for health can lead to differences in the levels at which people change from using one 
response category to the next—that is, differences in response category cut points. 
For example, a 90 year old man who struggles to climb the stairs might characterise 
himself as having “mild difficulties” in moving around, but a 40 year old man with 
the same mobility might describe himself as having “moderate difficulties.” These 
responses are incomparable because the individuals have different response category 
cut points for questions about mobility (Salomon, Tandon & Murray, 2004).  
 
One method to remedy this problem is to use anchoring vignettes (fixed descriptions 
of each response choice level, to increase consistency of respondents’ interpretations 
of them), it has been found that their use provides a powerful tool for adjusting for 
the influence of varying expectations on self-ratings of health (Salomon, Tandon & 
Murray, 2004). This can improve comparison of results (for example, older and 
younger people with the same level of health might rank themselves differently on a 
health status scale because of varying expectations of health and ability by age). 
 
However, psychometric theory stipulates that when a concept cannot be measured 
directly (for example, health status, QoL, health related quality of life), a series of 
questions that tap different aspects of the same concept need to be asked (Rust & 
Golombok, 2000). Items can then be reduced, using specific statistical methods, to 
form a scale of the domain of interest, and the resulting scale tested to ensure that it 
measures the phenomenon of interest consistently (reliability), that it is measuring 
what it purports to measure (validity), and is responsive to relevant changes over 
time. The satisfaction of these conditions is most probable when the resulting 
instrument contains several items to measure the concept of interest to permit testing 
for internal consistency and to minimise random measurement error (Rust & 
Golombok, 2000). 
 
Therefore, if future CM research aims to measure and compare, health status and 
quality of life over time (for e.g. pre- and post-test designs) and to other studies it 
would be advisable to use psychometrically valid and reliable instruments. 
Depending on the type of information the researcher is seeking there are two kinds of 
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measurement scales to choose from. The study could implement a comprehensive 
scale from the substance misuse field (please see below) and/or a self-rated health 
assessment measure (for example, Physical Functioning Scale; SPF-36 (Ware, Snow, 
Kosinski & Gandek, 1993, 2000), Schedule for the Evaluation of Individual Quality-
of-Life; SEIQoL (O’Boyle, McGee & Hickey, et al., 1993). 
  
Future research could use the European version of the Addiction Severity Index, the 
EuropASI (Kokkevi & Hatgers, 1995). The reasons are that the ASI (McLellan, 
Luborsky, Woody & O’Brien, 1980) is probably the most widely used clinical and 
research assessment instrument for individuals with substance misuse problems in 
the US. It is a valid, reliable and standardised diagnostic, and evaluative instrument 
that is suitable for general use in clinical research and, thus, facilitates greater 
comparability of research study results (Cacciola, Alterman, Habing & McLellan, 
2011). Furthermore, because of its multidimensionality, it is a comprehensive tool to 
evaluate treatment outcome, and would thereby facilitate the direct comparison of 
individual, psychosocial and treatment related attributes of the participants in CM 
studies. 
 
However because no psychometric test is without problems and disadvantages, the 
scientific community has criticized the ASI and the EuropASI for its limitations in 
several areas; it has been especially criticised for its composite drug use score 
(Wells, Hawkins & Catalano 1988). The authors raised the issue that the composite 
drug use score “would not differentiate between a user of a less serious drug, such as 
marijuana, and a user of a more serious drug, such as heroin, if the two users are 
equal in terms of the number of other drugs they use and their perception of a 
problem or a need for treatment” (p. 866). The authors point to the fact that two drug 
users with the same drug use frequency would be given different scores based on 
their own perception of how problematic the frequency of their drug use is to them. 
The ASI has also been criticized for its American domain specificity in areas of 
family/social functioning and employment as well as for the composition of the 
severity ratings (Hendriks, Kaplan, Van Limbeek & Geerlings, 1989). The authors 
argue that treating current as well as lifetime problems equally in terms of weight 
may spoil the reliability of the severity ratings. As a remedy they proposed that “the 
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definition of severity as ‘need for additional treatment’ suggests that current 
problems should be weighted more than problems in the past” (p. 140). Most 
recently, the ASI has been criticized for its lengthy interview, failure to address risk-
taking behaviours, and omission of drug use intensity, (e.g. Darke, et al., 1992; 
Marsden et al., 1998).  
 
Another option would be the use of the Maudsley Addiction Profile (MAP; Marsden, 
Gossop & Stewart et al., 1998), it is a brief multidimensional instrument for the 
assessment of treatment outcome for people with drug and/or alcohol problems. It is 
a valid and reliable research tool, and it has been utilised as a core instrument in the 
National Treatment Outcome Research Study in the UK (NTORS, Gossop, Marsden 
& Stewart, 1997). The disadvantage is that it has not been used in published US 
contingency management studies, hence it would not afford comparability of the 
results to US contingency management studies. The design of the MAP offers a 
number of advantages as well as a number of limitations. For instance, the inclusion 
of the intensity factor (amount of substance used in a certain time frame) may be 
seen as both a strength and as a limitation. There are concerns about self-reported 
amounts, doses and drug purity. According to the authors, however, “an estimate of 
the usual quantity of substances consumed is a desirable additional clinical and 
research measure, not least because at follow-up an individual may have maintained 
the same frequency of use but achieved a reduced level of consumption” (Marsden et 
al., 1998, p. 1858).  
 
A further limitation of the MAP, as well as other comprehensive substance use 
measures, is the possible impact of recent substance use on the severity of 
psychological problems. As such, problem severity on the psychological health 
domain of the MAP may either be substance related or purely mental health related 
(Barbieri, 2003). It is important to define this difference clinically for treatment 
purposes.  
 
Another limitation may be found in the relationship conflict domain, especially in 
what constitutes conflict. Conflict is defined by major arguments as well as by 
violence. What constitutes a major argument needs to be operationalised (Barbieri, 
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2003). The difference between what constitutes a major argument or a relatively 
minor argument is rather vague and may result in false positives or false negatives 
concerning client responses. The MAP has been developed as an outcome measure 
with a minimum outcome data set. As such, this measure may be used as a screening 
tool to identify problem areas for which more extensive clinical evaluation is 
necessary, using more specific and extensive assessment tools.  
 
Generally, multidimensional instruments in the addiction field that were developed in 
the UK as well as in other countries are limited (Barbieri, 2003). The use of a 
standardised comprehensive measure that is sensitive to change, is time-limited and 
quantifiable, using diverse populations and services will increase the certainty that 
matching client to treatment will actually result in treatment outcome improvement 
(McLellan & Alterman, 1991). The ability to compare results across treatment 
programmes and groups of clients across cultures is fundamental in developing some 
consensus with respect to addiction related assessment, treatment and outcome. 
 
Having outlined the shortcomings of the TOP, it is also important to highlight the 
advantages of the tool. One obvious advantage was that the TOP was already in use 
at the service, and hence drug workers and clients were familiar with the tool.  
Therefore, it was not necessary to burden the clients with the completion of an 
additional instrument. It also has the benefit of reliably measuring drug use and drug 
use severity for the presented substances. That is to say, reliable change can be 
determined by the drug worker based on the individual’s progress in reducing their 
substance use. Further, the measurement items ‘injecting risk behaviour’ can indicate 
a key step on a recovery journey and will have a significant impact on reducing 
wider health harms, including the prevalence of HIV (Barbieri, 2003). The 
measurement items related to housing problems have been identified as a significant 
issue in supporting a sustainable recovery. Evidence suggests that sleeping rough or 
having no fixed abode can have a negative impact on an individual’s recovery 
journey (Marsden et al., 2008). Overall, the problem domains, substance use, health 
risk behaviours and social functioning are vital when considering treatment outcome. 
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Fifth, the small sample size precluded the application of more advanced statistical 
methods such as a logistic regression analysis to examine the usefulness of 
participants’ demographic and baseline characteristics (independent variable) in 
predicting the likelihood of cocaine abstinence at three months of treatment and at 
six months follow up. Similarly, using other multivariate analysis techniques, 
possibly a multiple regression analysis to examine some of the TOP and CISS items, 
would have potentially contributed valuable knowledge about the influence of 
individual, psychosocial and treatment related aspects as predictors of outcome. A 
series of studies suggested that social interactions, behaviour of drug consumption 
and treatment participation are related (Buchanan & Latkin, 2008; Bohnert et al., 
2010) and, with some exceptions (McLellan et al., 1998), several studies have found 
that clients who are engaged in and satisfied with their treatment experience tend to 
stay in treatment longer or have better treatment outcomes (Holcomb, Parker & 
Leong, 1997; Sanders et al., 1998; Kasprow, Frisman & Rosenheck, 1999).  
 
An advantage of this study was that follow up data was collected. Although this data 
was self-reported (verified by weekly/fortnightly urinalysis results), it provided a 
measure of crack cocaine use six months after the CM intervention in comparison to 
the standard treatment group. Thus, beneficial effects of the CM procedure persisted 
beyond the intervention phase, and future research could address variables that 
promote more enduring behavioural changes. Longer durations of contingent 
reinforcement, booster reinforcement sessions, or gradual reductions in the frequency 
or probabilities of reinforcement may improve outcomes over longer timeframes. 
 
Since self-reported crack use was one of the main dependent variables in the study, it 
is vital to address the issue of self-reporting among substance users, as there are 
misconceptions that plague the field. Scales by definition rely upon self-reporting. 
Concern is often raised about the accuracy of such self-reporting, particularly 
amongst illicit drug users (Miller, Strang & Miller, 2010). In this field, however, 
self-reporting is often the only feasible methodology that can address the research 
questions of interest to the investigators. Investigation of drug use, criminal 
behaviours, needle sharing, etc., by their very nature, involve a reliance on self-
reporting from respondents.  
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Two major concerns are often raised. First, there is the commonly held view that 
drug users are ‘pathological liars’ by nature (Miller, Strang & Miller, 2010). Second, 
the nature of the activities being investigated is frequently illegal and socially 
undesirable. Respondents may be reluctant to admit to socially undesirable 
behaviours because of the stigma attached to these behaviours. There is no evidence 
for either of these assertions (Jackson et al., 2004). This is an area that has been 
extensively researched, and the self-reporting of drug users in research settings has 
repeatedly been demonstrated to have high levels of reliability and validity (Drake, 
1998; Welp et al., 2003; Jackson et al., 2004). This has been found to be true for 
substance use, crime, risk-taking, etc. Given accurate instrumentation, the researcher 
in the drug and alcohol field should have confidence in the data that are produced 
(Miller, Strang & Miller, 2010).  
 
A further advantage of this study was the use of the clinical significant change 
method to assess clinical significance at the individual level of analysis. Thomas and 
Hersen (2011) stipulate that effectiveness research should address not only whether 
clients have abstained from drug use but whether they have abstained from drug use 
for a clinically meaningful period, that is, whether clients improve their symptoms to 
the extent that they are more like non-distressed clients (i.e., ‘normal’ people). This 
allows individuals to make a more informed decision on their using behaviour, and 
cognitive functioning improves after a few days of abstinence (Stitzer, Iguchi & 
Felch, 1992). Natural recovery processes that take place during periods of sustained 
abstinence, including gradual diminution of response to drug related cues and 
lifestyle changes that provide alternative competing reinforcers, may then form the 
mechanisms for longer-term recovery of dependent individuals (Stitzer & Petry, 
2006).  
 
In a seminal article, Jacobsen and Revenstrof (1988) outline the problems with 
aiming for statistically significant change alone. They noted that, even though change 
may be reliable, it may not be meaningful. The authors noted that unless clients are 
becoming more like the non-clinical population than the clinical population, they 
have not made clinically significant change. The original method was developed as 
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part of a call for a more clinically meaningful way of reporting treatment outcome 
(Kazdin, 1977; Barlow, 1981; Kendall & Norton-Ford, 1982). Clinical significant 
change proponents have been advocating its effects for three decades, yet there is 
still a predominance of conclusions, which are based on small statistical effects of 
little practical importance. Moreover, there is a tendency toward over-interpreting 
group differences, which may not satisfy clients, but nonetheless are used by 
researchers to confirm their a priori hypotheses. The present researcher contends that 
most clients enter treatment wanting an end to their suffering, not simply a 
statistically reliable improvement. As Follette and Callaghan (1996) expressed it, 
until therapists and therapy researchers are willing to tell their clients and society at 
large that they cannot return people to normal functioning; this seems to be a 
reasonable criterion to employ (Jacobson, Roberts, Bem & McGlinchey, 1999). 
  
IV.1.  Summary and Conclusions 
The contingency management approach investigated in this study illustrates the 
potential utility of an operant approach to conceptualising and treating crack cocaine 
use in opiate maintenance clients. Crack cocaine use in opiate maintenance clients 
has been common, persistent and difficult to treat with conventional approaches 
(Silverman, 2004). Indeed, participants in the present study were selected because 
they continued to use crack at high rates despite exposure to conventional treatments.  
Despite the limited success of the CM intervention to engage sufficient numbers of 
participants in the present study, the firm scientific foundation on which the CM 
intervention is based, the prior demonstrated effectiveness of the CM intervention, 
and the detailed analysis of the data from this study (presented above) all suggest 
parameters of the CM intervention that could be adjusted to increase its effectiveness 
and could improve the prospects of success with this difficult to treat population. As 
Baer, Wolf, and Risley (1987) recognised, technological failure of this type “is an 
expected and indeed important event in the progress of any applied field, even those 
whose underlying theory is thoroughly valid” (p. 324). Addressing the technological 
issues that led to the limited success to engage some of the individuals in this study 
could lead to considerable improvements in the CM intervention.  
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A reasonable but tentative conclusion based on this study is that CM programme 
participation seemed to increase the abstinence rate during treatment and at 6 months 
follow up, in comparison to the baseline period and the standard treatment group. 
Furthermore, this study investigated the period during which abstinence was initiated 
in opiate maintenance clients from crack cocaine use who were beginning a CM 
treatment. Results from this study combined with previous research suggest 
timeframes for decision making in the event that a client does not respond. If clients 
were to become abstinent during the intervention period, they most often ceased 
using during the first 1 to 4 weeks of treatment (Weinstock et al., 2010). Thus, 
continued application of CM beyond this time period is unlikely to benefit many 
clients, and alternate treatments may be warranted for this subpopulation.  
 
It is a well recognised and documented problem that a substantial proportion of 
clients do not achieve significant drug free periods when abstinence alone is 
reinforced (Stitzer & Petry, 2006). One explanation for non-response to CM 
interventions is that the reinforcer (initial £5 voucher) may be too small to compete 
with the reinforcement associated with continued drug use. Clearly, higher 
magnitude reinforcers may be needed to change behaviours that themselves induce 
strong positive effects (drug use) compared with behaviours that induce smaller 
effects (attendance of a medical appointment or a therapy session). In other words, 
winning slips with a low probability of winning $25 may alter treatment engagement 
but may be unlikely to change drug use. A general rule is to choose a reinforcer that 
can compete with reinforcement derived from the behaviour targeted for change. The 
contrived reinforcement may be reduced once a new behaviour pattern has been 
established (Higgins et al., 1994b). 
 
Another possible explanation is that the response requirement may be too high. Two 
to five days of crack cocaine abstinence must be achieved for a urine specimen 
reading to be negative, and some individuals may not be able to attain this period of 
abstinence, especially early in treatment. Reinforcing successive approximations 
toward abstinence by providing reinforcers contingent upon quantitative reductions 
in drug metabolites may be one technique to overcome this obstacle (Elk et al., 
1995). However, most urine testing systems, especially on-site systems which are 
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better suited for CM procedures, are qualitative (Katz et al., 2002; Sigmon et al., 
2004). These technical issues must be considered in designing CM procedures to 
reinforce abstinence.  
 
It is of great interest to corroborate the applicability of this intervention to a different 
cultural setting by testing one of the most reliable findings from CM literature; the 
influence of reinforcement magnitude. Further research could evaluate the effects of 
quantitative urinalysis testing and voucher magnitude on crack cocaine abstinence in 
a European cultural context and in a community setting. Systematic research to 
improve the effectiveness of contingency management interventions in general, and 
CM interventions with opiate maintenance clients with concurrent crack cocaine use 
in particular, is critical if researchers are going to succeed with the substantial 
proportion of unresponsive clients who fail to respond to currently available 
treatment approaches.  
 
Overall, the application of CM principles to the treatment of drug misuse has altered 
the landscape and conceptualisation of treatment interventions in the US (Petry, 
2000). Novel applications have been developed that integrate CM into community 
treatment: for example, health promoting activities such as hepatitis B vaccinations 
and employment based models; for example, participation in paid job training or 
work in a programme operated data entry business, where the persons can only earn 
salary for the work on days when they have delivered opiate and cocaine free urine 
samples at the programme. In this novel conceptualisation of CM, earned salary is 
used as the contingent benefit, with the opportunity to work and earn salary being 
closely tied to and contingent upon abstinence (Silverman et al., 2001; 2002). These 
novel CM implementations expand the potential therapeutic application of positive 
reinforcement.  
 
Additionally, exciting research ventures have examined whether CM may additively 
and synergistically improve outcomes when combined with psychotherapy, 
specifically CBT. Although these studies have not yet shown clear benefits of the 
combined interventions above the voucher intervention alone, researchers in this 
field suggest that, in order to achieve a more reliable effect of the combination of 
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CM plus CBT, a better integration of CM in CBT could be advantageous (Farronato 
et al., 2013). As postulated by Farronato et al. (2013) and McKay et al. (2010), 
positive, rapid and enduring effects on cocaine use are reliably seen with CM 
interventions (up to 52 weeks) and measurable effects of CBT seem to emerge after 
treatment and do not seem to occur as reliably as with CM. However, in the follow 
up period of up to 1 year after the end of treatment, sleeper effects begin to manifest, 
indicating improvement in drug related outcomes in clients assigned to CBT. 
 
In future studies, reinforcers should be given not only for crack cocaine abstinence, 
but also for therapy attendance (McKay et al., 2010) or compliance with treatment 
plans, such as achieving steps toward treatment goals. This is an important area of 
investigation for understanding the mechanisms of behaviour change underlying 
long-term abstinence outcomes when external reinforcers are used during CM 
interventions to promote periods of sustained abstinence (Farronato et al., 2013). 
Furthermore, to improve the generalisability of the findings, it is important that 
research groups outside of the United States conduct trials integrating CM with CBT 
and other psychotherapy approaches.  
 
In conclusion, although that the applied CM programme was feasible, the execution 
of the CM programme at our service confirmed that it is a time and labour intensive 
treatment. The systematic application of the CM programme demands additional 
labour and funds, which may be difficult to sustain in clinical practice. The present 
protocol would not fit into existing structures and be delivered by front line staff as 
part of their day-to-day clinical duties. Accordingly, this study illustrates that it is 
challenging to strike a balance between clinical acceptability/feasibility 
considerations and fidelity to research based methods previously shown to be 
efficacious. 
 
However, it is vital to consider that there was a sub-sample of clients that engaged 
well with the CM programme and some clients achieved 12-weeks of crack cocaine 
abstinence. One innovation of the CM programme that could be tested in a larger 
study at UK community service to address the cost concern was the recently 
developed fishbowl method (Petry, Martin & Simic, 2005) that utilises principles of 
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intermittent reinforcement to reduce cost of CM interventions (for a more detailed 
description of the prize CM technique please see section; I.9.4. Contingency 
Management in Psychosocial Counselling Programmes and Methadone Maintenance 
Programmes). With this method, submission of a drug free urine sample results in 
the opportunity to draw tokens from a bowl, on which prize winnings are designated. 
Intermittent reinforcement is accomplished by having only half the tokens in the 
bowl result in prizes. Usually total earning value is less than half the total earnings 
possible in previous voucher incentive programmes in the US (Petry, Martin & 
Simic, 2005). This lower cost method would increase the feasibility and 
sustainability of abstinence incentive programmes overall.  
 
An alternative is the behavioural strategy of tailoring incentives to individual clients 
in order to attain various treatment plan goals. This method was adopted at our 
service after the CM programme concluded. Utilising this behavioural model we 
incentivised objective treatment plan goals that were in accordance with the harm 
minimisation approach and therefore reinforced behaviours that were related to 
rehabilitation, recovery and self-sufficiency. Incentives were offered to all opiate 
maintenance clients that continued to exhibit problematic behaviours (for example, 
concurrent drug use) or continued to miss scheduled appointments (for example, 
appointments with the nurse to screen for blood-borne viruses, the dentist or 
vocational advice). In collaboration, the client and drug worker identified a target 
behaviour the client aspired to address. The incentives comprised of the same retail 
vouchers that were used in the CM programme. It was financed from the remaining 
NTA funds. Appointments that were not held at our service required evidence of 
attendance. Many clients commented positively on this intervention and were 
actively involved in the goal setting of the target behaviour. This allowed focusing 
on smaller incremental steps of behaviour change that led in some cases to larger 
more sustained changes. Additionally, it highlighted to clients and drug workers alike 
that any step in the right direction could be a cause for celebration and that in the 
face of setbacks drug workers encouraged clients to try harder rather than criticise. 
Thus, this approach encouraged staff members to focus on the good things that 
clients did, not on their failings.   
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We believed it was important to demonstrate to clients and drug workers the value of 
setting up contingencies that reinforced smaller behaviour changes so that the more 
troubled and/or more severely dependent clients had the opportunity to benefit. It 
seems possible that community services could develop their own incentive 
procedures tailored to the specific needs of their own client population and the 
unique clinical priorities of their programme. Importantly, this model of 
dissemination is experiential rather than didactic, with the drug workers and 
psychologists providing their own monitoring and feedback in group supervision. 
This process could result in a rich array of insights about what works and what 
interferes with effective adoption of incentives at each service.  
 
Politics and ideology will clearly impact on the expansion of this technique in 
practice. However, objections toward ‘paying drug users to do what they should do 
anyway’ may be somewhat tempered by pragmatic and Machiavellian principles of 
doing whatever works best for this difficult to treat and often disenfranchised 
population (Petry, 2006). Evaluation of contingency management approaches in 
other cultures and societies ultimately may enhance prevention efforts in high risk 
groups and improve treatment outcomes of drug misusers throughout the world. 
 
The last section in the empirical paper considers some of the moral and ethical 
concerns about using incentives in health care, and some of the implications for 
future research and clinical practice. 
V.  INCENTIVES IN HEALTH CARE: RATIONALE, 
ETHICAL ISSUES AND CLINICIANS’ VIEWS  
Health as an asset is special in at least two ways: first, in a very obvious sense, good 
health matters in our lives in experiential, if not existential terms. Second, health has 
a clear impact on one’s civic and economic livelihood and the options one can make 
use of in a society based on fair equality of opportunity (Daniels, 2007). 
 
The classical homo economicus model holds that people are self-interested rational 
agents who are generally able to identify the means necessary to achieve goals 
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worthy of pursuit, and to act accordingly (Schmidt, Asch & Halpern, 2012). The case 
of health behaviour, along with other situations, such as retirement planning, 
challenges this assumption. Even though the desire to lose weight, to drink less or to 
stop smoking is felt strongly by many people, many also fail to act on it, despite 
being quite clear about the means that are required, such as eating less and exercising 
more. The reasons can be manifold and are often to do with people's specific 
circumstances in life. In addition to these and further circumstances, there appear to 
be powerful psychological constraints that can have a grip on people's ability to 
change their behaviour (Schmidt, Asch & Halpern, 2012).  
 
This section will first discuss some of the basic motivational processes involved in 
the acquisition and maintenance of health related risk behaviours, and then focus on 
some of the moral and ethical concerns about the use of health incentives and 
contingency management interventions. How these concerns impact on clinicians’ 
views and the adoption of CM into clinical practice is considered. It is suggested that 
it is important to consider these factors when designing a clinical trial and attempting 
to implement CM interventions. It is important to clarify at this point that this critical 
appraisal is a general brief discussion of incentives in health care and not limited to 
CM in substance misuse. 
 
Contingency management interventions in substance use are typically implemented 
to retain service users in treatment and to foster drug abstinence. CM interventions 
involve identification of a target behaviour such as abstinence which is reinforced 
with an incentive when it occurs, and the incentive is withheld when the target 
behaviour does not occur (Petry, 2006). Often a monetary voucher such as that used 
in the present study, detailed in the empirical paper, is used as an incentive.  
 
Motivational Processes and Systems 
There is growing recognition of the need for effective interventions to promote 
healthy behaviour change among those who already engage in various risk 
behaviours, as well as to prevent the acquisition of unhealthy behaviours among 
those who do not yet engage in them but are at risk for so doing (Marteau, Ashcroft 
& Oliver, 2009). In addressing the question of why look to incentives for this 
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purpose, some discussion of the basic motivational processes involved in the 
acquisition and maintenance of health related risk behaviours can be helpful. There is 
overwhelming scientific evidence that reinforcement and operant conditioning 
processes play a central role in the acquisition and maintenance of health related risk 
behaviours (Bickel, Yi, Landes, Hill & Baxter, 2011; Higgins, Heil & Lussier, 2004). 
The substances that people abuse and the fatty and salty foods that are so often over-
consumed, for example, share a common effect of directly stimulating dopamine-
based mesolimbic brain reward centres, which directly increases the likelihood that 
these same activities will be repeated in the future. That is, these risk behaviours are 
controlled to a considerable extent through the behavioural process of reinforcement 
(Bickel et al., 2011). Considering that the reinforcement process and associated brain 
systems evolved to support the survival of the species under conditions of constraint, 
it should not be surprising that the behavioural effects that it produces can be 
strikingly robust and resilient. As discussed in the thesis, incentive programmes can 
be especially helpful if constructed appropriately because they leverage that very 
same reinforcement process that drives unhealthy risk behaviours to promote healthy 
behaviour (Higgins, Heil & Lussier, 2004). Indeed, financial incentives activate 
those very same dopamine-based, mesolimbic brain reward systems that drive 
repeated drug use, fatty food consumption, and other operant behaviour (Knutson, 
Fong, Adams, Varner & Hommer, 2001).  
 
Three important and related aspects of existing scientific knowledge about these 
motivational systems are particularly relevant to understanding health related risk 
behaviours and why incentives have an important role to play in efforts to change 
them.  
 
First, there is evidence from preclinical laboratory settings, clinical laboratory 
settings, treatment outcome research, and epidemiological studies supporting the 
position that impoverished environments where there are few competing sources of 
alternative reinforcement render responding that is maintained by drugs and other 
basic sources of reinforcement more resistant to change (Campbell & Carroll, 2000; 
Carroll, 1993, Higgins, 1997; Higgins, Heil & Lussier, 2004). There certainly 
appears to be a substantive factor underpinning the overrepresentation of these risk 
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behaviours and associated problems among economically disadvantaged populations 
(Higgins & Chilcoat, 2009). 
 
Second, behavioural economic research has characterised some fundamental biases 
in the way that humans make choices between different reinforcement options that 
increase vulnerability to these risk behaviours, with one such bias being what has 
come to be referred to as the ‘present preference bias’ (Loewenstein, Brennan & 
Volpp, 2007). What this refers to is a tendency to prefer immediate over delayed 
reinforcement, even when the amount of reward associated with the more immediate 
option is smaller, and to also prefer lower over higher initial costs, even when the 
longer-term gain is greater in the option with a higher initial cost (Bickel & Marsch, 
2001). In other words, the pleasure of an extra helping of cake today will often be 
preferred over the pleasure of being healthier later — even if one's future self would 
prefer the alternative.  
 
Equally, it is not difficult to envision, for example, how this bias can factor into a 
pattern of repeatedly choosing the more immediate euphoria of drug use and abuse 
over the delayed health benefits of a drug free lifestyle, the alluring taste of fatty 
foods over the blander tasting but healthier longer-term benefits of fruit and 
vegetable consumption, or the comfort, warmth, and relatively low effort of 
sedentary activities over the initially more demanding but healthier long-term effects 
of participating in regular exercise (Higgins, Silverman, Sigmon & Naito, 2012). 
Indeed, there is a growing literature demonstrating a relatively greater bias for the 
present among individuals with various addictions, obesity, and low compliance with 
disease prevention regimens relative to otherwise comparable individuals who are 
without those problems (e.g., Bickel et al., 2007; Bradford, 2010). Moreover, the 
degree of this bias is negatively associated with level of income or educational 
attainment, which likely also contributes to the overrepresentation of these risk 
behaviours and chronic health problems among disadvantaged populations (Green, 
Myerson, Lichtman, Rosen & Fry, 1996; Jaroni, Wright, Lerman & Epstein, 2004). 
 
The underlying mechanisms that often lead to inertia and procrastination can, 
however, be turned around by exploiting the very principles that fuel them; for 
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example, by providing immediate feedback and rewards for behaviour change. A 
further important concept established in observational and experimental research 
relates to loss aversion (Kahneman & Tversky, 1979). What is meant here is that 
people disproportionately prefer avoiding losses to making gains (of equivalent 
value). These and other principles of behavioural economics (Loewenstein, Brennan 
& Volpp, 2007) have been applied successfully in many health care areas and 
produced measurable, tangible benefits using incentive programmes that included 
fixed sum discounts, cash rewards, lotteries, or deposit contracts in areas such as 
medication adherence, smoking cessation, weight loss or substance abuse 
management (Defulio & Silverman, 2012; Giuffrida & Torgerson, 1997; Higgins et 
al., 2012; Jeffery, 2012; Lussier et al., 2006; Paul-Ebhohimhen & Avenell, 2008; 
Volpp et al., 2006; Volpp et al., 2008a; Volpp et al., 2008b; Volpp et al., 2009). 
 
Third, an additional characteristic of human decision-making that merits mention in 
this context is a greater sensitivity to discrete and salient behavioural consequences 
over those that are more diffuse or subtle (Loewenstein et al., 2007). To grasp the 
potential impact of this characteristic on the matters under discussion here, one need 
only contrast the readily discernible onset and salient tastes associated with the 
consumption of fatty and salty foods that contribute to hypertension compared to the 
relatively diffuse and largely imperceptible benefits of exercise related reductions in 
blood pressure (Loewenstein et al., 2007).  
 
Ethical and Moral Issues of Contingency Management 
Despite the benefits, the use of incentives is controversial. The ethical discussion is 
closely linked to the broader debate about the role of personal responsibility for 
health, solidarity, coercion and autonomy, and privacy (Blacksher, Rigby & Espey, 
2010; Gollust & Lynch, 2011; Hoffman, 2011; Lynch & Gollust, 2010; Schmidt, 
2009a). Such debates have ramifications for the ethics of implementing CM in a 
health care setting such as the NHS. These arguments may also affect a clinician’s 
attitude to CM and its incorporation into clinical practice.  
 
Those who support the use of incentives in principle generally point to evidence that 
these programmes often work (Halpern, Madison & Volpp, 2009). They also note 
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that in addition to improving the health of individuals, programmes may help reduce 
health disparities at the population level (Oliver & Brown, 2012; Schmidt, 2009b). 
Opposition to incentive programmes takes several forms. One general objection is 
that the focus on individual-level behaviour is misguided, and that instead broader 
population-level approaches should be pursued: for example, free screening 
programmes, legal limits on fat, salt, and sugar-levels in foods and drinks, 
restrictions on advertising and availability of tobacco and alcohol, or improved 
access to safe and affordable exercise facilities. These initiatives are often regarded 
as more efficient and fair (Blacksher, 2008; Daniels, 2007; Minkler, 1986; Raikka, 
1996; Resnik, 2007; Wikler, 2004).  
 
There is also concern that health incentives can unduly penalise people for poor 
health (Bishop & Brodkey, 2006), and recent experimental work suggests that 
“financial incentives, whether rewards or penalties, are judged as less acceptable and 
less fair than medical interventions” (Promberger, Brown, Ashcroft & Marteau, 
2011, p. 682). Others note that it can be difficult to treat like cases alike: if we 
impose penalties on smokers or the obese on the grounds that their behaviours lead to 
avoidable harm, should we not do the same in other cases, such as poor dental 
hygiene, excessive sun exposure, unprotected sex, high-risk sports, or stressful 
careers? Deciding which risks are worthy of intervention can appear arbitrary 
(Wikler, 1978; Wikler, 2004). 
 
Concerns are also expressed that CM interventions discriminate against the poorest 
and most vulnerable in society. Interestingly, high rates of taxation on cigarettes, 
which can be considered as a disincentive and punitive, and arguably 
disproportionately affect the poorest, have been accepted by society (Kember, 2013). 
Halpern and colleagues (2009) emphasise that incentive programmes differ from 
disincentive interventions in that they offer more support to the disadvantaged and 
promote wellbeing.  
 
Personal Responsibility 
The concept of incentives carries an inherent risk of undermining personal 
responsibility for health and people’s intrinsic motivations to promote their own 
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health (Oliver, 2009; Schmidt, 2009a). Provision of incentives may diminish 
people’s sense of responsibility to contribute to the common good (Schmidt, 2008) In 
the conceptual framework of solidarity (Schmidt, 2008) and personal responsibility 
for health, (Steinbrook, 2006) financial incentives might offend the “First 
Formulation of Kant’s categorical imperative” (Lunze & Paasche-Orlow, 2013, p. 
661), where the motivation for healthy behaviour is derived from a duty to maintain 
our health and should not be motivated by external factors, such as a reward. On the 
other hand, health promotion aims to encourage people to act responsibility and 
make healthy choices. If enrolment in incentive programmes is voluntary, people can 
decide for themselves whether they endorse the aims of the programme. An 
alternative is to allow participants to donate their rewards, an option offered by some 
programmes (Barmer, 2012). 
 
A similar charge is that incentives may become the sole reason for action, thereby 
undermining or crowding out intrinsic motivation (Frey & Oberholzer-Gee, 1997), 
agency or patient autonomy (Ashcroft, 2011). In a broader sociological perspective, 
incentives could also be seen as part of the paradigm of ‘healthism’ in which ‘good 
health has become a new ritual of patriotism, a marketplace for the public display of 
secular faith in the power of the will’ (Levin, 1987; Steinbrook, 2006). 
 
Another risk of undermining personal responsibility for health is that if people 
become reliant on receiving a reward, then cessation of rewards (e.g., at the 
completion of a programme) might lead to cessation of the healthy behaviour or even 
a return to hazardous behaviour. Rewards programmes may also generate the 
expectation that rewards should be offered for other activities that are not yet 
incentivized. The fact that a programme provides incentives for, say, physical 
activity might create the expectation of getting rewarded for unrelated behaviours, 
such as dental hygiene practices. Indeed, the long-term effects of incentives are not 
known. Further research is needed to determine whether dependence on rewards is an 
outcome of such programmes. 
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Solidarity 
On an individual basis, regaining health in the case of sickness can be extremely 
costly, if not impossible to afford. Admittedly, countries that have made social health 
insurance mandatory have taken away a degree of liberty in relation to whether or 
not people should protect themselves against the consequences of poor health. But 
nonetheless, it is plausible to describe those brought together in social health 
insurance systems as being in a solidaristic relationship with others, which has the 
aim of providing mutual protection against the negative implication of diseases 
(Schmidt, 2008). 
 
Paying people for something they are supposed to do could weaken solidarity among 
individuals for the common good (Schmidt, 2008). The principal characterization of 
solidarity and personal responsibility is that the community as a collective, and 
people individually, are co-‘producers’ of health. The notion of co-responsibility has 
two important facets in this respect (Schmidt, 2008). First, it states that the ‘mutually 
supportive community’ has a certain degree of responsibility for the health of each 
individual. In this sense, individuals are entitled to claims against the community for 
assistance. Second, it also implies that the community has certain claims against 
individuals. Leaving prudential benefits aside, the appeal to staying healthy has the 
aim of containing overall expenditure and opportunity costs, for all care needs to be 
financed by the solidaristic community, and limiting one’s demands on the health 
care system reduces expenditure. Using services unnecessarily may also deprive 
another person in need of resources or medical attention, exacerbating resource 
allocation dilemmas (Schmidt, 2008). 
 
Consequently, people are entitled to ask the community for assistance, and the 
community has certain claims on individuals for community-minded behaviour. In 
this sense, healthy behaviour can be considered at least in part to stem from a form of 
civic duty (to minimize the collective risk pool) and should not be contingent on 
financial incentives (Lunze & Paasche-Orlow, 2013). Thus, there is potential to 
undermine this sense of duty by paying individuals for prevention. 
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Some argue that incentives negatively affect the risk-pooling principle of solidarity, 
because paying rewards to those who do not need incentives reduces the funds 
available to the collective, whereas others contend that offering incentives maintains 
the health of the risk pool (Schmidt, 2008). People may feel that they have no 
responsibility for maintaining a healthy population (representing the general risk 
pool of society); thus, if society wants a certain behaviour, then those people need to 
be incentivised to fulfil what should be their social duty. Although these arguments 
hold true in some cases, rewarding certain behaviours such as physical exercise 
might also lead to an increase in other beneficial behaviours, increasing solidarity 
within a mutually supportive community by making healthy behaviour the norm 
(Lunze & Paasche-Orlow, 2013). 
 
Coercion and Autonomy 
One argument against incentives is that they may make people act against their own 
wishes, (Ashcroft, 2011; London, Borasky & Bhan, 2012; Marteau, Ashcroft & 
Oliver, 2009; Popay, 2008) essentially undermining personal freedom of choice, 
because money or in-kind rewards might make people feel forced to participate, or 
induce them to ignore risks. However, the available evidence does not support this 
concept (Lunze & Paasche-Orlow, 2013). For coercion to occur, there must be a 
credible threat of negative ramifications (e.g., loss of health benefits) for not acting, 
(Halpern, 2011; Madison, Volpp & Halpern, 2011) which is not present in the case of 
reward based incentives. 
 
An alternative possibility is that incentives have the opposite effect, that of reducing 
barriers to autonomy. Abolishing cost barriers to behaviour change and health 
promotion, and making prevention cost-neutral, might have the potential to increase 
personal autonomy, such as when incentives facilitate a behaviour change to which 
people are already committed but have not yet implemented (London, Borasky & 
Bhan, 2012). 
 
Privacy  
The fourth concern with incentives relates to privacy. Because the efficacy of 
incentives must be monitored (for example, salivary or urinary measurements might 
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be used to document abstinence from substances), such programmes could increase 
the health care service (governments’) involvement in peoples’ private lives (Halpern 
Madison & Volpp, 2009). However, because the costs of peoples’ decisions are at 
least partly borne by third parties who pay for health care services, governments have 
legitimate interests in promoting health and reducing absenteeism. Furthermore, 
because incentive programmes should not be compulsory, people who value privacy 
more than rewards could avoid such monitoring by simply opting out from incentive 
programmes (Halpern Madison & Volpp, 2009).  
 
When implementing CM, the programme should aim to minimise intrusion. This is 
not only of relevance in terms of respect for autonomy but also with regard to the 
acceptability and sustainability of a programme seeking to promote responsibility. 
Intrusiveness therefore concerns the extent of interference and, in a wider 
assessment, whether a particular measure is likely to be the least intrusive, but most 
effective of a set of available options (Schmidt et al., 2012).  
 
Incentive a Form of Asymmetric Paternalism 
The approach of paying clients for healthy behaviour has been termed ‘asymmetric 
paternalism’ (Loewenstein, Brennan & Volpp, 2007) - paternalistic because private 
and public institutions encourage people to make decisions that will improve their 
lives (almost protecting them from themselves/’in spite of themselves), and 
asymmetric because it encourages people to make informed decisions that will 
improve their lives without restricting freedom of choice. Other promulgated terms 
include ‘optimal paternalism,’ ‘cautious paternalism,’ and ‘libertarian paternalism’ 
(Sindelar, 2008).  
 
For some proponents, incentive programmes represent an acceptable ‘nudge’ 
(Cookson, 2008), for others, they represent an unacceptable paternalistic 
‘shove.’(Popay, 2008; Marteau, Oliver & Ashcroft, 2008). Sunstein and Thaler 
(2003) state that it is inevitable that organisations make decisions and take action that 
will impact on people’s choices. Examples of such decisions range from 
implementing an opt-out organ donor scheme, to removing unhealthy food and 
snacks from school cafeterias. The authors suggest that taking actions that impact on 
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people’s choices does not necessarily equate to coercion. Drawing on some well-
established findings in behavioural economics and cognitive psychology, it is 
possible to emphasise that, in some cases, individuals make inferior decisions in 
terms of their own welfare -decisions that they would change if they had complete 
information, unlimited cognitive abilities, and no lack of self-control (Sunstein & 
Thaler, 2003).  
 
Asymmetric paternalism and providing an incentive does not limit the choices or 
options available to the individual. Incentives merely counter our self-defeating 
tendencies toward immediate gratification (Kane, Johnson, Town & Butler, 2004). 
Without constraining our options, it is difficult to argue that they infringe on 
autonomy (Bloch et al., 2006). In this way, incentive programmes are a good 
example of asymmetrical paternalism, (Lunze & Paasche-Orlow, 2010; Finkelstein, 
Linnan, Tate & Birken, 2007) in that they steer people toward making better choices 
without actually limiting what those choices are.  
 
Furthermore, it helps guide them towards making better choices, as judged as better 
by themselves (Halpern et al., 2009). Halpern and colleagues (2009) developed this 
argument further, explaining that people possess varying degrees of ability to change 
their behaviours that impact on their health. These abilities are affected by 
environmental, economic and genetic factors, and lifestyle behaviours. For instance, 
lifestyle behaviours reflect individual choice, but these choices are influenced by 
social context. People’s dietary habits are shaped by advertising, cost, social norms 
and emotional needs, and their ability to exercise is influenced by their commuting 
patterns, the safety of the environment and whether the environment feels safe 
(Schmidt, Asch & Halpern, 2012). Therefore, society has a responsibility to help 
people who encounter such obstacles.  
 
In other areas where asymmetric paternalism is exercised, involving a change of the 
‘default’ position, for example, changing an organ donation system from opt-in to 
opt-out, (as will be implemented in Wales in 2015), one could argue that an 
individual’s freedom of choice is being restricted as decisions are not consciously 
thought through (Rajan, 2012). This critical appraisal suggests that the same 
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argument is not as applicable in the case of CM for crack cocaine users in the present 
trial. Participants in the current trial are voluntarily attending an opiate substitution 
treatment, which has an explicit aim of reducing illicit drug use. Therefore, the 
accepted goal of reducing crack cocaine use has been consciously considered by the 
individual, and CM supports them in reaching this goal rather than being coercive.  
 
Clinicians’ Ethical Concerns and Views 
Clinicians can hold ethical concerns and negative views about CM which can effect 
the uptake of CM (Sinclair et al., 2011). Kirby and colleagues (2006) identify a 
concern amongst clinicians that CM does not address the underlying issues that lead 
to drug addiction. Rash et al., (2012) conducted a web based study to develop a 
measure assessing beliefs about CM and to examine the relation of these beliefs to 
clinician characteristics. The authors identified a number of other commonly held 
negative beliefs about CM that could affect its uptake. These included the cost of the 
intervention and a concern about what happens after the withdrawal of the incentive. 
Rash et al. (2012) also highlight an attitude that the empirical basis of CM is not 
relevant to everyday clinical populations. Attitudes toward treatment manuals, 
evidence based practice (Henggeler et al., 2008) and traditional views about 
treatment can be barriers to the adoption of a new treatment like CM (McCarty et al., 
2007). Another concern held by clinicians is that patients will use the incentive 
gained to obtain more drugs (Petry, 2006), although research suggests that when 
participants receive incentives during drug misuse research, they are able to use these 
payments in a responsible and safe manner (Festinger et al., 2005).  
 
Rash et al. (2012) states that the sort of negative beliefs described above reflect a 
limited understanding of CM. Cameron and Ritter (2007) surveyed drug practitioners 
and found that their attitudes were based on a cursory understanding of CM. 
Practitioners often used an over-inclusive definition of CM that involved providing 
positive reinforcement on an ad hoc basis as opposed to on a structured contractual 
basis.  
 
Roll and colleagues (2009) identified that a lack of familiarity with CM and its 
empirical support may affect its uptake. Cameron and Ritter (2007) found that 
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practitioners in their study changed their ideas about CM over the course of the study 
as a result of being provided with written information. Similarly, Rash et al. (2012) 
identified that receiving training in CM was associated with less endorsement of 
barriers to the uptake of CM. These findings indicate that providing information and 
training is vital to address clinicians’ understanding of CM which can affect their 
attitudes and perspectives and likelihood of using CM (Kember, 2013).  
 
Conclusions and Recommendations 
In summary, there are sound health and economic rationales for emphasising 
behaviour change in efforts to improve population health and, more specifically, for 
including the systematic use of financial incentives in such efforts. Financial and 
other material incentives can effectively reinforce healthy choices and, in doing so, 
enlist the same powerful process of reinforcement and associated neurobiological 
processes that drives unhealthy behaviour to promote health and prevent disease. 
Financial rewards can serve as healthy alternatives to those residing in relatively 
deprived environments and they can be delivered relatively immediately following 
healthy choices, thereby accommodating and leveraging the bias for the present. 
They can also be readily scheduled and delivered in a manner that underscores their 
salience and activates important neurobiological self-regulatory systems (Higgins et 
al., 2012). 
 
There are sound scientific rationales for why incentives are effective in this regard 
and evidence from controlled clinical trials across a wide range of different 
applications supports their efficacy. Nevertheless, there are many important 
questions that remain to be answered regarding the use of incentives for health 
related behaviour change, including optimal incentive values, appropriate 
intervention durations for different problems and populations, and cost-effectiveness 
(Higgins et al., 2012). To minimize the ethical risks, financial incentive programmes 
for clients should be: a) designed to overcome behavioural biases while maintaining 
clients’ freedom to make informed choices, specifically rewarding desired 
behaviours and not outcomes, b) designed to minimize current health and health care 
inequities (Lunze & Paasche-Orlow, 2013), and c) lastly, incentive programmes rest 
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on specific design features and, hence, require a case-by-case assessment, monitoring 
and evaluation. 
 
Future research is needed to identify target populations most amenable to incentives 
and will have to characterize the determinants of effective and efficient incentives. 
This will also help to better illuminate the ethical implications of incentives, many of 
which are common to the various types and settings of programmes. When 
programmes are designed in an ethically responsible manner and with appropriate 
safeguards, financial incentives can be offered to help improve health behaviours and 
neutralize opportunity costs associated with prevention and behaviour change (Lunze 
& Paasche-Orlow, 2013). 
 
Regarding the highlighted concerns from clinicians to implement CM, it is argued in 
this critical appraisal that the use of CM interventions in substance misuse can be 
considered asymmetrical paternalism as opposed to coercion. These interventions 
serve to offer more support to the disadvantaged and to promote their wellbeing, and 
help people to reach their own goals.  
 
The literature reviewed above identified that clinicians may have concerns regarding 
CM; for example, what will happen when the incentive is withdrawn, what the 
incentive may be used for, that it may not address the underlying issues causing drug 
dependence and that it is coercive. The literature suggests that negative views held 
by clinicians may be due to a cursory understanding and that providing information 
and training can affect clinicians’ attitudes and their likelihood of using CM 
(Kember, 2013). This has implications for clinical research investigating the use of 
incentives. It may be important to survey therapists involved in a clinical trial on 
their attitudes towards CM. Negative attitudes could have an impact on their 
adherence to the CM model and could also influence the therapeutic relationship. As 
the research shows that a cursory understanding of CM can lead to negative views of 
CM, it is important that therapists (and health workers) receive sufficient training, 
information and ongoing supervision to address the perceived barriers to using CM. 
It is likely that participants may also hold negative views about CM. Providing 
therapists with a comprehensive understanding of the principles of CM may 
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empower them to communicate this understanding to participants as necessary, and 
increase participants’ motivation to engage with the programme.  
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Part D: Critical Literature Review 
 
I. Introduction   
 
It is always interesting to speculate why certain ideas emerge at a particular time. It 
is especially intriguing to review the reasons why attention should be called to the 
use of self 7 in therapy. Indeed, the field of family therapy, which had started in the 
1960s as a movement questioning conventional patterns of therapy, initially focused 
on the development of theories and models in order to make this new form of therapy 
appear scientific, and thus valid (Baldwin, 2013). With the exception of a few 
psychologist and psychiatrists, most theorists and clinicians avoided paying attention 
to the self of the therapist, which did not seem a valid topic of scientific inquiry 
(Clarkson, 2003). What is somewhat puzzling is that the concern about scientific 
objectivity was arising at the time when scientists in basic disciplines such as 
physics, chemistry, and molecular genetics had begun to question the validity of a 
purely technological approach to life. They stated that pure objectivity is an illusion, 
that objects are changed by the very process of observation (Heisenberg, 1927), and 
that not everything that exists is observable (Lynch, 1977).  
 
According to systems theory, therapists are an unavoidable part of the treatment 
situation, both as therapists (change agents) and as themselves. They do not choose 
to be in or out, they can only choose to be aware or not. That this role can operate 
along a continuum from activity to passivity has been alluded to by a number of 
authors (Hollender & Szasz, 1956). Indeed, a major development of the past several 
decades has been the increasingly active and participatory role in such transactions 
accorded to the client. In this particular evolution, the seminal work of Carl Rogers 
(1987) must be noted, in that he saw the potential for self-direction in patients, whom 
                                                
7 The intention of the use of self in present review is the following: Self as the totality of personal 
experience and expression, self as living being. More specifically, the persons subjective realm: 
thoughts, attitudes, opinions, feelings, emotions, behaviour, therapeutic experience, memories, life 
histories, level of evolution toward mastery, inner cast of characters, style, personal story, family 
life, spiritual inclinations, philosophical beliefs, etc. The term is used inclusively and relatively 
neutrally and other terms like person, individual, organism, etc. are acceptable synonyms. 
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he began to refer to as clients, viewing the therapist as assisting rather than 
promoting the process of self-determination and development.    
 
It is not surprising that the movement toward a more humanistic psychology which 
emerged after World War II was accepted by many therapists, who found the 
determinism and reductionism of the Freudian view unsatisfactory from a personal 
and professional standpoint (Clarkson, 2003). This resulted in an outpouring of 
interest in the uniqueness and authenticity of human experience.  Belief in the self-
actualisation ability of people led to the formation of the human potential movement 
of the 1960s and 1970s (Maslow, 1962). Unfortunately, proponents of this movement 
often carried the idea of personal growth to the limits of personal license and failed 
to develop a disciplined and systematic examination of its assumptions and 
implications. Each person’s experience was considered valid in itself and, in the 
place of the rigidities of traditional psychiatry and psychology, there emerged a 
plethora of therapeutic systems and approaches, based on individual style, inclination 
and popularity (Clarkson, 2003). Indeed, the field of therapy appeared to move from 
an excessive dependence upon rigid theories and formats to an equally excessive 
emphasis on idiosyncratic techniques and therapeutic stratagems, that often as not, 
were more artificial and manipulative than the traditional approaches (Baldwin, 
2013). 
 
Regarding scientific research, one of the most important factors to emerge is the 
significance of the therapeutic relationship, which is thought to be common to all 
psychotherapies (Wampold, 2001). A constant focus has been on what it is that 
therapists do which leads to client change (Lambert, 2013). As it emerges from the 
research, it is very difficult if not impossible to establish with anything more than 
partisan preferences that any one psychotherapy is more effective than any other: 
“All have won and all must have a prize” (Luborsky et al., 1975, p.1; Wampold, 
2001; Cooper & McLeod, 2007). It seems that success in psychotherapy can best be 
predicted by the properties of the psychotherapist, the client and their particular 
relationship (Norcross & Goldfried, 2005). Lambert  (2013) has found that the client, 
the psychotherapist and the therapeutic relationship between them, are repeatedly 
more closely related to outcome than whatever technique has been used. Kahn in his 
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book, Between the therapist and the Client: The new Relationship (1991) proposes 
that the relationship is a central factor in all psychotherapy, and hence a powerful 
therapeutic tool, perhaps the most powerful tool. Kahn’s teacher said, “The 
relationship is the therapy” (Kahn, 1991, p. 1). Thus, there appears to be increasing 
acceptance among therapists of all persuasions that there is something in the unique 
nature of the therapeutic relationship and the person (self) of the therapist that plays a 
critical role in the process of therapy (Rogers, 1961, 1987; Truax et al., 1966a, 
1966b; Lambert, 2013).  
 
The self of the therapist is an important topic, because the therapeutic technique 
should not overshadow the fact that the self of the therapist is the funnel through 
which theories and techniques become manifest (Satir, 2013). In most instances, 
individuals who enter therapy are in pain and feel isolated, and unless the therapist 
makes a real contact with the individual, no real therapy can take place, since they 
will not take the risk of exposing their vulnerabilities (Baldwin, 2013).     
 
Common sense dictates that the therapist and the client must inevitably affect each 
other as human beings (Satir, 2013). This involvement of the therapist’s self or 
personhood, occurs regardless of, and in addition to, the treatment philosophy or the 
approach. Techniques and approaches are tools. They come out differently in 
different hands (Clarkson, 2003). Because the nature of the relationship between 
therapist and client makes the latter extremely vulnerable, it is incumbent upon the 
therapist to keep that relationship from being an exercise in the negative use of 
power, or of developing dependency, both of which ultimately defeat therapeutic 
ends.   
 
This review is about the inner world of the therapist, the self or person of the 
therapist, and how s/he relates to another self. The first part of the text is dedicated to 
the philosophical and psychological roots of the concept of self. Following this, the 
review emphasises the relevance of the I – Thou (You) relationship in human beings, 
and thus in the therapist and client relationship, as defined by Martin Buber (1923) in 
the early part of the last century. Approaches that conceptualise the multifaceted 
nature of self will be outlined, and finally, to converge the above reviewed topics, the 
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use of the self in therapy from an existential, dialogical and ethical point of view will 
be discussed.  
 
 
I.1. The Concept of the Self 
 
The concept of the self has intrigued writers and philosophers throughout the ages. 
Plato believed in the immortality of the soul, which he saw as separate and distinct 
from the body, from which it was released by death for full expression. Aristotle 
began as a Platonist, viewing the soul as immaterial, but in De Anima (On the Soul, 
1957) he later described the soul as the inseparable, substantial form of the living 
organism, guiding and directing it. He further defined the soul in terms of vegetative, 
animal, and rational functions, thereby setting the stage for later preoccupation with 
the mind and body relationship (Lana, 1991). 
 
This view reached its acme in Descartes’ famous statement ‘cogito, ergo sum’ (I 
think, therefore, I am), and the subsequent dualism of body and mind with which he 
is identified (Lowry, 1971). This position, of course, served to draw the battle lines 
between a concern with the external, objective, natural world of objects and the less 
accessible, subjective, inner world. Despite its limitations and the criticisms currently 
directed toward Cartesian dualism by bio-behavioural research, this concept enabled 
the development of critical inquiry in the physical sciences in a way that has made 
possible much of today’s progress in science and technology (Lana, 1976). Because 
of this emphasis, however, the objective and materialistic side of life achieved a 
commanding lead over that of the subjective and non-conscious, and it was not until 
philosophers such as Kierkegaard and Husserl, writers such as Dostoevsky and 
Tolstoy, and clinicians such as Freud, Jung and Adler, that the subjective world 
began to be explored in terms more appropriate to its understanding (Baldwin, 2013).  
 
Freud’s theories initiated a renewed attack upon the established lines of Cartesian 
dualism by adding the elusive concept of the unconscious to confuse the comfortable 
physical terms to which the domain of the mental and conscious had been assigned. 
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In his 1915 paper ‘The Unconscious,’ Freud (1953) differentiated between 
unconscious ideas, which continue to exist as formations after repression, and 
unconscious affects, which are discharged. He and his followers went on to describe 
a whole continuum of the unconscious, from lack of awareness of vegetative and 
neurological processes to fantasy and dreams (Baldwin, 2013). Although his 
emphasis on psychic determinism confused the philosopher, it served to stimulate a 
new and fruitful discussion of the concept of self, among, both his followers and 
those in other disciplines. At the same time, it must be remembered that Freud was 
basically a scientist and did not, himself, directly challenge the heavy investment 
which science had in Cartesian dualism. Thus, despite the efforts of William James, 
John Dewey, and others to examine the self on an empirical basis, the concept of a 
self, complete with philosophical, social and religious connotations, was largely 
ignored by an emerging psychology seeking to establish itself as a scientific 
discipline separate from philosophy (Marková, 1990). 
 
It was the writers and philosophers, primarily from the existential school, who 
continued to explore the world of subjective phenomenology (Marková, 1990). Still, 
it remained for George Herbert Mead (1934) to reintroduce the concept of the self as 
a basic unit of personality into scientific thought, along with the roles that the self 
learns to take in the course of its socialisation. He saw the self as a process rather 
than a structure, and maintained the self and the consciousness of self emerged from 
social interaction – the interaction of the human organism with its social environment 
(Marková, 1990). He believed that what made human unique was their capacity to be 
both subject and object at the same time (Mead, 1934). Since they would even be an 
object of their own thought and action - self-interaction- they stood in a markedly 
different relationship to their environment than the then-prevailing view of behaviour 
as resulting from external factors or internal drives (Marková, 1990). Mead’s work 
while not theoretically explicit, laid the groundwork for the later development of 
symbolic interactionism, a field that has greatly influenced modern sociology and 
psychological thought. Indeed, the revival of interest in the self has been so 
widespread that it is difficult to find a modern personality theory that does not place 
the self in a central position (Arieti, 1967; Kohut, 1971, 1985).  
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Special note must be made of the contributions of the developmentalists, such as 
Erikson (1950, 1959) and Greenacre (1958), who described the emerging self in 
terms of the psychosexual and ego development of the child. They noted the 
fundamental absence of a distinction between the self and the not-self as a basic 
characteristic of newborns, who, partly as a result of their perceptions, begin to 
differentiate various aspects of their body image from objects in the external world. 
Multiple self-presentations gradually lead to the formation of a concept of the self, 
which becomes more stable and permanent as a result of the achievement of object 
constancy (Baldwin, 2013). 
 
Closely related is the concept of identity (Greenacre, 1958; Erikson, 1950, 1959), 
which constitutes an awareness of separateness and distinction from all others, in 
which the borders of the self are hypercathected by the early experience of separation 
from the mother. Thus, the distinction of the I from the not-I is reinforced by a 
variety of internal and external experiences. Indeed, the mechanism of projection is 
based on the primal lack of distinction between the self and the not-self. These 
contributions have allowed Spiegel (1959) to define the “self as a frame of reference 
or zero point to which representations of specific mental and physical states are 
referred, and against which they are perceived and judged” (p.96). 
 
It is clear, however, that Cartesian dualism still plays an influential role in modern 
life and thought (Marková, 1990). As Buber (1955, 1965, 1970) points out, most of 
our transactions with our fellow human beings and our environment are in the nature 
of subject-object or I-It relationships. In calling attention to our essential need to 
participate in reciprocal I-Thou relationships, in which each person fully regards and 
accepts the subject both in self and others, Buber pleads for a reunification of our 
subjective and objective parts. Far from being merely the absence of an infantile 
distinction between the subjective and objective, or the self and not-self, this is the 
achievement of a new unity which, while existing in both conscious and unconscious 
spheres, is available and accessible to the dedicated searcher (Baldwin, 2013). 
 
The use of self in therapy, then, as a subject of theoretical and practical 
psychotherapeutic importance, emerges at this time in history, largely because of the 
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re-emergence of a concern with the uniqueness of human experience and relationship 
over the past century (Marková, 1987). 
 
I.2. The Contributions of Existential Philosophy 
 
Perhaps the most important influence on the twentieth-century view of humanity and 
on the emerging concept of the use of self in therapy comes from the existential 
philosophers, who take their lead from the seminal work of Søren Kierkegaard 
(Lowry, 1971). Writing out of the depths of his own personal concerns, Kierkegaard 
(1959) objected to Hegel’s efforts to unite the ambiguities of life in an abstract 
fashion through positing of a higher synthesis. He insisted that the dichotomies of 
life – good and evil, life and death, God and humans - could not be mediated, but that 
we were called upon to make decisions between the polarities (Perkins, 1997). He 
asked us to turn from the world of thought to that of existence as it is actually lived, 
believing that only through an examination of human experience in all its complexity 
could one approach the basic question: What is the meaning of life? 
 
Kierkegaard believed that meaning is to be found in the decisions between such 
polarities and that these decisions must be based on one’s own closely examined 
experience, rather than on any authority or abstract concept (Walsh, 2009). Such an 
act, of course, is fighting, in that one is asked to abandon the usual sources of support 
and to leap into the unknown. It was his belief that each individual must, of 
necessity, make fully conscious, responsible choices among the alternatives that life 
offers. His works, “Sickness Unto Death” (1980) and “The Concept of Dread” 
(1957), are classics of early depth psychology. The former alludes to the role of the 
unconscious in depression, while the latter makes a clear distinction between ‘Angst’ 
(dread), which he defines as feeling that has no definite object, and the fear and terror 
that derive from an objective threat (Lowry, 1971).  
 
It was not until some time after his death that the philosophical and psychological 
implications of Kierkegaard’s work began to be fully appreciated. Indeed, 
existentialism is generally viewed as twentieth-century phenomenon and has 
profoundly affected the development of philosophy, religion and psychology in this 
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century (Stewart, 2011). Within this century, seminal thinkers in the development of 
existentialism have included the religious thinkers Bultmann, Marcel and Tillich, as 
well as those who have clearly disassociated themselves from the religious view, 
such as Sartre and Camus. Of note in this development is the work of Edmund 
Husserl (1965), who introduced the phenomenological method in philosophy, calling 
upon us to examine our own experience. Of special importance was his insistence on 
‘intentionality,’ the idea that every meaningful word must be rooted in the experience 
of which it is only a name, stating, ‘consciousness is always conscious of something’ 
(Marková, 1982).  
 
Although he rejected the existential label, Heidegger (1962) is usually regarded as 
the figurehead of twentieth-century existentialism. He believed that we can learn 
something about the fundamental nature of human beings – our ‘being-in-the-world’ 
– through an analysis of our anxieties, particularly, our fear of death. He accepted life 
as fundamentally contingent, stating that the only way to live authentically is to 
accept our own finitude and to develop a capacity to care (Sorge). This includes, not 
just ‘solicitude’ for others, as suggested by the later existential psychologists, but 
also an ontological caring for, or custodianship, of ‘Being’ (Marková, 1982). 
 
Tillich (1961) differed from Heidegger in believing that it is in ‘the boundary 
situation’ – that situation in which one is denied the supports of authority and 
intellectualism, and even the traditional concept of God is found wanting – that one 
finds the unconditional certainty of the ‘Ground of Being,’ the ‘Being – itself,’ which 
appears when all else has been dissolved in anxiety and doubt. He believed that we 
are all aware of the contrast between the ideals that we hold and the lives we live, 
calling this the difference between ‘essence’ and ‘existence.’ He maintained that we 
can resolve this difference only in the boundary situation, defining authenticity as 
“the courage to be and, thus, to escape ‘non-being’” (Tillich, 1961, p.20). 
 
Perhaps the most radical of the modern existentialists was Jean-Paul Sartre (1950). 
He concluded that one is not only ‘en-soi’ (in oneself) – a passive recipient of fate – 
but also ‘pour-soi’ (for oneself), transcending the present. Thus, we are free from the 
limitations imposed by the world of experience. Indeed, we are forced to be free. To 
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live authentically means to accept this dreadful freedom and to see that values are 
merely projections of our decisions (Baldwin, 2013). Such a position suggests a 
radical nihilism and individualism that has strongly influenced the development of 
the field. 
 
I.3. The Influence of Martin Buber 
 
Although he rejected the label during his lifetime, Buber’s thought was profoundly 
influenced by existentialism (1923, 1955, 1965, 1970). He believed that our access to 
being comes from the capacity to enter into dialogue or relationship with the existent, 
or ‘the between.’ He rejected the reason as the distinctive characteristic of human 
beings, defining human being as a “creature capable of entering into living relation 
with the world and things, with men both as individuals and as the many, and with 
the ‘mystery of being’ – which is dimly apparent through all this but infinitely 
transcends it ”(Friedman, 1965, p.16). Thus we are unique in our capacity to 
participate in both finitude and infinity.  
 
Buber’s views were elaborated in Ich und Du (1923), in which he states that our 
relation to God, the Great Thou, enables us to participate in I – Thou relationship 
with other humans. For Buber, I – Thou establishes the world of relation, “into which 
both parties enter in the fullness of their being, with a sense of and appreciation for 
the subject and object in each.” It is a relationship “characterised by mutuality, 
directness, presentness, intensity and ineffability” (Friedman, 1965, p.12). 
 
This is contrasted with the I – It, or subject-object relationship in which others are 
regarded as mere tools or conveniences. I – It is the medium of exchange in the 
world of things and ideas, dealing with categories and connections, with 
experiencing and using. Indeed, the scientific method is our most highly perfected 
development of the I – It, or subject-object, way of knowing (Friedman, 1965).  
 
The I – Thou relationship also involves responsibility in the sense of one’s ability to 
respond to another. “There is reciprocity of giving: you say You to it and give 
yourself to it; it says You to you and gives itself to you” (Buber, 1970, p.84). It is 
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through this relation that one becomes known to oneself and to others as a self. “Man 
becomes an I through a You” (p.80). Self-realisation, thus, is the by-product, rather 
than the goal, as is often assumed. 
 
For Buber, the highest expression of the I – Thou relationship lies in the act of 
confirming the other. He sees mutual confirmation as the key element in the 
definition of the self. One realises one’s uniqueness only in relation to another who 
reciprocally defines oneself. Each becomes confirmed by the other in her/his true, 
real, present, authentic self.  True confirmation is mutual and involves making the 
other fully present in all her/his unity and uniqueness (Buber, 1970).    
 
In 1957, the Washington School of Psychiatry invited Buber to give a Memorial 
Lecture where he spoke of psychotherapy, “I have the impression (that) more and 
more therapists are not so confident that this or that theory is right and have 
(developed) a more ‘musical,’ floating relationship to their clients. The deciding 
reality is the therapist, not the methods” (quoted in Friedman, 1965, p.37).  “It is 
much easier to impose oneself on the patient than it is to use the whole force of one’s 
soul to leave the patient to himself and not to touch him. The real master responds to 
uniqueness” (p.38). For Buber, rather than adhering to dogmatic theory or 
techniques, the therapist must be ready to be surprised and to receive what he will 
receive.  
 
I.4. The Postmodern, Dialogical and Ethical Self 
 
In the last few decades there have been a growing number of therapeutic approaches 
that conceive of the self as plural, that is, constitutive of a multiplicity of states, 
positions and functions (Georgaca, 2010). This is due largely to dissatisfaction with 
psychology's pre-occupation with self-contained individualism that downplays the 
impact of sociocultural processes (Sampson, 1989).  
 
The dialogical self marries Mead's concept of self with the work of Russian literary 
scientist Mikhail Bakhtin. Bakhtin's concept of dialogism holds that language is a 
living body of utterances used in interactions, and that speech is always addressed to 
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someone, with every utterance having an addressee (Bakhtin, 1986). In light of this, 
the main proponent of the dialogical self in psychotherapy, Hubert Hermans, 
conceives of the self as a “dynamic multiplicity of relatively autonomous I-positions 
in an imaginal landscape” (Hermans, 1997, p. 33). Self is formed and performed 
through interactions in specific cultural contexts, whereby I-positions move about 
depending on time, place and situation.  
 
Larner (2008) acknowledges the self as formed discursively, but he draws upon 
Levinas and Derrida to argue that the self is simultaneously separate and unique. The 
dialogical view of the self is closely aligned to postmodernity, whilst Larner's thesis 
is predicated on deconstruction as an ethical movement that challenges the hegemony 
of a discourse from within (Larner, 2011).  
 
For Levinas (1996), being in relation with another evokes a responsibility that 
overrides all one's concepts and theorising insofar as “to be face to face is to be 
unable to kill” (p. 9). Following this, Derrida puts forth an ethic of hospitality where 
to be a self, one must first take in and speak the language of the other (Derrida, 
1998).  
 
For Derrida and Levinas, in the context of ethics and social justice, the self cannot be 
reduced to a discursive, dialogic or relational account. This is because the root of 
personal responsibility is a singular corporeal self that is able to exercise agency, 
“justice would not be possible without the singularity, the unicity of subjectivity” 
(Levinas, 1979, p. 246). Therefore, the ethical self is a complexity, both relational 
and autonomous.  
 
I.5. The Influence of Existential Philosophy on Psychotherapy 
 
Since existential philosophy maintains that the only true absolute is that there are no 
absolutes, this poses a fundamental question: How does a person who needs meaning 
find meaning in a universe that has none? 
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For centuries, of course, this answer has been found in the positing of a God-centred 
universe in which our purpose was to relate to and, if possible, emulate that God. 
Since this is patently impossible on an individual basis, most philosophers and 
theologians have arrived at the point of view, exemplified by the work of Pierre 
Teilhard de Chardin (1955), that each individual, by recognising and joining in this 
cosmic union, is provided with a personal sense of meaning. At the same time, 
Kant’s questioning of the existence of any fixed, objective reality calls such a view 
into question (Lana, 1991). Indeed, Camus and Sartre regard the tension between 
human aspiration and world indifference as the absurdity of ‘la condition humaine.’ 
Satir (Satir et al., 1991) refers to this as the ‘cosmic joke,’ but maintains that the 
development of a sense of self-worth enables one to tolerate the irony and to find 
meaning in the principle of the seed and organic growth.     
 
It is not surprising that many philosophers have disavowed identification as 
existentialists, because as Tillich (1961) has pointed out, “There is not, and cannot 
be, an existentialist system of philosophy” (p.9). “Existentialism is an element within 
a larger frame of essentialism” (p.10). Like most other philosophical concepts, each 
view achieves definition largely in terms of its opposite, and neither can be totally 
accepted without inviting rebuttal from the other. Thus, the apparent triumph of 
existentialism in the twentieth-century must be seen in a historical perspective that 
considers and balances the opposing views of idealistic or naturalistic essentialism 
(Tillich, 1961).  
 
Such a philosophical distinction has tremendous implications for psychotherapy. 
While it is clients’ problems that bring them into therapy, it is important to 
distinguish between those related to their nature and their daily lives and 
relationships, and those arising from their basic existential anxiety. The former are 
the appropriate concern and within the usual competence of most therapies and 
therapists, but psychotherapy cannot cure the existential anxiety that arises from the 
awful awareness of our own finitude – ‘la condition humaine’ – although it can 
attempt to give meaning to life (Baldwin, 2013). It does this in a uniquely human 
way – through offering to the seeker of help the self of the therapist as a significant 
symbol of faith and hope in the formers effort to bridge the finite and infinite. 
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Buber’s ‘I – Thou’ relationship appears to offer precisely this uniquely human act 
and experience of confirmation.  
 
The existentially oriented psychotherapist, then, does not manifest a particular 
technique or theory, nor are the valuable contributions of other psychological 
theories denied (Yalom, 1980). Rather, a selective approach is used, the central 
process of therapy being perceived as that of experiencing the full awareness takes 
precedence over cognitive awareness, the ‘here and now’ is emphasised rather than 
the past life of the client, and therapy is regarded as a creative, evolving process of 
self-discovery. In relating to the client, the therapist tries to establish a personal bond 
of trust and meaningful collaboration, based on a genuine belief in the therapist’s 
own potentialities and those of the client. While remaining observing and objective, 
the therapist attempts to enter the world of the client, wrestling with the frustrations 
and limitations of the therapeutic situation, trying to be fully present and subjectively 
real (Tillich, 1961). So far as possible, s/he attempts to manifest Martin Buber’s ‘I – 
Thou’ relationship of mutuality, trying to liberate the individual to seek and achieve 
optimal development. In short, the existential therapist functions as fully available 
person in a meaningful encounter with another. As Tillich (1961) holds, “a person 
becomes a person in the encounter with other persons, and in no other way …This 
interdependence of man and man in the process of becoming human is a judgment 
against a psychotherapeutic method in which the patient is a mere object for the 
analyst as subject” (p.15). 
 
It appears, then, that for the existentially oriented psychotherapist, the use of self is 
an essential element in therapy, whether it is with individuals, groups or families. 
Support for this position has come from the growing influence of general systems 
theory in psychiatry, which posits that the therapist must be viewed as an integral 
part of the therapeutic system and as having a major effect on the system of the client 
(Baldwin, 2013). What often is overlooked is that this is a two-way street. In general, 
this aspect is easier to observe and accept in the group and family therapy, where the 
very number and complexity of transactions involved make cognitive or technical 
control of the situation difficult at best. In such situations, it may be more effective 
for the therapist to ‘go with the flow’ – Buber’s musical or floating relationship – and 
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to focus on the meta-messages of the system and of her/his own internal state of 
being. This is not a passive process. An attitude of alert, active attentiveness is 
required to maintain the essential qualities of contact and receptivity. Nor does this 
imply having control over the situation or over the client through authority or 
technique (Satir, 2013). Rather, the central core of being within the therapist – the 
very sense of self – serves to communicate and maintain a centering and stabilising 
force or power in the process. While such an approach would appear to abdicate the 
traditional role of the therapist and encourage chaos to take over, this very act of 
relinquishment of control is precisely what many clients seem to require in order to 
rediscover and reassert their own sense of control over their lives. At the same time, 
this act loses its authenticity if used solely as a technique (Basescu, 1990). It is an 
intensely real and personal act – that of letting go – putting one’s belief in one’s self 
and in the self of the other on the line – exposing one’s true deepest self; in a sense, 
going naked into the encounter – allowing oneself to become truly vulnerable 
(Basescu, 1990). This ‘centred act of the centred self’ is truly the source of the 
creative and life-giving act of self-discovery and transformation (Tillich, 1961). 
Paradoxically, such a use of self implies a deliberate ‘non-use’ or suspension of self 
in its usual sense.  
 
I.6. The Influence of Multiplicity, Dialogism and Deconstruction of the 
Self in Psychotherapy 
 
Hermans has formulated a sophisticated framework for therapeutic practise that 
encompasses the dialogical view of the self whereby the therapist assesses an 
individual's various I-positions and the way they move from one to another. The 
extent to which this happens flexibly determines the psychological functionality of 
an individual (Hermans & DiMaggio, 2004). To this end, the aim of therapeutic 
practice is the facilitation of a complex subjectivity whereby different positions can 
be fluently articulated with an overall reflexive frame (Hermans, 2003).  
 
Clinicians from diverse orientations converge on the view of self as a multifaceted 
entity with internal multiplicity being present. Whilst this view may not be explicitly 
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acknowledged, it can be found in various therapeutic perspectives. For example, this 
may be the automatic intrusive thoughts in cognitive-behavioural therapy or internal 
objects in psychoanalysis (DiMaggio & Stiles, 2007). 
 
Indeed, Larner (2008) argues it is the very condition of self as relational and at the 
same time having a sense of unity, coherence and independence, that opens the 
possibility for many languages to describe the self in therapy. This could be a 
dialogical self, a systemic self, a cultural self and so on. In this sense, the therapist 
should acknowledge that the self is constructed through multiple meanings, 
narratives and dialogues, but at the same time be experienced as unique, autonomous 
and capable of taking responsibility and agency in life (ibid). 
 
British psychotherapists Cooper and McLeod have developed a methodological and 
technical framework of pluralistic therapy based on “'dissensus' rather than 
consensus” (Cooper & McLeod, 2007, p. 6). They maintain that psychological 
difficulties arise from multiple causes and as such, there is unlikely to be one 'right' 
therapeutic method for all situations. Rather, because different explanations will be 
true for different people at different points in time, different therapeutic methods will 
be helpful for different clients at different times (ibid). Whilst pluralistic frameworks 
are closely aligned with postmodern thought, Cooper and McLeod also draw upon 
Levinas, emphasising the therapist's acceptance of the otherness of the Other (Cooper 
& McLeod, 2011). The therapeutic encounter is respectful, valuing and open to 
cultural diversity in both the client and therapist. They maintain it is the collaboration 
between therapist and client that is the driving force behind healing and change 
(Cooper & McLeod, 2006). 
 
I.7. Conclusion 
 
To conclude, an attitude of alert, active attentiveness is required to maintain the 
essential qualities of contact and receptivity. Achieving and maintaining such an 
attitude is never easy, and it is impossible for some therapists, whose personal needs 
or belief system require them to maintain untouched or to be ‘in charge.’ Nor is it the 
province of any one theory or school (Clarkson, 2003). Great therapists of all 
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persuasions have always manifested the essential elements of this quality (Baldwin, 
2013). Nor does it mean that knowledge, skill and experience are not important. It is 
in this spirit that counselling psychology has created a legacy promoting the 
importance of personal and professional development through engagement with 
personal therapy and supervision across one’s professional career (Division of 
Counselling Psychology, 2005). At times, however, counselling psychology courses 
have disregarded the significant dimensions, of the self of the therapist in training. 
This resulted in perpetuating a focus on technique and theory that often obscured the 
deeply personal relationship involved. Such lessons need to be learned experientially 
through intense encounter with others, who are able to share openly in their own 
continuing search (Satir, 2013). While the vital learning experience is always deeply 
personal, it almost always occurs in relation with another person. Ultimately, what 
therapists have to offer is not a technique, not a theory, but who we are. Buber has 
said that the greatest thing one human being can do for another is to confirm the 
deepest thing within her or him. It is this act of confirmation which is ultimately 
implied in the use of self in therapy.  
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